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Abstract 
Sorting nexin (SNX) proteins are a large family of proteins with critical roles in endocytosis, 
membrane trafficking and intracellular signalling. Each SNX protein contains a Phox 
homology (PX) domain that typically recognizes phosphoinositide lipids to enable their 
anchoring to defined organelles. SNXs also contain additional domains other than the PX 
domain thus allowing them to participate in a wide range of functions such as protein-
protein interactions, membrane remodeling, lipid metabolism and other functions that are 
yet to be explored. My research focuses on the structural and functional characterization 
of two different sub-families of SNX proteins; those that have both PX and BAR 
(bin/amphiphysin/rvs) domains (SNX5, SNX6 and SNX32), and the poorly characterized 
SNX-RGS sub-family that contain a regulator of G-protein signaling (RGS) domain 
(SNX13, SNX14, SNX19 and SNX25). These protein families are required for membrane 
trafficking and lipid droplet formation, and are implicated in diseases including pathogen 
invasion and cerebellar ataxia respectively.  
 I first describe the structural mechanism for how a Chlamydial effector protein called 
IncE hijacks and recruits SNX5 related proteins to the bacterial inclusion membrane during 
Chlamydial infection (Chapter 2). Using X-ray crystallography, I demonstrate that the C-
terminal region of IncE forms a β-hairpin structure and binds to a unique α-helical insertion 
on the PX domain of SNX5, which is a separate site from the canonical PX lipid-binding 
site. Using isothermal titration calorimetry, I also investigate the binding mechanisms of the 
SNX5 homologs, SNX6 and SNX32 to IncE, and demonstrate that these three proteins 
share a common binding mechanism. These results suggest that the IncE protein mimics 
other SNX5-related proteins, where SNX5 PX might be functioning as a protein-binding 
scaffold that could potentially orchestrate the trafficking of certain transmembrane 
receptors. 
The research presented in Chapter 3 extends the work described in Chapter 2 
confirming the IncE binding site in the SNX32 PX domain using X-ray crystallography. The 
crystal structure of SNX32 PX-IncE complex not only confirmed the biophysical data from 
chapter 2, but also revealed the binding mechanism to be identical to the SNX5PX-IncE 
binding. In addition, this is the first reported structure of the SNX32 protein in either an apo 
or ligand bound state. This result further strengthens the idea that SNX-BAR proteins can 
act as receptor recyclers in the cell. 
In Chapter 4 using biophysical and structural studies, I next investigated the 
potential functional role of the SNX-BAR proteins in transmembrane cargo trafficking. My 
biophysical experiments directly confirmed the recent indirect proteomic studies that 
 iii 
suggested cargos including CIMPR, IGF1R and SEMAC can bind to SNX-BAR proteins, 
and my first low-resolution crystal structure of the SNX5 PX domain with a transmembrane 
cargo, CIMPR, further confirms my hypothesis that endogenous human transmembrane 
cargos binds SNX5 related proteins in an analogous manner to IncE. Even though CIMPR 
does not possess sequence similarity with IncE, the identified hydrophobic patch in SNX5 
is required and sufficient for the binding to the CIMPR peptide.  
In Chapter 5, I explore the idea of synthesizing cyclic peptides based on my 
structure of the linear IncE peptide, which when bound to SNX-BAR proteins I showed 
forms a β-hairpin. The N- and C-termini of IncE were linked through various 
macrocyclisation approaches, and this yielded a cyclic IncE derived peptide that binds to 
SNX5 related SNX-BAR proteins with a nanomolar binding affinity that is 30x higher than 
the standard IncE peptide, and ~300x higher than cellular cargo molecules. I further 
demonstrate the ability of this cyclic peptide to inhibit the binding of a transmembrane 
cargo, CIMPR to SNX5 in vitro. 
In Chapter 6, I describe my initial studies regarding whether the RGS domains of 
SNX-RGS proteins possess GTPase activating protein (GAP) activity for the small 
GTPase Gαs. My studies reveal that RGS domains of SNX13, SNX14 and SNX25 binds to 
Gαs, but do not possess GAP activity. My results lead to me to speculate that since SNX-
RGS proteins bind to Gαs but do not regulate its GDP/GTP-bound activity states, these 
proteins may still act as negative regulators of Gαs signaling through ways that are yet to 
be explored. 
In Chapter 7 I provide a summary of my attempts to successfully express and purify 
the structurally uncharacterized PXA domain from the SNX-RGS subfamily, which is 
directly implicated in lipid droplet biogenesis. My trials have yielded soluble PXA protein 
and initial crystal hits, which provides a solid foundation for further structural and functional 
studies of this domain.  
 Finally, in Chapter 8 I provide an overall summary of my work, both outcomes and 
future directions. Overall, my studies have revealed the crucial role of PX domains not only 
in membrane interactions but in direct protein-protein interactions required for cargo 
sorting, provides insights into how SNX proteins contribute to pathogen invasion and other 
diseases, and how structural information can be used to target these proteins with peptide 
tools in functional studies and in potential therapeutic approaches.  
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     Chapter 1 
Introduction 
1.1 Endocytosis and the endosomal system 
In 1963, Christian de Duve formulated the word “endocytosis” to describe the process by 
which eukaryotic cells internalise proteins, lipids, large particles and fluids from the cell 
surface into the cell cytoplasm (1). Endocytosis is essential for maintaining cellular 
homeostasis. Defects in endocytosis and underlying membrane trafficking pathways can 
lead to many different human diseases. The most well characterised endocytic process is 
receptor-mediated or clathrin-dependent endocytosis. However, the ultimate destination of 
all endocytic carriers is the intracellular endosomal system, where endocytosed material is 
sorted into different pathways of recycling, processing and degradation. 
1.1.1. Receptor-mediated endocytosis and protein sorting 
Receptor-mediated endocytosis or clathrin-dependent endocytosis provides a method for 
selective uptake of specific macromolecules, and this process involves the inward budding 
of certain domains of the plasma membrane. The macromolecules to be internalised are 
recognised by specific endocytic machinery, consisting of adaptor proteins that recognise 
structural motifs in the cytoplasmic domains of the cargo proteins that link them to the 
polymeric scaffolding protein called clathrin. This leads to formation of membrane 
invaginations called clathrin-coated pits, which bud away from the plasma membrane 
through the action of the dynamin GTPase protein. Cargo-containing vesicles move into 
the cell and fuse with the early endosomes (or sorting endosomes), an endomembrane 
compartment, which is enriched in the membrane lipid phosphatidylinositol-3-phosphate 
(PtdIns3P) (2,3). 
In the early endosomal compartment, endosome-associated proteins sort the 
cargoes to be delivered to their appropriate destinations. Cargoes are either recycled back 
to the cell surface for reuse (directly from sorting endosomes or indirectly through recycling 
endosomal carriers), or to the trans- Golgi network (which allows access to the secretory 
pathway), or are degraded in lysosomes (where the cargoes are transported from early 
endosomes to the lysosomes through late endosomes). Thus early endosomes or sorting 
endosomes play an important role as a sorting station where the fates of internalised 
proteins and lipids (regardless of the mode of internalisation) are determined (3-5). 
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Many receptors and ligands that are internalised using receptor-mediated endocytosis 
have been studied in the context of endocytic recycling. Among the best characterised 
include proteins involved in nutrient uptake such as low-density lipoprotein receptor 
(LDLR) (Fig. 1), the transferrin receptor (TfR), glucose transporter 4 (GLUT4), and 
proteins involved in signalling such as G-protein couples receptors (GPCRs), and receptor 
tyrosine kinases (RTKs) (4,5).  
 
Figure 1. Schematic diagram depicting the fate of a typical membrane protein low-density 
lipoprotein receptor (LDLR) 1) LDLRs are synthesised by ribosomes and folded in the endoplasmic 
reticulum (ER), 2-3) receptors are then modified in the Golgi and (3a) transported to the plasma 
membrane enroute recycling 4) when the LDL ligand binds to LDLR on the cell membrane the 
receptor- ligand complex gets internalised in a clathrin-coated pit, 5) this pinches off and becomes 
a clathrin-coated vesicle which then moves into the cell and 6) enters the early endosome and 
some are directly moved to the recycling endosomes (3b) which gets recycled back to the plasma 
membrane directly through recycling endosome or  7) this endosome fuses with the late endosome 
and because of the low pH (around 5) LDL particles dissociate from LDLRs. A vesicle or tubule 
that contains recycling receptors buds off and returns the LDLR back to the plasma membrane, 8) 
the late endosome containing the LDL fuses with the lysosome where LDL is degraded to release 
cholesterol and amino acids (scheme adapted from (6)). 
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1.2 Significance of endosomal trafficking 
Endocytic recycling and trafficking pathways control the balance between the late 
endosomal degradation and cargo retrieval, which in turn maintains the proper protein and 
lipid composition of the plasma membrane and various organelles such as lysosomes and 
the Golgi. Thus it is crucial in many major cellular processes including cell signaling, 
nutrient uptake, adhesion and all forms of cellular homeostasis (4). While our 
understanding of endosomal sorting and signaling has improved in recent years, it still 
remains limited and many questions remain unanswered.  
The importance of endosomal homeostasis is highlighted by the fact that many 
different human diseases are caused by defects in endosomal trafficking and regulation 
(7). Alterations in expression or mutations in a number of proteins involved in endosomal 
sorting are responsible for a variety of disorders related to dysfunction in specific 
endosomal pathways. One of the major protein families that play a critical role in 
endosomal sorting and cell signaling are the sorting nexins (SNXs) (7,8) 
1.3 Sorting nexins (SNXs) and endosomal sorting 
SNX proteins are members of a larger family of proteins called PX-domain proteins, 
defined by the presence of a phosphatidylinositol phospholipid (or phosphoinositide)-
binding module; the Phox-homology (PX) domain.  
 
  Figure 2. Classification of PX-domain proteins. Adapted from Reference (8). 
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Currently there are 49 PX domain-containing proteins identified in the mammalian 
genome. Teasdale and Collins (2012), published a revised classification of PX-domain 
proteins based on sequence homology and known domains, as well as their conserved 
secondary structure predictions (8) (Fig. 2). The best-characterised role of the PX domain 
is to bind to phosphoinositide lipids and promote the association of the PX-domain 
proteins with various membranes of the endocytic and secretory system. The most 
common lipid bound by the PX domain is phosphatidylinositol-3-phosphate (PtdIns3P). 
Thus this domain is frequently involved in targeting SNXs to early endosomal 
compartments that are enriched in PtdIns3P due to the activity of PtdIns-3 lipid kinases. 
SNXs play critical roles in endocytosis, endosomal sorting and membrane trafficking (Fig. 
3). 
 
Figure 3. Some of the known roles of sorting nexins (SNXs) in endosomal sorting and membrane 
signalling. 1) To its return to the plasma membrane, Transferrin receptor (TfR) is sorted into 
recycling endosomes. 2) Through path 1, certain tyrosine kinase receptors (TKRs) and G-protein-
coupled receptors (GPCRs) are recycled. Sometimes they are seen in late endosomes (2) to be 
transported for lysosomal degradation. 3) Pathway of hydrolases to and from the trans-Golgi 
network (TGN) to the late endosome, which are transported to the lysosome. 4) Sorting of proteins 
in the TGN for delivery to the plasma membrane. 5) SNX27-retromer promotes a fast recycling 
route where it transports cargoes containing PDZbms from endosomes to the plasma membrane.  
 6 
Most SNXs contain one or more additional domains other than the PX domain (Fig. 2), 
which allows them to perform a wide variety of functions that include mediating protein-
protein interactions, membrane remodelling, and lipid metabolism, as well as many other 
functions that remain unknown (7,8). With the fundamental roles of SNXs in endosomal 
sorting and signalling, comes their link to many diseases such as cancer, 
neurodegeneration, heart disease and chromosomal disorders (5,7,8). 
During my PhD I have focussed on studying the structure and function of SNX 
proteins from two distinct subfamilies.  
(ii) The first of these are the SNX-BAR proteins SNX5, SNX6 and SNX32, which 
contain a PX domain and an additional Bin/amphiphysin/Rvs (BAR) domain. Recent 
evidence suggests that these proteins might act as specific adaptors that bind and 
transport selected transmembrane cargos. Effector proteins that are secreted by the 
bacterial pathogen Chlamydia trachomatis also hijack specific SNX-BAR proteins.  
(i) The second subfamily I have studied are the unique transmembrane SNX-RGS 
proteins, SNX13, SNX14, SNX19 and SNX25, which play an important role in mediating 
interactions between the membranes of the ER, lipid droplets (LDs), and endosomal 
compartments, and potentially act as GAP proteins for Gαs subunits.  
 
Further details about these SNX sub-families are given in the following sections.  
1.4 The SNX-BAR protein family 
The largest and arguably best-studied sub-family of SNX proteins is the SNX-BAR sub-
family. This group consists of SNX1, SNX2, SNX4, SNX5, SNX6, SNX7, SNX8, SNX30 
and SNX32 (Fig. 2). The N-terminal PX domain within these proteins is generally believed 
to be the primary phosphoinositide-binding domain directing specific organelle recruitment. 
The C-terminal BAR (Bin/Amphiphysin/Rvs) domain is a protein motif that consists of three 
α-helices that dimerises and forms a rigid banana-shaped coiled-coil structure (Fig. 4). 
The concave surface is composed of positively charged basic residues that associate with 
negatively charged membrane phospholipids through electrostatic interactions. When 
coupled to the phosphoinositide-binding PX domain, the dimeric BAR domain structure 
can promote membrane curvature leading to membrane tubulation. This sub-family is 
evolutionarily conserved from yeast to humans and is important in endocytosis as well as 
in membrane sorting events (8-10). It is believed that different combinations of 
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homodimeric and heterodimeric SNX-BAR proteins may control different sorting events 
within the cell, although this remains poorly understood. 
  One of the major functions of the SNX-BAR proteins is to regulate tubular-based 
endosomal sorting. SNX1, SNX2, SNX5 and SNX6 form specific heterodimeric 
combinations, where SNX1 or SNX2 form heterodimers with SNX5 or SNX6 (11). A third 
brain specific homologue of SNX5 and SNX6 called SNX32 may function similarly, but it 
has not been studied to date. Their role in endosomal trafficking is often coupled to their 
interaction with a trimeric protein complex called ‘retromer’. Early studies on retromer 
demonstrated their role in regulation of cargo proteins from endosomes to the trans-Golgi 
network (TGN), allowing cargo retrieval away from late endosomal/lysosomal degradative 
pathway (12,13). Out of the many retromer cargoes, the best studied are the acid 
hydrolase receptors, cation-independent mannose-6–phosphate (CI-MPR) in mammals, 
and vacuolar protein sorting 10 (Vps10) in yeast. These receptor cargos are essential for 
lysosomal activity because they deliver acid hydrolase enzymes from the TGN to the 
vacuole (in yeast) or lysosome (in mammals). After releasing their substrates, these 
receptors recycle back to TGN via retromer/SNX-BAR interactions to facilitate future 
cargo-hydrolase transportation (14). Retromer/SNX-BAR complexes are also important for 
transport of other cargoes such as signalling molecules like Wntless (receptor for Wnt 
morphogens), SNAREs and SorLA (receptor for amyloid precursor protein) (9,10).  
1.4.1 The Retromer Complex 
A major regulator of retrograde trafficking (endosome-to-Golgi retrograde retrieval) is the 
SNX-BAR/retromer complex. In yeast this consists of the retromer subunits Vps26p, 
Vps29p, Vps35p, coupled to the heterodimeric SNX-BAR complex of Vps5p and Vps17p. 
Unpublished evidence from our lab shows that Vps26p, Vps29p and Vps35p (trimer) form 
an exterior scaffolding subcomplex, while Vps5p and Vps17p are the yeast SNX-BAR 
homologues that dimerise and mediate membrane interaction and remodeling (B. Collins, 
unpublished), which is slightly different to the schematic model shown in Fig. 4.  
In mammals, the SNX-BAR dimer binds to specific phosphatidylinositol lipids to 
determine its subcellular membrane association and thus helps in recruiting the Vps trimer 
to endosomal compartments. The mammalian counterpart of retromer consists of the Vps 
trimer (Vps26, Vps29 and Vps35) and alternative membrane interacting SNX-BAR dimers. 
These dimers consists of the Vps5p orthologues SNX1 or SNX2 and the Vps17p 
orthologues SNX5 or SNX6 (10,17). In the SNX dimer, SNX1 and SNX2 are 
interchangeable Vps5 orthologs (17). The highly similar proteins, SNX5 and SNX6, are 
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shown to have overlapping functions where they both have similar roles in the retrograde 
sorting of mannose-6–phosphate receptor, and they both form heteromeric complexes 
with the retromer-associated SNX1 protein. Thus SNX5 and SNX6 are thought to be 
functionally interchangeable orthologs of Vps17 in mammalian cells (15,18). 
 
 
 
 
 
 
A B 
Figure 4. Current model of SNX-BAR/retromer-mediated trafficking. A) In mammals SNX-BAR 
heterodimers (SNX1/SNX5 or SNX1/SNX6; SNX2/SNX5 or SNX2/SNX6) form transport coats in 
complex with the cargo-selective VPS26-VPS29-VPS35 subcomplex. SNX-BAR proteins promote 
the endosomal membrane curvature resulting in the formation of membrane tubules that transport 
cargo to the trans-Golgi network (TGN) (adapted from (15)); (B) Based on the accessory protein 
bound, there are three distinct retromer mediated trafficking pathways. One of the examples shown 
here is the SNX-BAR-retromer mediated retrograde trafficking of cargo called CI-MPR from the 
endosomes to the TGN (16). 
 
The retrograde machinery is important to maintain the distribution of lipids and 
proteins in endosomes and the TGN. Defects in retromer function are known to be 
involved in neurodegenerative disorders including Alzheimer’s and Parkinson’s (19-22). 
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Although currently it is not entirely clear which specific neuronal trafficking pathways are 
defective in these patients, the build-up of toxic species due to perturbed lysosomal 
function is believed to play an important part in disease progression. In addition, several 
plant, bacterial and viral proteins are known to depend on endocytosis and retromer-
dependent trafficking for their host cell entry and delivery to target organelles (10).  
1.4.2 The unusual structure of the SNX5 PX domain 
The PX domain is a phosphoinositide-binding domain, approximately 120 amino acids in 
length, and composed of a three-stranded β-sheet followed immediately by three α-
helices. The first and second α-helices are linked by an extended structure that is rich in 
Proline residues, called the polyPro loop (ΨPxxPxK loop; Ψ is a hydrophobic side-chain). 
Previous crystal structures of PX domains of SNX9 (23) and p40phox (24) in complex with 
PtdIns3P reveal the presence of four side chains that are required for binding the 
headgroup of the endosomal phosphoinositide lipid PtdIns3P. They are Arg, Tyr, Lys and 
Arg residues marked in Fig. 5 as 1, 2, 3 and 4 respectively. These residues are conserved 
in most PX domains including in SNX1 and SNX2. However, they are completely absent in 
SNX5, SNX6 and its closely related homologue SNX32. Moreover, SNX5, SNX6 and 
SNX32 contain a 30-residue insertion immediately after the ΨPxxPxK loop region that 
structurally forms an extended helix-turn-helix motif (Fig. 5 and Fig. 6) (8,25). These 
features set these proteins apart from the rest of the SNX family members.  
 
Figure 5. Amino acid sequence alignment of PX- domains of mammalian SNX- families. 
The X-ray crystal structure of the SNX5-PX domain confirms the lack of conserved 
residues required to form a pocket for PtdIns3P-binding, and in addition shows the 
structural insertion of the extended α-helical region obstructs the typical phospholipid 
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interaction site. Together these features suggest an inability to interact with 
phosphoinositide lipids in the same way that other PX-domain proteins do. Although there 
is some evidence from nuclear magnetic resonance (NMR) spectroscopy experiments for 
the weak association of the SNX5 PX domain with the lipid PtdIns(4,5)P2 (25) the structure 
of the SNX5 PX domain suggests this is likely an artefact and not functionally significant 
(Fig. 6B) It has remained unclear what the functional significance of this α-helical insertion 
is, other than it may contribute to an altered membrane binding and remodeling activity by 
these SNX-BAR proteins when forming heterodimers with SNX1 or SNX2. As described in 
this thesis however, I have now shown that it plays a critical role as a protein interaction 
site. 
 
Figure 6. (A) X-ray crystal structures of SNX5PX domain (PDB: 3HPB) and p40-PX domain (PDB: 
1H6H) and their best fit superposition (on the right) showing the most striking difference of α-
helical insertion region (circled) in SNX5-PX domain; (B) Phosphoinositide binding sites in the (left) 
p40-PX/PtdIns3P complex that shows a perfect PtdIns3P binding pocket and (right) a lack of 
binding pocket in SNX5-PX due to the obstruction caused by the α-helical region (figure idea taken 
from (25)). 
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1.4.3 Chlamydia trachomatis, membrane inclusion proteins (Incs) and host cell 
trafficking 
Although the SNX-BAR proteins play important roles in normal cellular function, two recent 
studies also indicate a potentially important role for SNX5 in host cell invasion by the 
bacterial pathogen Chlamydia trachomatis (26,27). As mentioned above, there are many 
plant, bacterial, and viral proteins that depend on endocytosis for their successful host cell 
entry and thus survival within the cell. Of the many pathogens that hijack retrograde 
trafficking pathways for effective infection C. trachomatis is one of the most striking 
examples, as well as being an important human pathogen that causes 100 million new 
infections each year worldwide. C. trachomatis is a major reason behind various human 
diseases for which no effective vaccine exists. The diseases include noncongenital 
blindness worldwide, sexually transmitted diseases and noncongenital infertility in Western 
countries (28,29). 
Once inside the human cell, C. trachomatis replicates within a membrane-bound 
vacuole called the inclusion. The intracellular cycle of development is common among all 
Chlamydiae, and alternates between two bacterial forms; the elementary body (EB), which 
is infectious but non-dividing, and the reticulate body (RB), which is non-infectious but 
dividing. Upon internalization of EBs by endocytic pathways, the bacteria reside in the 
inclusion, which is separated from the canonical endo-lysosomal organelles preventing 
normal cellular degradation and shielding the bacteria from innate cellular immune factors. 
The EBs then differentiate into RBs and thus the replication commences inside the 
growing inclusion. After replicating for 24-72 hours inside the ever-enlarging inclusion, the 
RBs re-differentiate to EBs, which are then released into the neighboring cells ready to 
infect (27,30). The surrounding inclusion membrane acts as the interface between the host 
cell and the bacteria. 
 Chlamydia genomes, despite their small size, encode a large number of genes that 
encode secreted virulence effectors. Soon after the beginning of chlamydial protein 
synthesis, the inclusion membrane is extensively modified through insertion of numerous 
type III secreted effector proteins called inclusion membrane proteins (Incs). Incs are a 
large family of proteins, which are highly diverse and expressed only during the context of 
infection and are specifically localised to the inclusion membrane. Incs possess little 
primary amino acid sequence similarity, however they are all composed of a cytoplasmic N 
terminal domain and a cytoplasmic C-terminal domain, separated by two closely spaced 
transmembrane regions connected by a short loop (Fig. 7). After inserting into the 
inclusion membrane, they position at the host-pathogen interface and extend their termini 
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into the host cytoplasm. There are 59 putative Incs in C. trachomatis and their functions 
are largely unknown. One function may be to interact with the host cell machinery to help 
with the chlamydial survival in the cell. Even though Incs are critical for the Chlamydial 
infection and the host-pathogen interactions, only a few host targets have been identified 
(31,32). As mentioned above it was recently found that SNX5 is targeted to chlamydial 
inclusions through the binding of one such inclusion protein called IncE (26). 
 
Figure 7. Predicted topology of Inc proteins in Chlamydia inclusion membrane. 
1.4.4 SNX5 and SNX6 interact with the Chlamydial inclusion protein IncE 
Recently Mirrashidi et al. reported a protein-protein interaction network between human 
host cell proteins and chlamydial Inc proteins identified by affinity purification and mass 
spectroscopy. This network revealed interactions between IncE (also called CT116) and 
SNX-BAR proteins that were subsequently confirmed in vivo and in vitro. These studies 
found that the IncE C-terminal cytoplasmic region (IncE 101-132) was necessary and 
sufficient to bind specifically to SNX-BAR proteins in immunoprecipitations. PSIPRED 
analysis suggested the 101-132 residues of IncE contain a β-hairpin structure, and the 
truncations demonstrated that this structure was required for SNX5 binding. IncE 101-132 
demonstrated no binding to the PX-domains of SNX1 and SNX2, whereas it bound directly 
to the PX domains of SNX5 and SNX6 (26).  
As described in the previous section SNX5 and SNX6 PX domains contain a unique 
30 amino acid long α-helical insertion, which is absent in SNX1 and SNX2. We speculated 
that it is because of this distinction that IncE specifically recognises SNX5 and SNX6, and 
not SNX1 and SNX2 (26). Further investigation is required to understand the molecular 
details of this interaction. 
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The role of SNX5 and/or SNX6 in C. trachamotis infection is still not clear. IncE 
directly recruits SNX5 and SNX6 to the inclusion membrane to form membrane tubules 
(and SNX1 and SNX2 via indirect heterodimerisation), and it was found by Mirrashidi et al. 
(2015) that SNX5/SNX6 depletion increases infectious progeny production. This suggests 
a role for the SNX-BAR proteins in restricting chlamydial infection. Retrograde trafficking 
might be involved in the recognition or clearance of Chlamydia. Retromer is implicated in 
maintaining the integrity of the trans-Golgi. Thus the IncE-mediated recruitment of retromer 
SNX-BARs away from the endosomal compartments may play a role in Golgi 
fragmentation observed during Chlamydia infection (33). This process promotes lipid 
acquisition by C. trachomatis, which may lead to enhanced progeny production that is 
exacerbated upon further SNX5/SNX6 depletion (26,33). Mirrashidi et al. reported that 
IncE and SNX-BARs colocalise on the inclusion membrane and tubules, and that ectopic 
expression of IncE is sufficient to induce SNX-BAR-mediated membrane tubulation. 
Depletion of SNX-BAR components limits inclusion tubulation (34).  
Studies on other intracellular pathogens have demonstrated that other strategies 
can also be employed to repurpose retromer and SNX-mediated trafficking. Silencing of 
retromer components abrogates HIV, HPV, Coxiella and Salmonella infections (26,35-37). 
In addition to retromer SNX-BAR proteins, Salmonella is found to recruit the VPS complex. 
On the other hand, Chlamydia IncE recruits only retromer SNX-BAR proteins. Based on 
this, Mirrashidi et al. developed a model of where IncE directly interacts with SNX5 and 
SNX6 to recruit the SNX-BAR proteins to the inclusion membrane, which can result in two 
functional consequences; a) inclusion membrane tubulation can be induced by the SNX-
BAR proteins due to the functional ability of the proteins with BAR domains to induce 
membrane curvature, b) the segregation and recruitment of SNX-BAR proteins may result 
in the dysfunction of normal retromer functions, thus disabling them from imposing a 
restriction on C. trachomatis and thus the infection (Fig. 8). 
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Figure 8. Figure demonstrating the binding model of IncE to SNX5/SNX6 and possibly SNX32. 
From reference (26). 
1.5. The SNX-RGS protein family 
The SNX-RGS proteins are a SNX sub-family that are conserved in all eukaryotes. The 
human genome encodes four homologues SNX13, SNX14, SNX19 and SNX25, while 
Saccharomyces cerevisiae possess a single homologue called Mdm1p. These proteins 
have a conserved architecture, composed of two N-terminal transmembrane helices, an N-
terminal PX-associated domain (PXA), a regulator of G-protein coupled receptor (RGS) 
domain (present in all proteins except SNX19), a central PX domain, and a C-terminal PX-
associated domain (PXC) (8,38) (Fig. 9). Note that the PXA and PXC domains are not 
related in sequence or structure to each other. Out of the four globular domains in SNX-
RGS proteins, the PX and RGS domains are the best characterised, while the structures 
and the functions of the PXA and PXC domains are completely unknown.  
Mitochondrial distribution and morphology 1 protein (Mdm1p) is the SNX-RGS 
protein found in S. cerevesiae. Secondary structure predictions of Mdm1p indicate the 
presence of identical domain organisation to mammalian SNX-RGS proteins. The 
Drosophila melanogaster snazarus protein also contains all the putative domains, thus 
making Mdm1p and snazarus evolutionary homologs of the mammalian SNX-RGS 
proteins (38). 
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Figure 9. Diagram of human (SNX13, SNX14, SNX19, SNX25) and yeast (Mdm1p) SNX-RGS 
proteins showing PXA, RGS, PX and PXC domains. Potential ligands for the domains are 
indicated above. Adapted from (38). 
1.5.1 Regulator of G-protein signalling (RGS) domain 
G-protein coupled receptors (GPCRs) consist of seven transmembrane α-helical 
domains with an N-terminal extracellular and a C-terminal intracellular tail. Upon binding of 
a ligand the GPCRs are activated, which leads to a conformational change that allows the 
activation of associated Gα-GDP/ Gβγ complexes by the release of GDP and thus allowing 
the binding of GTP on the Gα subunit (39,40). When bound to GDP, the heterotrimeric 
GTP-binding proteins (G-proteins) are considered to be in the off state and when bound to 
GTP they are in the on or activated state that is able to bind to subsequent effector 
molecules. The GTP-bound state of Gα subunits controls the duration of G-protein signals 
downstream of the activation of associated GPCRs (Fig. 10). The RGS domain is a small, 
α-helical structure that serves as a GTPase-activating protein (GAP) for Gα subunits of 
heterotrimeric G-proteins. RGS domains bind to these activated Gα subunits and act as 
GAPs, which accelerates the hydrolysis of GTP to GDP and switches off GPCR signalling 
(Fig. 10) (38,41,42). 
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Figure 10. Schematic diagram depicting how RGS proteins regulate GPCR signaling. Adapted 
from (43). 
1.5.1.1 Structural insight into the mechanism of intrinsic GTP hydrolysis by Gα 
subunits 
The inactive Gα subunit interacts with GDP within a nucleotide-binding pocket that 
contains residues from both the Ras-like domain and the α-helical domain, which contains 
a six-helix bundle. When activated, the GDP gets exchanged for GTP and the residues in 
the binding pocket interact with the γ-phosphoryl group of the GTP, which induces a 
structural rearrangement within three switch regions (SI–SIII) of Gα. X-ray crystallographic 
data from Gα transition state-mimetic forms (i.e., Gα bound to GDP and AlF4−) have shed 
light into the structural mechanism behind the intrinsic GTP hydrolysis by Gα (44) (Fig. 
11).  
 
Figure 11. Structural mechanism of 
intrinsic GTP hydrolysis by Gα subunits. 
(A) The GDP (magenta) binding site is 
located between the Ras-domain (blue) 
and the α-helical domain (green) of the 
Gα subunit (PDB: 1GP2). (B) Structural 
differences between GDP- and GTP- 
bound states. (C) Structural mechanism 
of GTP hydrolysis by Gα. Figure adapted 
from (45) 
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The hydrolysis of GTP reaction is promoted by three Gα amino acids that are 
conserved. The critical nucleophilic water molecule required for the GTP γ-phosphate 
hydrolysis is coordinated by the Gln-204 residue in switch II, whereas the switch I residues 
Arg-178 and Thr-181 stabilizes the leaving group and the Thr-181 coordinates a bound 
Mg2+ ion (44) (Fig. 11). 
1.5.1.2 Structural insights into how RGS domain stabilise a Gα subunit 
The RGS domain is composed of nine α-helices that bind to the Gα transition state for 
GTP hydrolysis. The nine helices consists of two subdomains, the first one is composed of 
helices α1, 2, 3, 8, and 9; the second subdomain consists of helices α4, 5, 6, and 7. Each 
subdomain is antiparallel to each other. The unrelated GAPs for small G-proteins have a 
critical arginine at the active site that contributes to the GTP hydrolysis. In contrast, RGS 
proteins do not contribute a specific residue to the nucleotide-binding pocket for the 
catalytic mechanism. X-ray crystallographic and NMR studies have shed light into the 
structures of RGS proteins, as well as the mechanism by which they interact with and 
regulate Gα proteins. Gα-GDP bound with the planar ion aluminum tetrafluoride (AlF4−) 
mimics the transition state of Gα (GTP → GDP + Pi). RGS proteins are typically selective 
for binding to this transition state of Gα (46,47).  
There are three critical contacts formed between RGS proteins and Gα. As shown 
in Fig. 12, the side chain of Asn-122 residue in RGS8 forms a hydrogen bond with the 
important Gln-204 residue of Gα, which is responsible for GTP hydrolysis. This hydrogen 
bond enables the Gln-204 residue to stabilize the GTP γ-phosphate that is being 
hydrolyzed. Asn-82 residue (RGS8) interacts with the hydroxyl group of Thr-182 (Gαi3) 
residue from switch I thus enabling the side-chain hydroxyl to contact the Lys-210 (Gαi3) 
residue from switch II. These interactions locks the Gα switches I and II into their transition 
state conformations, thus allowing accelerated GTPase activity. An Asp-157 residue 
(RGS8) that is conserved in all RGS proteins (except RGS2), functions as the stabilizer of 
the backbone amine of the Gα Thr-182 residue (switch I) to allow the side-chain hydroxyl 
group of the adjacent Thr-181 residue to stabilize the Mg2+ cation [35](47) (Fig. 12). 
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Figure 12. Structural mechanism behind the stabilisation of Gα by RGS proteins using a diagram 
of the RGS8/Gαi3 structure. The Gαi3 α-helical domain (green), the Ras-like domain (dark blue), the 
three switch regions (SI, SII, and SIII) (cyan), the nucleotide (magenta), AlF4− (red), Mg2+ (yellow) 
and RGS8 (orange) are shown in the figure. Figure adapted from (45). 
1.5.1.3. The RGS domains of SNX-RGS proteins  
All proteins except SNX19 have the RGS domain upstream of the PX domain (Fig. 9). 
Previous studies have reported that SNX13 has GAP activity specific for the Gαs isoforms 
of the heterotrimeric G-proteins, which are involved in cAMP signalling from GPCRs such 
as serotonin and β-adrenergic receptors (48). SNX13 is shown to bind Gαs and promote a 
20-fold increase in the intrinsic catalytic rate of GTP hydrolysis; which in turn attenuates 
Gαs-mediated signalling (48). Until recently it was unknown whether the RGS domain from 
other SNX-RGS proteins share the same GAP activity as SNX13. Ha et al. (2015) studied 
the activity of the SNX14 RGS domain and found that it does not appear to share this GAP 
activity. But it did appear to bind specifically to and sequester Gαs and thus inhibit 
downstream cAMP production, essentially resulting in a similar functional outcome to 
activating GTP hydrolysis (49). Whether the SNX25 RGS domain possesses GAP or Gα 
binding activity remains unknown, but has been reported to be involved in transforming 
growth factor-β (TGF-β) signalling, lysosomal trafficking and degradation of TGF-β 
receptor 1 (TβRI) by regulating interaction of with TβRI (38,49).  
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1.5.2 Structural insight into the PX domains of SNX-RGS proteins 
Even though most PX domains are commonly thought to bind the early endosomal lipid 
marker PtdIns3P, our lab showed that mammalian SNX-RGS proteins have a wider range 
of phosphoinositide binding preferences. This may direct recruitment to specific 
membranes, to control their roles in membrane trafficking and signalling at different cellular 
compartments (8,38).  
A 
B 
Figure 13. PX domains of SNX-RGS proteins. (A) Amino acid sequence alignment of human and 
mouse SNX-RGS PX domains showing the PtdIns3P binding residues marked as 1, 2, 3 and 4. (B) 
Supernatant (S) and pellet (P) fractions from the liposome pelleting assay of human SNX-PX PX 
domain with PtdIns3P, and the X-ray crystal structures of SNX19 (4P2I) and SNX14 (4PQO) PX 
domains (taken from (38)). 
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Previous crystal structures of PX domains of SNX9 (23) and p40phox (24) in 
complex with PtdIns3P reveal the presence of four side chains that are required for 
PtdIns3P binding. They are Arg, Tyr, Lys and Arg residues marked in Fig. 13A as 1, 2, 3 
and 4 respectively. These residues bind to the 3-phosphate, inositol ring, 1-phosphate and 
4-,5-hydroxyls of PtdIns3P respectively. SNX13 and SNX19 contain these critical residues 
for PtdIns3P binding, whereas they are not all conserved in SNX14 and SNX19. As seen 
in Fig. 13B SNX14 contains a Lys instead of Arg at site 4, whereas SNX25 possesses a 
Leu at site 2 instead of Tyr and Ser instead of Arg at site 4. These studies suggested a 
significantly altered binding pocket in SNX14 and SNX25, which will make these proteins 
unable to coordinate the 3’ phosphorylated phosphoinositide in their binding pocket in the 
same way as SNX13 and SNX19 (38). 
Liposome pelleting assays and NMR studies of phosphoinositide binding confirmed 
the predictions from SNX-RGS PX domain sequences and X-ray crystallographic 
structures. SNX13 and SNX19 were found to bind to membranes supplemented with 
PtdIns3P, whereas SNX14 and SNX25 did not show significant binding to this endosomal 
phosphoinositide (38). Unpublished studies from the Collins lab indicate that while SNX14 
does not bind to any phosphoinositides, SNX25 actually binds to a large variety of 
phospholipids via a novel lipid-binding site distinct from the canonical lipid binding site (C. 
Mas and B. Collins unpublished data). The functional significance of these divergent 
phosphoinositide binding properties remains to be explored. 
1.5.3 PX-associated A (PXA) and PX-associated C (PXC) domains  
The PXA domain sits N-terminal to the RGS and PX domains, whereas the PXC domain 
lies downstream to the PX domain in the C-terminal region (Fig. 9). The PXA domain is 
around 200 amino acids in length and the secondary structure predictions indicate this 
domain is α-helical. In SNX13 and SNX25, a short α-helical region called PXA’ follows 
PXA, which is around 50 amino acids long. The PXC domain is around 150 amino acids in 
length. Secondary structure predictions indicate that this domain is also α-helical, although 
PXA and PXC domains are not similar to each other in sequence (38). My PhD project 
focuses primarily on the PXA domain with the goal of understanding the structure and 
function of these novel domains. Details on the domains and the specific aims and 
significance of this project will be described towards the end of this chapter. 
1.5.4 What we know so far about the functions of SNX-RGS proteins  
The SNX-RGS family to-date remains relatively poorly characterized. The first study of 
these proteins examined SNX13.  
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SNX13 is highly expressed in heart, and also in skeletal muscle. SNX13 was first 
identified as a regulatory protein for Gαs, and was shown to form a heteromeric complex 
with both Gαs and Hrs on endosomes and co-operate in the lysosomal targeting of the 
EGFR (41,48). Thus SNX13 is suggested to have a bifunctional role both in signalling and 
trafficking. SNX13 knockout mice show embryonic lethality, and the embryo yolk-sac 
endoderm cells display disrupted endosome morphology thus suggesting a role in 
endosomal function that is critical for normal development. This also suggests that other 
SNX-RGS proteins are unable to compensate for SNX13 loss. Li et al. (2014), reported 
that SNX13 deficiency correlates with severe heart failure and thus might have a potential 
role in the regulation of cardiac function (50).  
 SNX14 shows a wider pattern of expression with significantly high expression in the 
nervous system, whereas complete absence of expression in heart and muscle where 
SNX13 is known to be abundant (49). Recently, Ha et al. (2015) demonstrated SNX14 is 
involved in accelerated internalization and degradation of 5-hydroxytryptamine (5-HT or 
serotonin) subtype 6 receptor (5-HT6R). The same report demonstrated that SNX14 
translocated to the plasma membrane from endosome-like punctate structures on addition 
of receptor-activating ligand 5-HT.  
SNX19 is expressed in a broad range of tissues including stomach, intestine and 
stronger levels in testis. This protein plays an important role in the formation of cartilage 
(chondrogenesis), and prevents cartilage degradation in osteoarthritis (38). 
SNX25 is highly expressed in lungs, and has been demonstrated to regulate 
transforming growth factor (TGF) signalling and lysosome trafficking, and degradation of 
TGF receptors (51). TGFβ signalling pathways are altered in epilepsy, and SNX25 also 
expresses in the temporal cortex and has been suggested to be associated with temporal 
lobe epilepsy (52). The closest homologue of SNX25 is the D. melanogaster snazarus, 
which has been identified to play a role in regulating longevity. Snazarus mutants 
demonstrate increased lifespans (8,53).  
1.5.5 The role of SNX-RGS proteins in disease 
While the precise cellular function of the SNX-RGS proteins is still unclear, recent studies 
have shown an important role for SNX14 in neurological development. This was shown by 
several labs who found that mutations in SNX14 lead to intellectual disability and 
cerebellar ataxia, with an associated loss of Purkinje cells in affected individuals (54-56). 
All disease causing SNX14 mutations result in protein truncations and are likely to 
significantly affect its expression, stability, and overall function. At the cellular level the 
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primary finding in both patients and zebrafish models (with SNX14 depletion by 
morpholino) was an accumulation of late endosomes and autophagic structures containing 
electron dense undigested cellular material (54,55). This suggests a defect in lysosomal 
maturation that results in defective breakdown through normal cellular processes. The 
precise mechanism behind this defect however is unknown. 
 In addition to the disease associated mutations in SNX14 a recent study has also 
shown that single-nucleotide polymorphisms in SNX25 are correlated with altered life-
expectancy in patients with Alzheimer’s disease caused by mutations in the presenilin 
protein (57). Again the mechanism for this is unclear but it is tempting to speculate that 
changes in SNX25 expression may affect the normal transport of the transmembrane 
presenilin-containing γ-secretase protein complex, and therefore affect its ability to cleave 
the amyloid precursor protein leading to amyloid β-peptide production. Further studies will 
be needed to confirm this.  
1.5.6 Are the RGS-SNX proteins a new family of endosomal membrane tethers? 
Until recently the only report on the functions of the poorly characterised PXA and PXC 
domains was that the SNX25 PXA domain was able to localise to EEA1-positive 
endosomes independently of the other domains and was important in the role of SNX25 in 
TGF-β receptor degradation (38,51). In 2014, a new study suggested that SNX13 
expression levels might be correlated with heart failure (50). This study found that 
reduction in SNX13 expression facilitated lysosomal degradative sorting of apoptosis 
repressor with caspase recruitment domain (ARC). This process leads to apoptotic 
pathway activation, and results in the loss of cardiac cells and thus a decrease in cardiac 
function (50). Expression of ARC in the heart has cardioprotective functions against 
development of heart failure by inhibiting intrinsic and extrinsic apoptotic death pathways 
through inhibiting caspase-8 activity (58). SNX13 is found to bind directly to ARC and acts 
as a regulator of the interaction between ARC and caspase-8. ARC sorting may be 
disrupted under reduced SNX13 expression conditions, thereby causing ARC trafficking 
defects and premature degradation with subsequent caspase-8 over-activation and 
apoptotic cardiomyocyte death. Domain deletion approaches in this study suggest that the 
N-terminal PXA, but not PX, RGS and the PXC domains of SNX13 mediates ARC 
endosomal sorting (50).  
In terms of understanding the precise function of the SNX-RGS proteins perhaps 
the most exciting finding came recently from studies of the yeast homologue Mdm1p (59). 
Henne et al. (2015), reported that Mdm1p deletion lead to the disruption of the normal 
 23 
contacts between the yeast endoplasmic reticulum (ER) and the vacuole/endosome, and 
also to a defect in normal sphingolipid metabolism. Conversely, overexpression of Mdm1p 
led to increased ER-vacuole tethering. This work suggests that the SNX-RGS proteins 
may act as novel interorganelle tethering proteins that localise to the ER via their N-
terminal transmembrane domains, and form contacts with endosomal membranes through 
the PX domain. A model for this is presented in Fig. 14. This might suggest that this 
protein family may represent a new class of ER-endosome tethers, mediating normal 
membrane trafficking and lipid transport and metabolism within the endomembrane 
system. 
 
 
Figure 14. (Top) Model for SNX-RGS proteins showing their potential role in interorganelle 
tethering and lipid metabolism. (Bottom) SNX-RGS protein model based on the recent findings. 
 
A more recent study from the same laboratory reports that the yeast ER–vacuole 
contact sites (NVJs) serve as sites for lipid droplet (LD) biogenesis in response to 
nutritional stress. Their studies points to the fact that the ER-vacuole tether protein Mdm1p 
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is sufficient to generate a LD associated ER–vacuole contact site. Mdm1p overexpression 
expands the NVJ and promotes LD production. It is suggested that the formation of LDs 
near the vacuole is a metabolic strategy to facilitate their efficient turnover by lipophagy 
during nutritional starvation. The loss of MDM1p may affect the organization or activity of 
the fatty acid-activating enzymes with which it is found to interact, or even the turnover 
rate of LDs by lipophagy at the vacuole (60). This recent finding regarding the role of 
Mdm1p at the ER-vacuole site in yeast may suggest that the mutations in SNX14 leading 
to neuronal defects in autophagy (54,55) are caused by defects in the ER-tethering 
process or disruption to the lipid droplet function. Neurological diseases are reported to 
cause accumulation of sphingolipids and vacuoles in intracellular granular-like deposits 
(59,61). Thus it is speculated that the disease-associated SNX14 alleles on top of 
perturbing ER-endolysosomal communication, may perturb lipid droplet biogenesis, 
contributing to the neurological disease.  
1.6 Aims and scope of this thesis 
Although the role of the PX domain in association with PtdIns3P has been studied in 
detail, the potential of PX domains to mediate protein-protein interactions is very poorly 
characterised. In addition, there is also a significant lack of knowledge regarding the 
structure and function of domains other than PX domains found within proteins of the SNX 
and PX family (8). A better understanding of the mechanisms of action of these additional 
domains is essential for understanding their roles in endosomal trafficking and signalling. 
This will also help us to determine whether SNXs are suitable as therapeutic targets, and if 
so how such interventions might be achieved. The SNX proteins, as described above, 
even though they fall under the same larger PX-protein family, play diverse roles in 
endosomal transport, remodelling and cell signalling. Thus the overall aim of my PhD 
project is to study the structure and function of SNX proteins from two distinct subfamilies. 
(i) SNX-BAR proteins: SNX5, SNX6 and SNX32, which contain an additional 
Bin/amphiphysin/Rvs (BAR) domain, display a novel ability to associate with secreted 
effector proteins of bacterial pathogens. 
By understanding the structural basis for IncE binding of SNX5, SNX6 and SNX32 
will enable us to understand how intracellular pathogens like Chlamydia and the proteins 
involved manipulate the host cell and mammalian retrograde pathway to cause infection. 
This work also provides the very first insights into how a PX domain binds to another 
protein rather than lipids. This also provides an idea that the PX-domains of SNX5, SNX6 
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and SNX32 can potentially regulate the recycling of certain transmembrane cargos. 
(ii) SNX-RGS proteins: SNX13, SNX14, SNX19 and SNX25, which may play an important 
role in mediating interactions between the membranes of the ER and endosomal 
compartments, and also potentially act as GAP proteins for Gαs subunits. 
When I began my PhD project, little was known about the precise cellular functions 
of the SNX-RGS proteins, except that they were highly conserved and are required for 
normal development. Thus the goal was to use structural biology in order to gain insights 
into the functions of these proteins, with a particular focus on the structurally 
uncharacterised PXA and PXC domains. Our initial hypothesis was that they could 
represent novel protein-protein interaction sites. New findings published in the last 24 
months that SNX-RGS proteins play a critical role in neurological disease, and that their 
function may be to regulate communications between ER, LDs and endosomal 
compartments are changing the way we view this protein family. In particular, it opens 
possibilities that the SNX-RGS proteins may not only participate in phosphoinositide and 
Gα interactions through PX and RGS domains but also can control membrane tethering 
and regulate lipid transfer. Thus my structural studies of the PXA domain will in the future 
be combined with analysing whether they participate in novel protein-protein interactions 
and/or protein-lipid binding. This project also involves understanding the GAP activity of 
the RGS domains for Gαs subunits. 
In chapter 2, (presented as a first author paper published in eLife), I provide the 
first insight into the structural mechanism behind the binding of IncE with the SNX5 PX 
domain. These findings are confirmed using biophysical techniques and also using cell 
studies performed in the lab of Assoc. Prof. Rohan Teasdale (UQ). Besides these findings 
we also shed light into the functional role of the highly conserved binding site on SNX5 PX 
domain. 
In chapter 3, (part of an article in the process of submission), we elucidate the high-
resolution structure of the SNX32 PX domain in complex with the Chlamydial protein IncE. 
The work validates the biophysical experiments presented in chapter 2 and also confirms 
the mode of binding here is the same as SNX5 PX-IncE binding.  
In chapter 4, (part of an article to be submitted), I build on the novel findings from 
my studies of the SNX5-IncE interaction. These studies identified a conserved surface 
groove in SNX5, SNX6 and SNX32 that I speculated might be involved in binding to 
endogenous proteins. This idea was subsequently supported by work from the lab of our 
collaborator Prof. Peter Cullen (University of Bristol). In chapter 4, I examine the direct 
binding of the SNX5/6/32 PX domains to putative cargo molecules identified by proteomics 
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in the lab of Prof. Peter Cullen. Biophysical experiments reveal peptide sequences 
conserved in several cargoes bind directly to the PX domains of these SNX-BAR proteins. 
I also provide crystallographic data presenting the first molecular explanation of how 
critical endosomal cargos bind to these selected SNX-BAR proteins.  
In chapter 5, (chapter to be submitted as an article), I further analyse the structural 
data from chapter 2 and 3, where the structure of IncE bound to SNX5 revealed a tight β-
hairpin peptide interaction. I speculated that cyclisation of this IncE sequence might 
enhance and stabilise the interaction with SNX5PX. ITC experiments of many different 
variants of IncE-derived cyclic peptides confirm this hypothesis. I discuss how such cyclic 
peptides could now be used as tools for studying the functions of the SNX-BAR protein 
family in cargo trafficking, and potentially as leads for therapeutically modulating their 
activity.  
In chapter 6, (chapter to be submitted as an article), I systematically investigate the 
ability of human SNX13, SNX14 and SNX25 RGS domains to bind to the Gαs subunits 
using in vitro GST pull downs and ITC experiments, and their GAP activity against Gαs in 
vitro. I also present the X-ray crystallographic structure of the apo SNX25 RGS domain, 
and my initial screens of the RGS-Gαs complexes. 
In chapter 7, I describe my attempts to express and purify the novel PXA domain of 
SNX-RGS proteins. I was able to design constructs and define purification protocols that 
eventually yielded soluble and homogeneous protein samples, and identified hits in initial 
crystallisation screens. Future work will aim to optimize these constructs and crystals for 
high-resolution structure determination. 
Finally, in chapter 8 I provide an overall summary of the work as well as the future 
directions. 
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2.1 Abstract 
During infection chlamydial pathogens form an intracellular membrane-bound replicative 
niche termed the inclusion, which is enriched with bacterial transmembrane proteins called 
Incs. Incs bind and manipulate host cell proteins to promote inclusion expansion and 
provide camouflage against innate immune responses. Sorting nexin (SNX) proteins that 
normally function in endosomal membrane trafficking are a major class of inclusion-
associated host proteins, and are recruited by IncE/CT116. Crystal structures of the SNX5 
phox-homology (PX) domain in complex with IncE define the precise molecular basis for 
these interactions. The binding site is unique to SNX5 and related family members SNX6 
and SNX32. Intriguingly the site is also conserved in SNX5 homologues throughout 
evolution, suggesting that IncE captures SNX5-related proteins by mimicking a native host 
protein interaction. These findings thus provide the first mechanistic insights both into how 
chlamydial Incs hijack host proteins, and how SNX5-related PX domains function as 
scaffolds in protein complex assembly.  
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2.2 Introduction 
To counter host defence mechanisms intracellular bacterial pathogens have evolved 
numerous strategies to evade immune detection, replicate and cause infection. Many 
pathogens manipulate endocytic pathways to gain entry into host cells and generate a 
membrane-enclosed replicative niche. This frequently involves hijacking or inhibiting the 
host cell trafficking machinery, first to generate the pathogen containing vacuole (PCV) 
and subsequently to prevent fusion with lysosomal degradative compartments. 
Concomitantly the pathogen often endeavors to decorate the PCV with host proteins and 
lipids that mimic other host cell organelles in order to circumvent innate immune detection, 
expand the replicative niche and acquire nutrients to support intracellular replication 
(62,63). This process is orchestrated through the action of molecular syringe-like secretion 
systems that deliver bacterial effector proteins directly into the host cell cytoplasm. 
Chlamydia trachomatis is arguably one of the most successful human bacterial 
pathogens by virtue of its capacity to hijack host cell intracellular trafficking and lipid 
transport pathways to promote infection (31,64-66). C. trachomatis causes nearly 100 
million sexually transmitted infections annually worldwide, and if left unchecked leads to 
various human diseases including infection-induced blindness, pelvic inflammatory 
disease, infertility and ectopic pregnancy (67,68). Even though chlamydial infections can 
generally be treated with antibiotics, persistent infections remain a challenge (69,70).  
All Chlamydiae share a common dimorphic life cycle, where the bacteria alternates 
between the infectious but non-dividing elementary body (EB) form, and the non-infectious 
but replicative reticulate body (RB) form. Following internalization of EBs through a poorly 
defined endocytic process, the bacteria reside in a membrane-bound vacuole termed the 
inclusion, where EBs convert into RBs and replication occurs over 24-72 hours. RBs 
eventually redifferentiate back to EBs in an asynchronous manner, and are then released 
to infect neighboring cells (30,62,71). The encapsulating inclusion membrane provides the 
primary interface between the bacteria and the host cell’s cytoplasm and organelles. From 
the initial stages of invasion until eventual bacterial egress the chlamydial inclusion is 
extensively modified by insertion of numerous Type-III secreted bacterial effector proteins 
called inclusion membrane proteins or “Incs”. The Incs modulate host trafficking and 
signaling pathways to promote bacterial survival at different stages, including cell invasion, 
inclusion membrane remodeling, avoidance of the host cell innate immune defense 
system, nutrient acquisition and interactions with other host cell organelles (31,66,72).  
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Chlamydiae secrete more than fifty different Inc proteins. While Incs possess little 
sequence similarity, they share a common membrane topology with cytoplasmic N- and C-
terminal domains, separated by two closely spaced transmembrane regions with a short 
intra-vacuolar loop (32,72-75) (Fig. 15). The cytoplasmic N- and C-terminal sequences of 
the Inc proteins act to bind and manipulate host cell proteins. Reported examples include 
the binding of the small GTPase Rab4A by CT229 (76), Rab11A by Cpn0585 (77), 
SNARE proteins by IncA (78), centrosomal and cytoskeletal proteins by Inc850 and 
inclusion protein acting on microtubules (IPAM) (79-81), myosin phosphatase by CT228 
(82), 14-3-3 and Arf family proteins by IncG and InaC (83,84), and the lipid transfer protein 
CERT by IncD (85,86). Despite these reports, there are no known structures of Inc family 
members either alone or in complex with host effectors.  
Two recent studies have greatly expanded the repertoire of host cell proteins known 
to associate with chlamydial inclusions and Inc proteins (26,27). Both reports confirmed 
that membrane trafficking proteins are major components of the inclusion proteome; and in 
particular members of the endosomal sorting nexin (SNX) family are highly enriched. 
Specifically it was shown that the C. trachomatis IncE/CT116 protein could recruit SNX 
proteins containing bin-amphiphysin-Rvs (BAR) domains SNX1, SNX2, SNX5 and SNX6 
(26). SNX1 and SNX2 are highly homologous and form heterodimeric assemblies with 
either SNX5 or SNX6 to promote endosomal membrane tubulation and trafficking (87). A 
fifth protein SNX32 is highly similar to SNX5 and SNX6 but is almost exclusively 
expressed in the brain and has not yet been characterized. SNX recruitment to the 
inclusion occurs via the C-terminal region of IncE interacting with the phox-homology (PX) 
domains of SNX5 or SNX6 (26) (Fig. 15). Interestingly, RNAi-mediated depletion of 
SNX5/SNX6 does not slow infection but rather increases the production of infectious C. 
trachomatis progeny suggesting that the SNX recruitment is not done to enable bacterial 
infection. Instead it was proposed that because SNX proteins regulate endocytic and 
lysosomal degradation, the manipulation by IncE could be an attempt to circumvent SNX-
enhanced bacterial destruction (26,27).  
 
Figure 15. IncE from C. 
trachomatis binds the PX 
domains of SNX5, SNX6 and 
SNX32. Schematic depiction of 
the domain organisation and 
interactions between IncE and 
SNX5-related proteins. 
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Here we use X-ray crystallographic structure determination to define the molecular 
mechanism of SNX5-IncE interaction, and confirm this mechanism using mutagenesis 
both in vitro and in cells. When bound to SNX5, IncE adopts an elongated β-hairpin 
structure, with key hydrophobic residues docked into a complementary binding groove 
encompassing a helix-turn-helix structural extension that is unique to SNX5, SNX6, and 
the brain-specific homologue SNX32. A striking degree of evolutionary conservation in the 
IncE-binding groove suggests that IncE co-opts the SNX5-related molecules by displacing 
a host protein (as yet unidentified) that normally binds to this site. Our work thus provides 
both the first mechanistic insights into how protein hijacking is mediated by inclusion 
membrane proteins, and also sheds light on the functional role of the SNX5-related PX 
domains as scaffolds for protein complex assembly. 
2.3 Materials and methods 
2.3.1 Peptides 
All synthetic peptides used for isothermal titration were purchased from Genscript (USA). 
For ITC experiments, peptides were weighed and dissolved in 50 mM Tris (pH 8.0) and 
100 mM NaCl (ITC buffer) to make a stock peptide concentration of 2 mM, which was 
diluted to 0.75 mM before use.   
2.3.2 Antibodies and reagents 
Polyclonal antibody against C. trachomatis HtrA was generated previously (88). 
Monoclonal antibodies against EEA1 (610457, 1:100) and SNX1 (611483,1:100) were 
supplied by BD Bioscience. Monoclonal antibodies against the myc epiptope (9B11, 
1:2000) were supplied by Abcam. Rabbit polyclonal antibodies against GFP (A-6455, 
1:500) were purchased from Molecular Probes (Invitrogen). Secondary antibodies were 
purchased from Molecular Probes (Life Technologies) and Li-Cor Bioscience. Wortmannin 
was supplied by Sigma-Aldrich (W1628). VPS34-In1 was from Merck Millipore (532628).  
2.3.3 Molecular biology and expression constructs 
The IncE sequence used in this study is from the L3 serovar L3/404/LN (NCBI reference 
WP_015506602) (89). The pGEX-4T-2 bacterial expression plasmid encoding the human 
SNX5 PX domain (residues 22-170) was generated using a standard PCR-based cloning 
strategy, and its identity confirmed by sequencing. All other bacterial expression 
constructs for human SNX proteins were synthesized and cloned into pGEX-4T-2 by 
Genscript (USA). These included the SNX5 PX domain IncE fusion (SNX5 residues 22-
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170 with IncE residues 108-132 fused at the C-terminus, SNX6 (residues 29-170), SNX32 
(residues 17-166), and SNX5 PX domain mutants. The pcDNA3.1-N-eGFP mammalian 
expression constructs encoding full-length human SNX5, SNX5(F136A), IncE(91-132) and 
IncE(91-132)(F116D) with N-terminal GFP-tags were generated by Genscript (USA). The 
pCMU-myc-SNX5 was as described previously (90), and the SNX6 and SNX32 genes 
cloned into the pcDNA3.1-nMyc vector at BamHI and XhoI restriction sites (91). SNX5, 
SNX32 and SNX8 were also cloned by polymerase chain reaction, restriction digest and 
ligation into pEGFP-C1 for expression with N-terminal GFP tags as described previously 
(92).  
2.3.4 Recombinant protein expression and purification 
All proteins except SNX5 PX domain mutants were expressed in Escherichia coli Rosetta 
cells, whereas mutant constructs were expressed in BL21 Codon Plus supplemented with 
appropriate antibiotics. Single colonies from cultures grown on LB agar plates were 
inoculated into 50 mL LB2+ with ampicillin (0.1 mg/mL) and chloramphenicol (0.1 mg/mL), 
and grown at 37°C with shaking overnight. The following day, 30 mL from the overnight 
culture was used to inoculate 1 L LB media containing ampicillin (0.1 mg/mL) and 
chloramphenicol (0.1 mg/mL) and incubated at 37°C. Cells were grown to an optical 
density (OD) of 0.5-0.6 at 600 nm and induced with 0.5 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) (except for the SNX5-IncE fusion, where expression was 
induced at OD600 of 0.8 with 1 mM IPTG). Cultures were incubated with shaking overnight 
at 18°C until the cells reach an O.D of 3.0 (~24 h). Cells were harvested using a Beckman 
rotor JLA 8.1000 at 4000 RPM for 30 min at 4°C. Pellets were resuspended in 10 mL lysis 
buffer (50 mM Tris (pH 8.0), 100 mM NaCl, 5% glycerol, 1 mM DTT, 0.1 mg/ml 
benzamidine, 0.1 mg/ml DNase) per litre of culture. The cells were subjected to cell 
disruption and centrifugation using JA 25.50 rotor at 18,000 RPM for 30 min at 4°C. The 
soluble fractions were first purified using affinity chromatography with glutathione-
sepharose, and when required the GST tags were cleaved by thrombin while still bound to 
the column. The proteins were eluted in 50 mM Tris (pH 8.0), 100 mM NaCl, 5% glycerol, 
and 1 mM DTT, and then further polished using gel filtration chromatography (Superdex 
200, GE healthcare) in a buffer containing 50 mM Tris (pH 8.0), 100 mM NaCl. The 
fractions corresponding to the respective proteins were then pooled and used directly for 
ITC or were further concentrated for crystallisation. 
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2.3.5 Isothermal titration calorimetry  
ITC experiments were performed on a Microcal iTC200 instrument at 25°C. The proteins 
were buffer exchanged into ITC buffer (50 mM Tris (pH 8.0) and 100 mM NaCl) by gel 
filtration prior to ITC experiments. IncE peptides at 750 µM were titrated into 50 µM PX 
domain samples. The binding data was processed using ORIGIN 7.0 with a single site 
binding model to determine the stoichiometry (n), the equilibrium association constant Ka 
(1/Kd), and the enthalpy (ΔH). The Gibbs free energy (ΔG) was calculated using the 
equation ΔG = -RTIn(Ka); binding entropy (ΔS) was calculated by ΔG = ΔH –TΔS. Three 
experiments were performed for each set of samples to determine the average ± standard 
error of the mean (SEM) for thermodynamic quantities, except for the peptide truncation 
experiments where only single experiments were performed. For these truncated peptide 
experiments, all experiments were performed using the same batch of protein to allow 
direct comparions to be made.  
2.3.6 Crystallisation, data collection and structure determination 
The SNX5 PX domain fusion with IncE was concentrated to 15 mg/ml for crystallization. 
Eight 96-well crystallization hanging-drop screens were set up using a Mosquito Liquid 
Handling robot (TTP LabTech) at 20°C. Optimized diffraction-quality crystals were 
obtained using streak seeding in sitting drop vapor diffusion plates. Crystallisation 
solutions are provided in Table 3. Data were collected at the Australian Synchrotron MX1 
and MX2 Beamlines, integrated with iMOSFLM (93), and scaled with AIMLESS (94) in the 
CCP4 suite (95). The structures were initially solved by molecular replacement with 
PHASER (96) using the apo-SNX5 PX domain crystal structure as the input model (PDB 
code 3HPB), minus the extended α-helical domain. The resulting model was rebuilt with 
COOT (97), followed by repeated rounds of refinement with PHENIX (98). All structural 
figures were generated using PyMOL (DeLano scientific). 
2.3.7 Cell culture and transfections 
HeLa cells stably expressing mCherry-Rab25 were previously generated within the lab 
(99) and were maintained in DMEM (Gibco) supplemented with 10% (v/v) Fetal Calf 
Serum (FCS) (Bovogen) and 2mM L-glutamine (Invitrogen) in a humidified air/atmosphere 
(5% CO2) at 37°C. Cells were transfected at 70% confluence with pcDNA3.1-N-eGFP 
plasmid constructs using Lipofectamine 2000 as per manufacturer’s protocol (Invitrogen) 
and examined 18-24 hrs later. The HeLa cell line used in this study was from America 
Type Culture Collection (#ATCC CCL2). Parental and stable cells lines were negative for 
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mycoplasma by DAPI staining, and authenticated by STR profiling (Cell Bank Australia). 
For inhibitor treatments, cells were treated with either 100 nM wortmannin or 1 µM Vps34-
IN1 for 1 h. 
2.3.8 Chlamydial infection assays 
C. trachomatis serovar L2 (ATCC VR-902B) was used to infect cells at a multiplicity of 
infection (MOI) of ~0.5. Cells were infected 2 h post-transfection in normal DMEM (Gibco) 
supplemented with 10% (v/v) FCS (Bovogen) and 2 mM L-glutamine (Invitrogen) in a 
humidified air/atmosphere (5% CO2) incubator at 37°C. After 2 h media was replaced with 
fresh media.  
2.3.9 Microscopy 
Transfected and infected cells (18-24 h post-infection) were fixed with 4% 
paraformaldehyde, permeabilised using TritonX-100 (Sigma) and immunolabeled as 
described previously (99) and counter-stained with DAPI. The coverslips were imaged 
using a confocal laser-scanning microscope (LSM 710 meta, Zeiss) with 63x oil immersion 
objective. Time-lapse videomicroscopy was carried out on individual live cells using a 
Nikon Ti-E inverted deconvolution microscope using a 40x, 0.9 Plan Apo DIC objective, a 
Hamamatsu Flash 4.0 4Mp sCMOS monochrome camera and 37°C incubated chamber 
with 5% CO2. GFP was excited with a 485/20nm LED and captured using a 525/30nm 
emission filter, and mCherry was excited using a 560/25nm LED and captured using a 
607/36nm emission filter. Data was processed using ImageJ (https://imagej.nih.gov/ij/) and 
compiled using Adobe Illustrator CS6.  
2.3.10 Image quantification 
The immunofluorescence colocalisation of GFP-SNX5 with chlamydial inclusion 
membranes imaged on a confocal microscope was measured by Mander’s correlation 
coefficient of red pixel (EEA1 or mCherry-Rab25) over green pixel (GFP-SNX5) signals, 
which were determined using ImageJ (https://imagej.nih.gov/ij/) with the JACoP plugin 
(100). A total of 10 cells from two biological replicates were used in the analysis of 
statistical significance, which was determined using unpaired non-parametric t-Test with 
Mann-Whitney test using Prism7 software. Punctate structures were automatically counted 
using ImageJ analyse particle tool across total of 10 cells from two biological replicates. 
Statistical significance was obtained as stated. To quantify the effect of PI3K inhibitors on 
SNX recruitment, Z-stacks were captured with a Zeiss 710 confocal laser scanning 
microscope using a 40x objective. Maximum projections were generated with FIJI 
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(https://fiji.sc/) and Pearson’s correlation coefficients for individual cells determined using 
the FIJI ‘Coloc 2’ function with Costes threshold regression and 100 Costes 
randomisations. Co-localization analyses were conducted on 2 independent experiments 
from 5 images per condition each containing at least 20 cells (>100 cells analysed per 
condition).  
2.3.11 Co-precipitation of GFP-SNX5 and endogenous SNX1 
HeLa cells were transfected with pcDNA3.1-N-eGFP plasmid constructs overnight at 70% 
confluence and the cells were lysed using lysis buffer (H2O, 50 mM HEPES, 150 mM 
NaCl, 1% Triton-X100, 10 mM Na4P2O7, 30 mM NaF, 2 mM Na3VO4, 10 mM EDTA, 0.5 
mM AEBSF and protease inhibitor cocktail). Cell lysates were incubated with GFP nano-
trap agarose beads (Protein Expression Facility, UQ) after preclear using protein G-
agarose beads (Invitrogen). Protein complexes attached to the beads were detached by 
boiling for 5 min with 5x denaturing and reducing buffer (0.625 M Tris pH 6.8, 50% 
glycerol, 10% SDS, 0.25% Bromophenol blue and 500 mM DTT). Denatured and reduced 
proteins were separated by molecular mass using SDS-PAGE. Proteins were transferred 
onto PVDF-FL membrane (Immobilon) and were detected by immunoblotting with 
polyclonal anti-GFP and monoclonal SNX1 antibodies, and near-infrared fluorescent dyes 
(LI-COR). Immunolabelled proteins were visualised using LI-COR Odyssey imaging 
system. 
2.3.12 Modelling of the SNX5-SNX1 heterodimer 
Human SNX5 and SNX1 sequences were submitted to the PHYRE2 server for automated 
homology-based model building (101). For both proteins the top scoring modelling 
template was the crystal structure of the SNX9 PX-BAR domains (PDB ID 2RAJ) (23) with 
Confidence Scores of 100% (and sequence identities of 19% and 16% respectively). The 
PX domain of the SNX5 model generated using this structural template was missing the 
extended α-helical insert, so to complete the model the SNX5 PX domain-IncE complex 
was substituted and a dimer of SNX5 and SNX1 PX-BAR domains generated by 
overlaying with the SNX9 dimer in the PtdIns3P-bound state (PDB ID 2RAK) (23). The 
resulting model was subjected to simple energy minimisation in PHENIX (98). 
Conservation of surface residues was computed using the CONSURF server (102).  
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2.4 Results 
2.4.1 IncE specifically binds and recruits SNX5, SNX6 and SNX32 to C. trachomatis 
inclusions  
It was previously shown that the sorting nexins SNX1, SNX2, SNX5 and SNX6 are 
recruited to the inclusion membrane in C. trachomatis infected cells (26,27). We first 
confirmed this for SNX1, SNX2 and SNX5 in HeLa cells infected with C. trachomatis 
serovar L2 (MOI~0.5) for 18 hr. All three proteins were recruited to the inclusion 
membrane as assessed by co-localisation with the inclusion marker mCherry-Rab25 (Fig. 
16A) (99), as were GFP-tagged SNX1 and SNX5 but not the more distantly homologous 
GFP-SNX8 (Fig. 16B).  
A 
 
 
 
 
B 
Figure 16. SNX5, SNX32 and SNX1 are recruited to C. trachomatis inclusions and membrane 
tubules. (A) HeLa cells stably expressing the mCherry-Rab25 inclusion membrane marker (red) 
were infected with C. trachomatis serovar L2 (24 hr) and transfected with myc-tagged SNX 
expression constructs. The samples were fixed and immunolabeled with anti- myc (green) and 
anti-chlamydial HtrA antibodies (white) and counterstained with DAPI (blue). (B) Hela cells were 
transiently transfected with GFP-tagged SNX and mCherry-Rab25 proteins as indicated, and 
infected with C. trachomatis serovar L2. Cells were imaged by confocal fluorescence microscopy 
for GFP-tagged proteins (green), endogenous SNX1 (blue), mCherry-Rab25 (red) and DAPI-
stained nuclear material (white). Both GFP-SNX5 and GFP-SNX32 are recruited to inclusion 
membranes, but the distantly related SNX-BAR protein SNX8 is not. 
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We also observed localization of the SNX proteins to extensive inclusion-associated 
membrane tubules in a subset of infected cells as described previously (Fig. 17) (26,27).  
 
Figure 17. An example of SNX1-decorated tubules (green) often observed emanating from 
inclusion membranes (mCherry-Rab25 in red; DAPI staining in blue). The image is a maximum 
projection. 
 
Interestingly, when infected cells are treated with wortmannin, a pan-specific inhibitor of 
phosphoinositide-3-kinase (PI3K) activity, we see a loss of the SNX proteins from punctate 
endosomes, but not from the inclusion membrane (Fig. 18; Video 1). A similar result is 
seen for specific inhibition of PtdIns3P production by Vps34 using Vps34-IN1 (Fig. 18). 
This offers two possibilities; that either SNX recruitment to the inclusion occurs via protein-
protein interactions, and does not depend on the presence of 3-phosphoinositide lipids 
that typically recruit SNX proteins to endosomal membranes, or alternatively that PI3Ks 
are not present at the inclusion and therefore wortmannin treatment has no effect at this 
particular compartment. Given our structural and mutagenesis studies below we favor the 
former explanation.   
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Figure 18. Recruitment of SNX1, SNX2 and SNX5 to inclusions is not dependent on 3-
phosphoinositides. HeLa cells stably expressing mCherry-Rab25 were infected with C. trachomatis 
serovar L2 (MOI ~0.5) for 24 hr and imaged by immunofluorescence microscopy using antibodies 
to SNX1, SNX2 and SNX5. mCherry-Rab25 provides marker for the inclusion membrane. The 
upper panels show control infections and lower panels show cells treated with wortmannin or 
Vps34-IN1 with concomitant loss of SNX association with endosomal compartments while 
inclusion localisation is unaffected. The images are maximum projections. Endosomal 
compartments are labeled with antibodies to endogenous Rab5 or Vps35 and Pearson’s 
correlation coefficients used to quantify loss of endosomal recruitment (100 cells per group; error 
bars, S.D). A movie showing the effect of wortmannin on GFP-SNX5 is shown in Video 1. 
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Mirrashidi et al., (2015), demonstrated an in vitro interaction between IncE and the 
SNX5 and SNX6 PX domains. To confirm their direct association we assessed the binding 
affinities using isothermal titration calorimetry (ITC) (Fig. 19A; Table 1). Initial experiments 
with the human SNX5 and SNX6 PX domains showed a robust interaction with the IncE C-
terminal domain (residues 107-132). The affinities (Kd) for SNX5 and SNX6 were 
essentially indistinguishable (0.9 and 1.1 µM respectively), but we detected no interaction 
with the PX domain of SNX1 confirming the binding specificity. The PX domains of SNX5 
and SNX6 possess a helix-turn-helix structural insert (25), which is not found in any other 
SNX family members except for SNX32 (Fig. 19B), a homologue expressed primarily in 
neurons (BioGPS (103)). Confirming a common recruitment motif in the SNX5-related 
proteins, ITC showed a strong interaction between IncE and the SNX32 PX domain similar 
to SNX5 and SNX6 (Kd = 1.0 µM) (Fig. 19A; Table 1), and SNX32 was robustly recruited 
to inclusion membranes in infected cells (Fig. 16A; Fig. 16B). Overall, our data indicates 
that a common structure within the SNX5, SNX6 and SNX32 PX domains is required for 
IncE interaction.  
 
Figure 19. (A) Binding affinity between IncE peptide (residues 107–132) and SNX PX domains by 
ITC. Top panels show raw data and lower panels show normalised integrated data. (B) Sequence 
alignment of human SNX1, SNX5, SNX6 and SNX32 PX domains. Conserved residues are 
indicated in red. Side-chains that directly contact IncE in the crystal structure are indicated with 
black circles. Mutations that block IncE binding are highlighted with red triangles, and mutations 
that do not affect binding indicated with green circles. Secondary structure elements derived from 
the SNX5 crystal structure are indicated above. (C) Sequence alignment of IncE from C. 
trachomatis and putative homologues from C. muridarum and C. suis. IncE side-chains that 
directly contact SNX5 in the crystal structure are indicated with black circles. Mutations that block 
SNX5 binding are highlighted with red triangles, and mutations that do not affect binding indicated 
with green circles.  
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Finally we tested a series of IncE truncation mutants for their binding to the SNX5 
PX domain (Fig. 20A, 20B and 20C; Table 2).  
 
Figure 20. (A) Representative ITC experiments for truncated IncE peptides. These experiments 
were conducted using a single batch of SNX5 PX domain to minimize batch-to-batch protein 
variation. (B) Plots of the affinity constants for selected peptides to highlight the progressive loss of 
binding with N and C-terminal truncations. (C) Sequences of the truncated IncE peptides are given, 
with a qualitative indication of binding strength relative to the IncE_1 peptide containing residues 
107–132. Full binding is indicated by ‘++’ reduced binding by ‘+’ and lack of binding by ‘−‘.All 
sequence information and their Kd values are given in Table 2. When compared to the reference 
ITC experiment the binding affinity of peptides was unaffected when the first three N-terminal 
residues were removed (IncE_2, IncE_3 and IncE_4) and gradually became weaker until IncE_7, 
after which binding was abolished. Results from IncE_6 are inconclusive due to the difficulty in 
successfully dissolving the peptides in buffer (n.d.). C-terminal truncations showed that IncE_14 
and IncE_15 had similar high binding affinities to the reference, while the binding of IncE_16 and 
IncE_17 became progressively weaker and peptides shorter than IncE_17 showed no binding. 
This data indicates that the minimal IncE binding sequence retaining full SNX5 binding is 
GPAVQFFKGKNGSADQVILVT, and a shorter fragment VQFFKGKNGSADQVIL can bind to 
SNX5, albeit with a slightly reduced affinity. 
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Synthetic peptides were used with single amino acids removed sequentially from 
the N and C-terminus to determine the minimal sequence required for binding. These 
experiments showed that the shortest region of IncE able to support full binding to SNX5 
encompasses residues 110-131 (GPAVQFFKGKNGSADQVILVT), while a shorter 
fragment containing residues 113-130 (VQFFKGKNGSADQVILV) can bind to SNX5 with a 
slightly reduced affinity. While variations are observed across the different C. trachomatis 
serovars (89) the SNX5-binding sequence appears to be preserved in all detected variants 
(Fig. 21). A comparison with other chlamydial species suggests that IncE is not very 
widely conserved in this Genus, being clearly identifiable only in the closely related 
mouse-specific C. muridarum and swine-specific C. suis (Fig. 19C). Residues required for 
binding to SNX5 are preserved in these IncE homologues, but whether SNX proteins are 
also recruited during infection by these other chlamydial species remains to be 
determined.  
 
Figure 21. Sequence alignment of IncE from different C. trachomatis serovars. 
2.4.2 The crystal structure of IncE in complex with the SNX5 PX domain 
The canonical PX domain structure is composed of a three-stranded β-sheet (β1, β2 and 
β3) followed by three close-packed α-helices. The first and second α-helices are 
connected by an extended proline-rich sequence. Typically PX domains have been found 
to bind to the endosome-enriched lipid phosphatidylinositol-3-phosphate (PtdIns3P) via a 
basic pocket formed at the junction between the β3 strand, α1 helix and Pro-rich loop. In 
contrast SNX5, SNX6 and SNX32 possess major alterations in the PtdIns3P-binding 
pocket that preclude canonical lipid head-group docking. In addition they possess a unique 
extended helix-turn-helix insert between the Pro-rich loop and α2 helix of unknown 
function (Fig. 19B) (25).  
To determine the structure of the SNX5-IncE complex we generated a fusion 
protein encoding the human SNX5 PX domain (residues 22-170) and C. trachomatis IncE 
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C-terminal sequence (residues 108-132) attached at the PX domain C-terminus (Fig. 
22A). This construct readily crystallised in several crystal forms, and we were able to 
determine the structure of the complex in three different spacegroups (Table 3; Fig. 22B). 
Confirming that the fusion does not alter complex formation, the short linker region is 
disordered, and the mode of IncE-binding to SNX5 is identical in all three structures (Fig. 
22C and 22D). 
 
Figure 22. (A) Sequence of the SNX5 PX domain fusion protein with the IncE C-terminal peptide. 
(B) Refined 2fo-fc electron density contoured at 1.5σ for the SNX5-IncE structure in spacegroup 
P212121. (C) Overlay of each independent SNX5-IncE complex observed in the crystal forms. (D) 
Ribbon structures indicating the locations of the linker regions in each crystal form. The C-terminal 
SNX5 residues and the N-terminal IncE residues are shown by sphere with distances indicated. 
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Because of the higher resolution, we limit our discussions to the structure of the 
SNX5 PX-IncE complex observed in the P212121 crystal form. The first three IncE N-
terminal residues (Pro107, Ala108, Asn109) and the last three IncE C-terminal residues 
(Val130, Thr131, Gln132) were not modeled due to lack of electron density, suggesting 
disorder and matching precisely with our mapping experiments showing these residues 
are not necessary for SNX5 association.  
The IncE sequence forms a long β-hairpin structure that binds within a 
complementary groove at the base of the extended α-helical insertion of the SNX5 PX 
domain and adjacent to the β-sheet sub-domain (Fig. 23A; Video 2). The β-hairpin 
structure of IncE (N-terminal βA and C-terminal βB strands) is directly incorporated as a β-
sheet augmentation of the β1, β2 and β3 strands of SNX5 (Fig. 23B).  
 
Figure 23. (A) Crystal structure of the SNX5 PX domain (yellow) in complex with IncE residues 
107-132 (magenta) shown in cartoon representation. (B) Backbone atoms of the SNX5 and IncE 
proteins are shown to highlight the prominent β-sheet augmentation mediating the association 
between the two molecules. (C) Close up view of the SNX5-IncE interface highlighting specific 
contact areas at the N-terminus of the IncE peptide. (D) Close up of the SNX5-IncE interface 
highlighting specific contact areas at the hairpin loop of the IncE peptide shown at 90º to Fig. 23C. 
(E). Close up of the SNX5-IncE interface highlighting contact areas at the C-terminus of the IncE 
peptide in approximately the same orientation as Fig. 23C. Residues in SNX5 (Phe136) and IncE 
(Phe116) that are critical for binding based on mutagenesis are boxed.     
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The N-terminal βA strand of the IncE sequence (Gly111-Lys118) forms the primary 
interface with SNX5, making main-chain hydrogen bonds with the β1 strand of the SNX5 
PX domain for the stable positioning of the IncE structure. The two anti-parallel β-strands 
of IncE are connected by a short loop (Gly119-Ala124) that makes no direct contact with 
the SNX5 protein, and the C-terminal IncE βB strand (Asp125-Val130) forms an interface 
with the extended α-helical region of the SNX5 PX domain. 
Detailed views of the SNX5-IncE interface are shown in Figs. 23C, 23D and 23E. 
Aside from main-chain hydrogen bonding to form the extended β-sheet, IncE engages in 
several critical side-chain interactions with the relatively hydrophobic SNX5 binding 
groove. At the N-terminus of the βA strand Val114 of IncE inserts into a pocket formed 
primarily by Tyr132 and Phe136 on the SNX5 α’’ helix (Fig. 23C). A major contribution 
comes from IncE Phe116, with π-stacking occurring with the Phe136 side-chain and 
hydrophobic docking with Val140 of SNX5 (Fig. 23D). Adjacent to IncE Phe116 at the end 
of the βA strand Lys118 makes an electrostatic contact with SNX5 Glu144. Finally, at the 
C-terminal end of the IncE βB strand Val127 and Leu129 contact an extended SNX5 
surface composed of Leu133, Tyr132 and Met106 (Fig. 23E).   
2.4.3 Mutations in the SNX5-IncE interface disrupt complex formation in vitro and in 
cells 
To verify the crystal structure we mutated residues from both SNX5 and IncE and 
measured their affinities using ITC (Fig. 24 top; Table 2). At the interface between SNX5 
and IncE several side chains make key contributions to peptide recognition. Because 
Leu133 and Phe136 residues in SNX5 are located at the core of the IncE-binding 
interface, and also due to the structural rearrangements these residues make on binding 
(see below), we reasoned that L133D and F136A mutations would inhibit the interaction. 
Indeed these mutants abolished association with the IncE peptide (Fig. 24A). The 
reciprocal mutations in IncE residues F116A and V127D also abolished binding to the 
SNX5 PX domain (Fig. 24B), and the SNX6 and SNX32 PX domains (Fig. 24C), 
demonstrating the importance of these hydrophobic and π-stacking interactions for stable 
complex formation. In contrast mutations predicted to disrupt an observed electrostatic 
contact (IncE K118A or SNX5 E144A) had little effect on binding. Thus the core 
hydrophobic interactions are critical for IncE binding but the peripheral electrostatic contact 
is not essential.  
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Figure 24. (Top) Mutations in the SNX5 and IncE proteins prevent complex formation in vitro and 
in cells (A) ITC experiments testing the effect of SNX5 mutations on IncE binding. Both L133D and 
F136A mutations prevented IncE binding, but the E144A mutation had little effect. (B) ITC 
experiments testing the effect of IncE mutations on SNX5 binding. F116A blocked SNX5 
interaction, while Q115A had a partial effect and K118A had no effect on association. (C) SNX6 
and SNX32 PX domains bind IncE at the same site as SNX5. ITC experiments testing the effect of 
IncE peptide mutations on binding to SNX6 and SNX32 PX domains. The IncE F116A mutation 
blocks interaction with both PX domains similarly to SNX5. 
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To confirm the role of IncE in direct SNX5 protein recruitment to the chlamydial 
inclusion we examined the localisation of GFP-tagged SNX5 in HeLa cells infected with 
Chlamydia trachomatis L2 (CTL2) for 24 h (MOI~0.5). Cells expressing the GFP-SNX5 
protein showed clear and uniform recruitment to the limiting membrane of the inclusion as 
defined by mCherry-Rab25 (Fig. 25A), which is consistent with the localisation observed 
by others (26,27). In contrast, the GFP-SNX5 (F136A) mutant protein showed no 
recruitment to the chlamydial inclusion. The change in relative distribution of these GFP-
SNX5 proteins on the inclusion was quantified for wildtype SNX5 (Mander’s coefficient 
0.67 ± 0.14) and GFP-SNX5 (F136A) (0.041 ± 0.051) (Fig. 26A).  
  
Figure 25. Mutations in the SNX5 and IncE proteins prevent complex formation in cells (A) Single 
amino-acid mutation in the PX domain of the SNX5 (F136A) abolishes recruitment to the 
chlamydial inclusion. HeLa cells stably expressing mCherry-Rab25 (red) were transfected 
transiently with GFP-SNX5 or GFP-SNX5 (F136A) (green) and infected with Chlamydia 
trachomatis L2 for 18-24 h. The cells were fixed and the nucleic materials were counter-stained 
with DAPI (blue). (B) HeLa cells were transfected transiently with GFP-IncE(91-132) or GFP-
IncE(91-132)(F116D) (green) and co-labelled for the early endosomal marker EEA1 (red). Mutation 
in the SNX5 binding IncE peptide (F116D) abolishes recruitment to endosomal structures.  
*Represents the inclusion. Scale bar 20 µm. 
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Like wild-type GFP-SNX5 the GFP-SNX5 (F136A) mutant was recruited to punctate 
endosomal structures throughout the cytoplasm of these cells, and in addition was able to 
co-immunoprecipate endogenous SNX1 in heterodimeric complexes identically to the wild-
type GFP-SNX5 protein (Fig. 26B). This implies that BAR-domain mediated heterodimer 
formation with SNX1 or SNX2 is required for endosomal recruitment, and is not perturbed 
by the IncE-binding mutation in the PX domain.  
 
Figure 26. GFP-IncE C-terminal domain is localised to endosomes but not inclusions. (A) 
Quantitation of the degree of overlap between the GFP-SNX5 constructs and the mCherry-Rab25 
inclusion membrane marker from Figure 20A. Mander’s correlation coefficient of mChRab25 signal 
over GFP-SNX5 signals (10 cells per group; error bars, S.D). (B) Co-immunoprecipitation of GFP-
SNX5 from HeLa cells shows that both the wild-type and mutant protein (F136A) interact equally 
with endogenous SNX1. This indicates that both proteins are correctly folded and otherwise 
functional. (C) HeLa cells stably expressing mCherry-Rab25 (red) were transfected transiently with 
GFP-IncE(91-132) or GFP-IncE(91-132)(F116D) (green) and infected with C. trachomatis L2 for 
18–24 hr. Mutation in the SNX5 binding IncE peptide (F116D) abolishes recruitment to endosomal 
structures. Neither construct is recruited to inclusions, which is consistent with the lack of 
transmembrane regions. *Represents the inclusion. Scale bar 20 µm. 
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Lastly, we tested the importance of IncE residues for SNX interaction in situ by 
expressing the GFP-tagged IncE C-terminal domain. The wild-type GFP-IncE(91-132) was 
recruited to endosomal structures via its interaction with SNX5-related proteins in both 
uninfected and infected HeLa cells (Fig. 25B; Fig. 26C). In contrast however, GFP-
IncE(91-132)(F116D), a SNX5-binding mutant, was exclusively cytosolic. Note that neither 
IncE construct is localised to the inclusion, as expected due to lack of signal peptides and 
transmembrane domains (Fig. 26C). 
2.4.4 A model for SNX-BAR recruitment to the inclusion membrane by IncE 
Superposition of the SNX5-IncE complex with the SNX5 PX domain in the apo state 
(25) reveals a significant conformational change in the α-helical extension, as well as 
localized alterations in the loop between the β1 and β2 strands to accommodate peptide 
binding (Fig. 27A). In essence the IncE β-hairpin acts as a tether between the core PX fold 
and extended α-helical hairpin, pulling the two sub-structures closer together. Overall the 
α-helical extension undergoes a maximal movement of ~8-10 Å at the furthest tip, 
facilitated by the flexibility of the structure following the Pro-rich linker and an apparent 
hinge-point at Pro97 (Fig. 27A upper panel). In the immediate vicinity of Pro97 the SNX5 
loop that encompasses Asp43 is significantly shifted and stabilized by the repositioning of 
Arg103. At both the start of the first α’ helix of the extension and the end of the second α’’ 
helix more subtle changes occur in the positions of Met106, Leu128, Tyr132, Leu133 and 
Phe136. These changes result in formation of the hydrophobic pocket that engages the 
IncE side-chains Val114, Phe116, Val127 and Leu129 (Fig. 27A, middle and lower 
panels).  
 To better understand how IncE can recruit the SNX5-containing SNX-BAR 
complexes to inclusion membranes we constructed an in silico model of the SNX5-SNX1 
heterodimeric PX-BAR proteins (Fig. 27B). Consistent with the length of the IncE C-
terminal cytoplasmic sequence the model predicts that the IncE sequence will bind to the 
surface of SNX5 close to, but oriented away from, the inclusion membrane. While PX 
domains are commonly able to recognise PtdIns3P lipid headgroups, SNX5-related 
proteins lack the typical binding pocket (Fig. 27B right panel), and there is some 
controversy regarding their ability to mediate specific membrane interactions (8,25). We 
propose that in the context of C. trachomatis infection, SNX5-related proteins are directly 
associated with the inclusion via IncE protein-protein interactions in a phosphoinositide-
independent manner, and are able to recruit their heterodimeric partners SNX1 and SNX2 
(87,104,105). The PX-BAR-domain containing complexes are then localised to the 
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inclusion in a retromer-independent manner (26), and may contribute to the formation of 
the dynamic inclusion-associated membrane tubules.  
 
Figure 27. Conformational changes in SNX5 and a model for SNX-BAR recruitment to inclusion 
membranes (A) Comparison of the SNX5-IncE complex (yellow-magenta) with the previously 
reported apo- SNX5 PX domain crystal structure (blue) (PDB ID 3HPB)(25). The α-helical 
extension undergoes a significant displacement in the bound state. The enlarged panels to the 
right show several close-up views of the binding pocket highlighting conformational changes that 
are required to accommodate IncE. (B) A model for the SNX5-SNX1 PX-BAR heterodimer and its 
interaction with IncE at the inclusion membrane. The PX-BAR structure was modeled in silico (see 
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methods). The left panel shows cartoon representations of the structure, viewed from the side and 
from the membrane surface. Middle panels show the same structures in electrostatic surface 
representation (red, negative; blue positive). The right panels show close ups of the putative 
PtdIns3P-binding pocket in SNX1 and SNX5, with a PtdIns3P head-group (shown in spheres) 
docked by aligning the previous SNX9 crystal structure (23). SNX1 has a canonical PtdIns3P 
pocket, while SNX5 lacks a clear site for lipid head-group binding. (C) Sequence conservation of 
SNX5-related proteins was calculated and plotted using CONSURF. The surface representation 
indicates exposed side-chains that are evolutionarily conserved in green. The IncE peptide binds 
to a highly conserved surface groove, while the putative phosphoinositide binding region (25) on 
the opposite face is neither highly conserved nor poised to allow docking. (D) Cartoon model 
depicting the recruitment of SNX5 and related proteins to the inclusion membrane. Heterodimers 
with SNX1 or SNX2 will be recruited via IncE in infected cells, and this recruitment will be in 
competition with the binding of SNX1 and SNX2 to PtdIns3P for normal endosomal association, as 
well as interactions with other proteins including retromer and unidentified molecules that 
potentially bind to the conserved groove of the SNX5 PX domain. 
 
Interestingly, when a cross-species evolutionary analysis of side-chain conservation 
in the SNX5-related proteins is performed it is clear that the IncE peptide binds a 
hydrophobic surface groove that is strictly conserved in this protein family (Fig. 21C). This 
very strongly implies that the site is normally engaged in a protein-protein interaction with 
an as yet unidentified binding partner(s) required for SNX5’s regular biological function, 
and that IncE is directly competing for this interface.    
Videos 
 
Video 1. Movie showing that wortmannin disrupts 
SNX5 recruitment to endosomes but not the 
chlamydial inclusion. HeLa cells stably expressing 
mCherry-Rab25 (red) were transfected transiently 
with GFP-SNX5 (green) and infected with 
Chlamydia trachomatis L2 for 24 hr. Time-lapse 
videomicroscopy was performed using an interval of 
1 min on an inverted Nikon Ti-E deconvolution 
microscope with environmental control at 40 x 
magnification. 10 min into recording 100 nM 
wortmannin was added. 
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Video 2. Animation highlighting the mechanism of 
interaction between SNX5 and IncE. The SNX5 PX 
domain is shown in yellow ribbons and the IncE 
peptide is shown in magenta. 
 
Table 1. Thermodynamic parameters of IncE binding to SNX PX domainsa  
Sample 
Cell 
Titrant Kd 
(µM) 
 
ΔH 
(kcal/mol) 
 
TΔS 
(kcal/mol) 
 
ΔG 
(kcal/mol) 
 
N 
 
SNX5 PX IncE 
peptideb 
0.95±0.07 
 
-6.9 ± 0.3 
 
-1.9±0.05 
 
-8.2±0.01 
 
1.01±0.01 
 
SNX6 PX IncE 
peptide 
1.13±0.08 -5.0± 0.9 -3.0±1 -8.0±0.07 1.01±0.08 
 
SNX32 PX IncE 
peptide 
1.15±0.07 -6.9± 0.4 -1.3±0.8 -8.2±0.4 1.06±0.005 
SNX1 PX IncE 
peptide 
No 
binding 
    
a. Values are the mean from three experiments ±SEM. 
b. IncE synthetic peptide sequence PANGPAVQFFKGKNGSADQVILVTQ.  
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Table 2. ITC data for SNX5 PX domain binding to truncated and mutated IncE 
peptidesa 
Protein Peptide Sequence Kd 
(µM) 
ΔH 
(kcal/mol) 
TΔS 
(kcal/mol) 
ΔG 
(kcal/mol) 
N 
 
SNX5 PX IncE_1 PANGPAVQFFKGKNGSADQVILVTQ 0.95±0.07 -6.9 ± 0.3 -1.9±0.05 -8.2±0.01 1.01±0.01 
 IncE_2  ANGPAVQFFKGKNGSADQVILVTQ 1 -5.0 -2.6 -8.1 0.98 
 IncE_3   NGPAVQFFKGKNGSADQVILVTQ 0.93 -6.7 -1.4 -8.1 1.03 
 IncE_4    GPAVQFFKGKNGSADQVILVTQ 0.87 -6.8 -1.2 -8.2 1.03 
 IncE_5     PAVQFFKGKNGSADQVILVTQ 2 -5.9 -1.2  -8.3  0.99 
 IncE_6      AVQFFKGKNGSADQVILVTQ / / / / / 
 IncE_7       VQFFKGKNGSADQVILVTQ 2.2 -6.9 -1.1  -7.7 0.99 
 IncE_8        QFFKGKNGSADQVILVTQ No binding / / / / 
 IncE_9         FFKGKNGSADQVILVTQ No binding / / / / 
 IncE_10          FKGKNGSADQVILVTQ No binding / / / / 
 IncE_11           KGKNGSADQVILVTQ No binding / / / / 
 IncE_12            GKNGSADQVILVTQ No binding / / / / 
 IncE_13             KNGSADQVILVTQ No binding / / / / 
 IncE_14 PANGPAVQFFKGKNGSADQVILVT 0.72 -5.1 -1.6  -8.4  1 
 IncE_15 PANGPAVQFFKGKNGSADQVILV 0.97 -6.5 -1.3  -8.2 0.98 
 IncE_16 PANGPAVQFFKGKNGSADQVIL 1.1 -5.6  -1.4  -8.12  0.99 
 IncE_17 PANGPAVQFFKGKNGSADQVI 8.7 -2.7  -2.5  -6.9  0.99 
 IncE_18 PANGPAVQFFKGKNGSADQV No binding / / / / 
 IncE_19 PANGPAVQFFKGKNGSADQ No binding / / / / 
 IncE_20 PANGPAVQFFKGKNGSAD No binding / / / / 
 IncE_21 PANGPAVQFFKGKNGSA No binding / / / / 
 IncE_22 PANGPAVQFFKGKNGS No binding / / / / 
 IncE_23 PANGPAVQFFKGKNG No binding / / / / 
 IncE_24 PANGPAVQFFKGKN No binding / / / / 
 IncE 
Q115A 
PANGPAVAFFKGKNGSADQVILVTQ 6.3 -5.3 -1.6 -6.9 0.90 
 IncE 
F116D 
PANGPAVQAFKGKNGSADQVILVTQ No binding     
 IncE 
K118A 
PANGPAVQFFAGKNGSADQVILVTQ 2.8 -6.0 -1.5 -7.5 0.91 
 IncE 
V127D 
PANGPAVQFFKGKNGSADQDILVTQ No binding     
SNX5 PX 
L133D 
IncE_1 PANGPAVQFFKGKNGSADQVILVTQ No binding     
SNX5 PX 
F136A 
IncE_1 PANGPAVQFFKGKNGSADQVILVTQ No binding     
SNX5 PX 
E144A 
IncE_1 PANGPAVQFFKGKNGSADQVILVTQ 15 -9.9 -3.1 -13 0.99 
a. Except for IncE_1 all other peptide-binding experiments were performed only once. 
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Table 3. Summary of crystallographic structure determination statisticsa 
Crystal SNX5 PX-IncE  
Form 1 
SNX5 PX-IncE  
Form 2 
SNX5 PX-IncE  
Form 3 
PDB ID 5TGI 5TGJ 5TGH 
Data collection    
Wavelength (Å) 0.95370 0.95370 0.95370 
Space group P212121 I2 P32 
Cell dimensions      
    a, b, c (Å) 60.7, 67.5, 88.2 58.4, 80.3, 94.6 100.6, 100.6, 71.7 
    α, β, γ  (°)  90, 90, 90 90, 97.2, 90 90, 90, 120 
Resolution (Å) 60.7-1.98 (2.03-
1.98) 
31.9-2.6 (2.72-2.60) 50.3-2.80 (2.95-
2.80) 
Rmerge 0.104 (0.525) 0.153 (0.659) 0.101 (0.713) 
Rmeas 0.112 (0.572) 0.18 (0.777) 0.124 (0.873) 
Rpim 0.042 (0.225) 0.096 (0.408) 0.051 (0.363) 
<I> / σI 12.4 (3.4) 39.6 (3.2) 11.7 (2.3) 
Total number reflections 178868 (11000) 46691 (5757) 115149 (16861) 
Total unique reflections 26075 (1805) 13432 (1632) 20001 (2923) 
Completeness (%) 100 (100) 99.9 (100.0) 100 (100) 
Multiplicity 6.9 (6.1) 3.5 (3.5) 5.8 (5.8) 
Half-set correlation (CC(1/2)) 0.997 (0.868) 0.986 (0.55) 0.997 (0.683) 
    
Refinement    
Resolution (Å) 45.1- 1.98 (2.02-
1.98) 
31.9-2.6 (2.69-2.60) 41.2-2.8 (2.87-2.80) 
No. reflections/No. Rfree 26021/ 2000 13421/1342 
(1208/134) 
19975/1972 
(1301/144) 
Rwork/Rfree 0.192/0.214 
(0.221/0.246) 
0.199/0.242 
(0.276/0.332) 
0.236/0.254 
(0.329/0.372) 
No. atoms    
   Protein 2579 2619 5189 
   Solvent 281 69 0 
Average B-factor (Å2) 31.8 42.5 56.0 
R.m.s deviations    
    Bond lengths (Å) 0.012 0.011 0.015 
    Bond angles (°) 1.27 1.15 1.27 
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2.5 Discussion 
Although more than fifty putative Incs have been identified in C. trachomatis, the exact 
roles of these inclusion membrane proteins are still poorly understood. Chlamydiae 
manipulate the host cellular and signaling networks via interactions between the 
cytoplasmic region of Incs and numerous host cell proteins. Recent studies reported 
retrograde trafficking proteins as significant components of the inclusion, with sorting nexin 
family members being particularly enriched (26,27). In this study, we present the first 
reported crystal structure of a chlamydial inclusion protein (IncE) binding to its host effector 
protein (SNX5). While the detailed mechanism of IncE-mediated protein recruitment will be 
specific to this family member, the principle of extended cytoplasmic Inc sequences 
engaging with cellular host proteins on the inclusion is certain to be a general one. A 
simple analogy would be to consider the Inc proteins as being like a molecular ‘velcro’ that 
recognises and attaches host machinery needed for bacterial replication and survival.  
The manipulation of endocytic transport machinery is clearly critical for the obligate 
intracellular survival of C. trachomatis (26,27,31). In addition to C. trachomatis, SNX1, 
SNX2, SNX5, SNX6 and the associated retromer complex have also been directly 
implicated in the cellular pathogenesis of Coxiella burnetii (37), Salmonella enterica 
serovar Typhimurium (106), hepatitis C virus (107), human papilloma virus (108,109), and 
Legionella pneumophila (110). Broadly then the manipulation of SNX proteins and 
endosomal trafficking machinery by viral and bacterial pathogens is a common occurrence 
during intracellular infection, and points to a wide-ranging role in host-pathogen 
interactions. 
Typically PX domains of sorting nexins, including SNX1 and SNX2 (111,112), play 
an important role in endosomal membrane recruitment by binding the endosome-enriched 
lipid PtdIns3P through four conserved residues (8,38). These residues are conserved in 
most PX domains including in SNX1 and SNX2, but are entirely absent in SNX5, SNX6 
and SNX32. Although there is evidence for the weak association of the SNX5 PX domain 
with the lipid PtdIns(4,5)P2 from nuclear magnetic resonance (NMR) spectroscopy 
experiments (25), the crystal structure does not point to a clear binding mechanism. A 
second feature that sets SNX5-related proteins apart from the rest of the SNX family is the 
presence of an extended α-helical insertion. Our work confirms the central importance of 
this unique insert for the binding of the IncE inclusion protein, and provides the first clear 
description of how a PX domain can function as a protein-protein interaction scaffold as 
opposed to a lipid-binding domain.  
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The high degree of conservation in the IncE binding surface of SNX5 implies that 
this site is critical for the normal function of SNX5 and its homologs. Previously, the 
expression of a GFP-tagged IncE C-terminal domain was shown to interfere with the 
SNX5/SNX6-dependent retrograde trafficking of the cation-independent mannose-6-
phosphate receptor (CI-MPR) (26). Combined with our structural data, this infers that IncE 
is mimicking and interfering with SNX5/SNX6-mediated protein interactions, with a 
ligand(s) required for normal endosomal trafficking that remains to be discovered. Once 
recruited to the inclusion, SNX-BAR proteins are localized to the bulk membrane and 
dynamic tubules. While it is logical to imagine they could play a positive role in the 
sculpting of the inclusion, this is somewhat difficult to reconcile with the effect of SNX5 and 
SNX6 knockdown, which results in an increased production of C. trachomatis infectious 
progeny. Alternatively, although a pool of SNX5/SNX6 and associated SNX1/SNX2 
proteins remain on endosomes in C. trachomatis infected cells, their sequestering by the 
chlamydial inclusion may interfere with normal endosomal trafficking (Fig. 27D). It was 
thus proposed that the role of IncE could be to compete for SNX-retromer endosomal 
interactions, resulting in the breakdown of normal trafficking of the CI-MPR and lysosomal 
hydrolases and hence perturbation of the endolysosomal system’s capacity for bacterial 
destruction (26,27). Defining the precise role of SNX proteins and other endocytic 
machinery in chlamydial infection will clearly require further study.  
In conclusion, our work provides novel molecular insights into the mechanism of 
SNX protein coercion by the IncE chlamydial effector, and presents a blueprint for future 
studies of other inclusion protein activities. In addition, our results provide a possible clue 
to understanding how SNX5-related molecules mediate protein interactions required for 
canonical cell trafficking pathways.  
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    Chapter 3 
Recombinant expression of the SNX32 PX and SNX6 PX 
domains and their structural characterisation  
3.1 Introduction and Significance 
SNX32, a protein primarily expressed in neurons, is a SNX-BAR family member that is 
highly homologous to SNX5 and SNX6. As mentioned in chapter II, these proteins share a 
unique structure within their conserved phox homology (PX) domain, which sets them 
apart from the rest of the SNX protein family. In the previous chapter I reported the three-
dimensional X-ray crystallographic structure of the human SNX5 PX domain in complex 
with the IncE protein from Chlamydia trachomatis (113). The PX domain of SNX5 
possesses a helix-turn-helix structural insert (25), which is not found in any other SNX 
family members except for SNX6 and SNX32 (Fig. 33A). SNX5, SNX6 and SNX32 
proteins were shown to be recruited to Chlamydial infected cells and data from biophysical 
studies confirmed that a common structure within the SNX5, SNX6 and SNX32 PX 
domains is required for IncE interaction. The mutation of the key Phe116 side chain in the 
IncE peptide blocks binding to both the SNX6 and SNX32 PX domains as it does to the 
interaction with the SNX5 PX domain (113). 
In this chapter, using X-ray crystallography, I demonstrate and confirm that the 
SNX32 PX domain is closely structurally homologous to SNX5, and that it binds to IncE in 
an essentially identical manner. For this I have successfully performed recombinant 
expression and purification of the SNX32 PX domain, crystallised it in complex with a 
peptide derived from IncE and solved its crystal structure at a resolution of 2.3 Å. Although 
I was able to express and purify the SNX6 PX domain, to date I have only been able to 
grow microcrystals of this protein in complex with IncE that have so far resisted 
optimisation.  
As the mode of binding of IncE to SNX32 is found to be highly similar to the SNX5 
PX-IncE binding mechanism, it suggests that in this case also IncE might be mimicking 
endogenous cellular proteins that bind to this highly conserved SNX32 binding site. My 
structural studies thus confirm the biophysical data that was previously published and also 
provides indirect support for the idea that SNX32 functions in cargo recycling similarly to 
the well-characterised retromer-associated SNX-BAR proteins SNX6 and SNX6.  
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3.2 Material and methods 
3.2.1 Constructs and Peptides 
All synthetic peptides used for protein crystallisation were purchased from Genscript 
(USA). For the crystallisation set up, peptides were weighed and dissolved in water to 
make a stock peptide concentration of 10 mM. For crystallisation, this was diluted down to 
x2 molar excess to the protein molar concentration. 
The pGEX-4T-2 bacterial expression plasmids encoding the human SNX32 PX 
domain (residues 17-166) and the human SNX6 PX domain (residues 29-170) were 
synthesised and cloned by Genscript (USA). The constructs are N-terminally GST-tagged 
with site- specific thrombin cleavage sequence located between the GST moiety and the 
protein of interest. 
3.2.2 Transformation of expression plasmids using heat shock method 
Plasmid DNA encoding hSNX32PX and hSNX6PX were transformed into E. coli BL21 
CodonPlus competent cells with ampicillin and chloramphenicol (Amp+/Cm+) antibiotics. 
The competent cells were allowed to thaw on ice. Transformation was performed by 
transferring ~2-3 µl of around 0.1-1 µg of the particular cDNA into ~70 µl of thawed 
competent cells. The tube was gently tapped to mix. This mixture was incubated on ice for 
15 min, which was followed by heat shocking of cells at 42°C for 75 s. The incubation was 
continued on ice for another 2 min. 400 µl of Luria Bertani (LB) media was added into the 
mixture and was allowed to grow by incubating for 1 h at 37°C. After the incubation, 50 µl 
of the cells were plated onto the LB agar plates with ampicillin and chloramphenicol 
antibiotic resistance. The plates were incubated overnight at 37°C. 
3.2.3 Recombinant protein expression 
A single colony was picked from the LB agar plate and inoculated into LB media with 
ampicillin (0.1 mg/mL) and chloramphenicol (0.034 mg/mL). The media was then 
incubated at 37°C with under agitation overnight. The following day, 30 mL from the 
overnight culture was used to cultivate 1 L LB media containing ampicillin (0.1 mg/mL) and 
chloramphenicol (0.034 mg/mL) and incubated at 37 °C. Cells were grown until optical 
density at 600 nm (OD600) reached 0.5-0.6, and expression was induced with 0.5 mM 
IPTG. The growth is continued at 18°C for 16 h. Cells were harvested by centrifugation of 
the culture using Beckman rotor JLA 8.1000 (4,000 x g, 15 min, 4°C). The resulting pellets 
were resuspended in lysis buffer (50 mM Tris pH 8.0, 500 mM NaCl, 5% glycerol, 1 mM 
DTT, 50 µg/mL benzamidine and 1 µg/mL DNAseI) and stored at –80°C until required or 
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are directly subjected to cell disruption to continue with protein purification. 
3.2.4 Recombinant Protein purification 
The thawed cell suspension was lysed using a cell disruptor at 27 kPa at 5ºC. The cellular 
components of the lysed cells were pelleted using JA25.50 rotor at 15000 RPM for 30 min. 
Purification was performed using a two-step protocol: affinity chromatography with 
glutathione sepharose followed by gel filtration using Superdex 75 (16/600) column. The 
supernatant from the centrifugation step was collected and incubated with the equilibrated 
glutathione sepharose 4B resin (GE Healthcare) for 1 h at 4°C before eluting the flow 
through. After the flow through was eluted, the resin was washed with 10 bed volumes of 
equilibration buffer (50 mM Tris pH 8.0, 100 mM NaCl, 5% glycerol, 1 mM DTT). GST tag 
was cleaved by adding 100 units of Thrombin protease (Sigma-Aldrich) to the resin slurry 
and by incubating at room temperature overnight. The cleaved protein was eluted using 
the equilibration buffer and was subjected to further purification by fast protein liquid 
chromatography (FPLC) on a Superdex 75 (16/600) column (GE healthcare) which was 
pre-equilibrated using gel filtration buffer (50 mM TRIS pH 8.0 and 100 mM NaCl). 
Fractions corresponding to the protein of interest were pooled together and concentrated 
down (Amicon ultra-15 centrifugal units with a cut off of 10 kDa) to the desired protein 
concentration for further experiments. 
3.2.5 Protein crystallisation, data collection and structure determination 
SNX32 and SNX6 PX domains were concentrated to 12 mg/ml and 17 mg/ml respectively 
for crystallisation. These proteins were directly mixed together with the appropriate IncE 
peptide at a 2:1 molar ratio of peptide to protein and were incubated on ice for 1 h. To 
increase the chances of identifying a crystallisation condition for crystal nucleation, eight 
96-well crystallisation hanging-drop screens were set up using a Mosquito Liquid Handling 
robot (TTP LabTech) at 20°C in the UQ ROCX facility. After setting up these 96-well 
screens, the trays were incubated at 20°C in a Rockimager storage hotel (Formulatrix), 
where the drops were imaged at different time points for 21 days. For SNX32PX, 
optimized diffraction-quality crystals were obtained using streak seeding in sitting drop 
vapor diffusion plates. The crystallisation condition for SNX32 PX was 20% PEG 8000, 0.1 
M Tris base pH 8.0, 0.01 M MgCl2. Data were collected at the Australian Synchrotron MX1 
and MX2 Beamlines, integrated with iMOSFLM (93), and scaled with AIMLESS (94) in the 
CCP4 suite (95). The structures were initially solved by molecular replacement with 
PHASER (96) using the SNX5PX-IncE crystal structure as the input model (PDB code 
5TGI). The resulting model was rebuilt with COOT (114), followed by repeated rounds of 
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refinement with PHENIX (98). All structural figures were generated using PyMOL (DeLano 
scientific).  
For SNX6PX domain in complex with IncE, the reservoir condition that produced 
positive crystal hits in the initial 96-well plate was further optimized in a pH versus 
precipitant concentration grid screen around the reservoir condition 20% PEG 6000, 0.1 M 
NaAc pH 5.0, 0.01 M ZnCl2 using a sitting drop vapor diffusion method in a 24-well plate. 
3.3 Results 
3.3.1 Purification of the SNX6 PX domain 
In order to confirm the structural mechanism of SNX6 PX-IncE interaction I successfully 
expressed and purified SNX6 PX domain as described under 3.2.3 and 3.2.4. Samples 
from every step of purification were analysed on SDS-PAGE to ensure the presence of the 
protein of interest.  
 
 
 
Figure 28. FPLC chromatography profile of untagged SNX6-PX. The peak between 60-70 mls 
corresponds to the single bands (MW=16.2 kDa) on the gel (fractions 15-19). 
 
The theoretical molecular weight of untagged hSNX6-PX is around 16.2 kDa and 
was expected to elute as a monomeric species (when compared to the column standards) 
between 60 mL and 70 mL on a Superdex 75 (16/600) column. The affinity purified SNX6 
PX was eluted as one peak at the expected molecular weight. Fractions 15 to 19 
        Fractions  
 15  16  17  18   19 
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corresponding to the elution peak contained relatively pure SNX6 PX as shown in SDS-
PAGE analysis (Fig. 28). The protein was concentrated to 20 mg/ml for further ITC 
experiments as described in chapter II, and crystallisation experiments. 
3.3.2 Crystallisation trials of SNX6 PX in complex with IncE 
Out of eight different initial screens that I tried in 96-well trays, two conditions produced 
microcrystals of SNX6PX-IncE complex in 2 days. The reservoir conditions were 20% 
PEG 6000, 0.1 M NaAc pH 5.0, 0.01 M ZnCl2, and 20% PEG 4000, 5 mM CdCl2, and 0.1 
M Tris pH 8.0. These conditions were optimised in 24-well plates using a grid screen 
strategy. While I was able to successfully reproduce the crystals at a larger scale in both 
the conditions, unfortunately the crystals were still small, highly nucleated or clustered.  
 
A B C 
Figure 29. Crystals of SNX6PX-IncE complex from 20% PEG 6000, 0.1 M NaAc pH 5.0, 0.01 M 
ZnCl2 (A) Crystals obtained in the 96-well plate. (B) and (C) Crystals obtained after optimizing in 
24-well plate. 
 
Despite trying several optimisation strategies including decreasing the protein 
concentrations and precipitant concentrations, streak seeding into diluted reservoir 
solutions, adding glycerol to slow down the rate of nucleation upon mixing of protein with 
the conditions, I was not able to produce macrocrystals good enough for a high resolution 
structural analysis. The crystals from 20% PEG 6000, 0.1 M NaAc pH 5.0, 0.01 M ZnCl2 
were too clustered and small to collect any diffraction data (Fig. 29). Using the MX2 high 
intensity microfocus beamline at the Australian Synchrotron I was able to see protein 
diffraction to a resolution of ~6 Å from microcrystals obtained from the condition 20% PEG 
4000, 5 mM CdCl2, and 0.1 M Tris pH 8.0 (Fig. 30). While this is promising, the crystals 
still require further optimisation to yield macrocrystals. 
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Figure 30. Crystals of SNX6PX-IncE complex from 20% PEG 4000, 5 mM CdCl2, and 0.1 M Tris 
pH 8.0 (left panel). Right panel shows that these crystals diffracted to 6 Å (images obtained at the 
Australian Synchrotron MX2 beamline). 
3.3.3 Purification of SNX32PX domain 
As described in Chapter 2 the IncE protein binds equally well to the three proteins SNX5, 
SNX6 and the poorly characterized brain specific homologue SNX32. Fig. 31 shows the 
purification of the SNX32 PX domain after removal of the GST tag using a Superdex 75 
column, which yielded recombinant SNX32PX protein with a final purity of more than 95%. 
The SNX32 PX purification steps are described in greater detail in the materials and 
methods.  
 
 
 
Figure 31. FPLC chromatography profile of untagged SNX32-PX domain. The fractions (15 to 19) 
from the major peak around 60-70 mls correspond to the single bands on the gel (MW=15.6 kDa).  
        Fractions  
 15  16  17  18  19 
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3.3.4 Crystallisation and structural determination of SNX32-PX in complex with IncE 
Performing crystallisation screens of the SNX32 PX domain in the presence of the IncE 
peptide (similar to SNX6 described above) yielded rectangular-shaped and needle-shaped 
crystals in two conditions out of 760 initial screen conditions using commercial kits.  
After trying several optimization strategies including decreasing the protein 
concentrations and precipitant concentrations, and streak seeding into diluted reservoir 
solutions, I obtained single macro crystals that were used to obtain X-ray diffraction at the 
Australian Synchrotron beamlines. The reservoir condition that yielded the diffracting 
crystal was 20% PEG 8000, 0.1M Tris base pH 8.0, 0.01M MgCl2 (Fig. 32).  
 
A B 
Figure 32. Crystals of SNX32PX-IncE complex in the reservoir condition 20% PEG 8000, 0.1M 
Tris base pH 8.0, 0.01M MgCl2 before (A) and after (B) streak seeding 
 
After collecting high-resolution diffraction data I then determined the structure of the 
SNX32-IncE complex using molecular replacement, with the SNX5 PX domain as my 
initial template structure. The final refined structure of the SNX32 PX domain is highly 
similar to SNX5 as expected (Fig. 33B). It is composed of a three-stranded β-sheet (β1, 
β2 and β3) followed by three closely packed α-helices. The first and second α-helices are 
connected by an extended proline-rich sequence. Typically PX domains have been found 
to bind to the endosome-enriched lipid phosphatidylinositol-3-phosphate (PtdIns3P) via a 
basic pocket formed at the junction between the β3 strand, α1 helix and ΨPxxPxK loop 
(Pro-rich loop). In contrast SNX5, SNX6 and SNX32 possess major alterations in the 
PtdIns3P-binding pocket that preclude canonical lipid head-group docking. In addition they 
possess a unique extended helix-turn-helix insert between the ΨPxxPxK loop and α2 helix 
of unknown function.  
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Figure 33. (A) Sequence alignment of human SNX1, SNX5, SNX6 and SNX32 PX domains. 
Conserved residues are indicated in red. Side-chains that directly interact with IncE in the 
crystal structure are indicated with black circles. Mutation that block IncE binding is highlighted 
with red triangle. (B) Crystal structure of the SNX32 PX domain (green) in complex with IncE 
residues 107-132 (orange) shown in cartoon diagram. All structure images were generated 
using PyMOL (Delano Scientific) (C) Superposition of crystal structure of SNX32PX-IncE 
backbone with SNX5PX-IncE backbone. 
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The crystals of SNX32PX-IncE diffracted to a resolution of 2.26 Å and belong to 
spacegroup I121 (Table 4). The superposition of SNX32PX-IncE and SNX5PX-IncE 
crystal structures reveal the mode of IncE binding in both cases as nearly identical (Fig. 
33C). Just as in SNX5PX-IncE crystal structure, the IncE sequence forms a long β-hairpin 
structure that binds within a complementary hydrophobic groove, at the base of the 
extended α-helical insertion of the SNX32 PX domain and adjacent to the β-sheet sub-
domain (Fig. 33C). The β-hairpin structure of IncE is directly incorporated as a β-sheet 
augmentation of the β1, β2 and β3 strands of SNX32. Aside from main-chain hydrogen 
bonding to form the extended β-sheet, IncE Phe116 forms a π-stacking with the SNX32 
Phe136 side-chain similar to what is seen in the SNX5 complex (Fig. 34A and 34B). In our 
previous paper it has been shown that mutation of the IncE Phe116 completely abolishes 
the binding of SNX32 to the Chlamydial protein IncE (113).  
 
 
Figure 34. Interactions between SNX32 (green) and IncE (orange). (A) Close up of the SNX32PX-
IncE interface highlighting the important interactions between SNX32PX and the N-terminus of 
IncE. (B) Close up of the SNX32PX-IncE interface highlighting the important interactions between 
SNX32PX and the C-terminus of IncE. (C) Sequence conservation of SNX32PX and its related 
proteins (calculated using CONSURF). 
 68 
Table 4. Summary of crystallographic structure determination statistics 
Data collection  
Wavelength (Å) 0.95370 
Space group I121 
Cell dimensions    
    a, b, c (Å) 90.8, 46.0, 134.2 
    α, β, γ  (°)  90, 105.58, 90 
Resolution (Å) 83.68-2.26 (3.27-2.27) 
Rmerge 0.151 (0.894) 
Rmeas 0.176 (1.046) 
Rpim 0.063 (0.540) 
<I> / sI 10.7 (2.5) 
Total number reflections 187434 (15896) 
Total unique reflections 25168 (2222) 
Completeness (%) 99.7 (97) 
Multiplicity 7.5 (7.2) 
Half-set correlation (CC(1/2)) 0.996 (0.726) 
  
Refinement  
Resolution (Å) 43.77- 2.27 (2.35-2.27) 
No. reflections/No. Rfree 25103/ 1280 
Rwork/Rfree 0.186/0.235(0.193/ 0.231) 
No. atoms  
   Protein 2676 
   Solvent 57 
Average B-factor (Å2) 26.3 
R.m.s deviations  
    Bond lengths (Å) 0.014 
    Bond angles (°) 1.264 
3.4 Discussion 
The main objective of this chapter was to understand how the chlamydial inclusion protein 
IncE binds to SNX32PX and also to compare the binding mechanism with that of 
SNX5PX-IncE. The binding affinity of the IncE C-terminal sequence 
(PANGPAVQFFKGKNGSADQVILVTQ) towards SNX32 was found to be Kd ~1.15 µM in 
chapter 2, which was very similar to the binding affinity of IncE to SNX5 (Kd ~1 µM). This 
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data basically confirmed that IncE would be binding within the same site. The X-ray crystal 
structure clearly confirms this model.   
In vivo, SNX32 appears to be exclusively expressed in neuronal cells based on 
microarray studies (biogps.org). Therefore it is unlikely it would ever actually encounter 
chlamydial pathogens during their infection cycle. However, the fact that SNX32 binds to 
IncE in the same way as SNX5 leads us to the same conclusion that IncE is mimicking 
endogenous SNX5, SNX6 and SNX32 binding proteins, which would normally bind to the 
same conserved groove for their normal function in the cell (Fig. 34C). There have been 
recent reports that suggest the SNX5 may directly interact with transmembrane cargos 
sorted by the SNX-BAR protein at endosomes via its PX domain. For example, both 
CIMPR and IGF1R were found to be interacting with the SNX5 PX domain via their 
cytoplasmic domains (115,116). As described in the following chapter, I now show that 
these cargos do indeed bind to the same site as IncE, and begin to dissect this normal 
functional role of the conserved SNX5/SNX6/SNX32 proteins.  
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   Chapter 4 
Structural basis for the interaction of transmembrane cargoes 
with the SNX-BAR proteins 
4.1 Introduction and significance 
The retromer complex is a highly conserved multiprotein complex that co-ordinates 
recycling of various transmembrane cargo proteins from endosomes either to trans-Golgi 
network (TGN) or back to the plasma membrane. In yeast, retromer is composed of two 
subcomplexes; i) the vacuolar protein sorting (Vps) core consists of three proteins Vps35, 
Vps29 and Vps26 and ii) two members of the sorting nexin (SNX) protein family Vps5p 
and Vps17p. Vps5 and Vps17 contain C-terminal bin-Amphiphysin-Rvs (BAR) domains 
that form Vps5p/Vps17p heterodimers, and assemble into higher order helical arrays 
promoting membrane curvature to encourage endosomal membrane tubulation (117). 
Both subcomplexes contribute towards separate roles during the recycling of cargoes. 
According to the current working model of retromer-dependent cargo recycling, the Vps 
core directly binds to the intracellular cytosolic domains of the transmembrane cargo 
molecule and promotes the enrichment of cargo molecules in endosomal retrieval 
subdomains, away from the subdomains assigned for protein degradation. Once the local 
concentration of the selected cargo is high enough, cargoes are coupled by retromer to 
the Vps5p/Vps17p membrane tubules to form cargo-containing tubular transport carriers, 
which then enable the recycling of cargoes to different destinations (16,17,118). 
In mammalian cells, the core retromer components are very highly conserved and 
the model of retromer activity is considered to be generally the same as in yeast. The 
major difference is that the SNX-BAR dimers present in mammalian cells are composed of 
either SNX1 or SNX2 (orthologues of Vps5p) heterodimers with SNX5 or SNX6 
(orthologues of Vps17p) (16,18,87). However, the biochemical evidence for a stable 
interaction between the Vps core and SNX-BAR sub complexes in mammalian cells has 
been more elusive than with the yeast counterparts. So far, the accepted connection 
between these two sub complexes was through their proposed mutual functional role in 
the retrograde trafficking of cation-independent mannose 6-phosphate (CI-MPR) 
(119,120). This receptor delivers lysosomal hydrolases from the Golgi to the endosomes, 
and then is recycled back to the Golgi from endosomes (14,121,122) through a process 
that was believed to require direct interaction of the CI-MPR tail with the VPS trimer of the 
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retromer complex (119,120).  
This previously accepted model of retromer activity and the co-operation of Vps 
core and SNX-BAR dimer subcomplexes was recently questioned by two separate studies 
from the Steinberg and Cullen laboratories (115,116). These two groups found that the 
Vps35/Vps26/Vps29 core complex was less important for CI-MPR trafficking (and 
trafficking of a variety of other receptors) than the SNX-BAR dimer heterodimers. Using 
several knockdown, knockout and rescue experiments, these reports showed that the loss 
of SNX-BAR dimers results in steady state redistribution of CI-MPR from the Golgi to the 
endosomes, due to an inability to enter transport tubules. In contrast the loss of Vps 
trimers did not cause CI-MPR redistribution on endosomes. Simonetti et al. and Kvainickas 
et al. also observed in WT cells that the CI-MPR receptor predominantly overlaps with 
SNX-BAR dimer in an endosomal subdomain spatially separate from Vps trimer, thus 
contradicting previous studies that reported interaction of CI-MPR with Vps35 (119).  
While this work and the relative contributions of the Vps timeric core and the SNX-
BAR proteins are still debated (123), it is clear that the SNX-BAR proteins play a key role 
in cargo recruitment in mammalian cells. The proteomics studies identified a number of 
important transmembrane cargo proteins whose trafficking is specifically dependent on 
SNX5 and SNX6 (115,116). In addition to CI-MPR, these cargoes included Insulin-like 
growth factor 1 receptor (IGF1R) and Semaphorin- 4C precursor (SEMA4C). In chapter 2 
and 3, I have reported that the Chlamydial effector protein IncE binds to a conserved 
hydrophobic groove on the PX domain of SNX5 (113). Elwell et al. further showed IncE 
displaces CI-MPR from SNX5 (124), which leads to the speculation that the same binding 
site on SNX5 (and possibly SNX6 and the brain specific homologue SNX32) mediates 
interactions with the transmembrane cargoes. Mutation of the SNX5 PX domain residues 
F136D and Y132D revealed loss of CI-MPR and IGF1R binding supporting this model 
(115,116). The WLM motif in the cytoplasmic tail of CI-MPR was found to be required for 
their binding and sorting by the SNX-BAR dimer (115,120). Since not all cargoes contain 
this motif, different binding motifs on the cargoes might explain the cargo selectivity for 
these SNX-BAR proteins.  
In unpublished work, our collaborators Dr. Boris Simonetti and Prof. Peter Cullen 
(Bristol, UK) have mapped the binding of SNX5 to several selected cargoes (CI-MPR, 
IGF1R and SEMA4C) through immunoprecipitation experiments of various receptor 
truncations. This work has identified a region with a conserved sequence on all three 
cargoes V-x-[F/Y]-x-Y-S (where x can be any amino acid) (Fig. 35). Our hypothesis is this 
sequence represents a specific sorting motif mediating direct interaction between the 
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transmembrane cargoes and the PX domains of SNX5, SNX6 and SNX32.  
Figure 35. Sequence alignment of the cytoplasmic tail of CIMPR, IGF1R and SEMA4C showing 
the conserved V-x-F/Y-x-Y-S sequences that could potentially be the binding site on the 
transmembrane cargoes. 
 
 In this chapter, using isothermal titration calorimetry (ITC) and X-ray 
crystallography, I demonstrate and confirm that the PX domains of SNX5, SNX6 and 
SNX32 directly bind to the conserved cytoplasmic motifs from each of these receptors 
CIMPR, IGF1R and SEMA4C. I also report the first crystal structure of the PX domain of 
SNX5 bound to a transmembrane cargo protein, providing the very first structural 
information on how SNX-BAR proteins can directly regulate transmembrane protein 
recycling. For this I have successfully performed recombinant expression and purification 
of the SNX5, SNX6 and SNX32 PX domains and studied their interaction with the cargo 
peptides using ITC, crystallised the SNX5 PX domain in fusion with CIMPR and solved its 
crystal structure at a resolution of 3.1 Å.  
The results from this chapter validate and confirm the hypothesis from chapter 2 
(113), chapter 3 and the recent publications (115,116) that the SNX-BAR proteins bind 
directly to the transmembrane cargoes, independent of the Vps core subcomplexes. This 
confirms the that SNX5 PX domain functions as a site for the normal transporting of 
proteins/cargoes that is fundamental to all living cells. My structural studies will now be 
used to design specific point mutations in SNX5 and the cargo receptors to confirm the 
importance of these interactions in receptor recycling in cell assays to be performed in 
Bristol. Further optimisation of SNX5-CIMPR crystal data and future crystal structures of 
SNX5-IGF1R fusion and SNX5-SEMA4C complexes will provide molecular insights into 
the biologically critical endosome to trans-Golgi network (TGN) and endosome-to-plasma 
membrane trafficking of potentially many different transmembrane cargoes via the SNX-
BAR-mediated pathway.  
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4.2 Material and methods 
4.2.1 Peptides and expression constructs 
All synthetic peptides used for ITC experiments (Table. 5) were purchased from Genscript 
(USA). For the ITC experiments, peptides were weighed and dissolved in 50 mM HEPES 
(pH 8.0) and 100 mM NaCl (ITC buffer) to make a stock peptide concentration of 2 mM, 
which was diluted to 0.75 mM before use.  
All bacterial expression constructs for human SNX proteins were synthesized and 
cloned into pGEX-4T-2 by Genscript (USA). These included the SNX5PX-CIMPR fusion 
(SNX5 residues 26–170 with CI-MPR residues 17–44 fused at the C-terminus), SNX5PX-
IGF1R fusion (SNX5 residues 26–170 with IGF1R residues 313-341 fused at the C-
terminus) SNX5PX-SEMA4C fusion (SNX5 residues 26–170 with SEMA4C residues 45-73 
fused at the C-terminus), SNX32PX-CIMPR (SNX32 residues 17-166 with CIMPR 
residues 17-44 fused at C-terminus) and SNX5PX (residues 26-170) F136D mutant. The 
constructs are N-terminally GST-tagged with site- specific thrombin cleavage sequence 
located between the GST moiety and the protein of interest.  
 
Table 5. List of transmembrane cargo peptides used in this chapter 
Peptides Sequences 
CIMPR_1 SNVSYKYSKVNKEEETDENETEWLMEEIQ 
CIMPR_2 SNVSNKYSKVNKEEETDENETEWLMEEIQ 
CIMPR_3 SNVSYKYSKVNKEEETDENETEAAAEEIQ 
IGF1R_1 GFREVSFYYSEENKL 
IGF1R_2 REASAYASEENKLPE 
SEMA4C WDPVGYYYSDGSLKIVPGHARCQPG 
4.2.2 Recombinant protein expression and purification 
All constructs were expressed in Escherichia coli BL21 Codon Plus supplemented with 
appropriate antibiotics. Single colonies from cultures grown on LB agar plates were 
inoculated into 50 mL Luria-Bertani (LB) broth with ampicillin (0.1 mg/mL) and 
chloramphenicol (0.1 mg/mL), and grown at 37°C with shaking overnight. The following 
day, 30 mL from the overnight culture was used to inoculate 1 L LB media containing 
ampicillin (0.1 mg/mL) and chloramphenicol (0.1 mg/mL) and incubated at 37°C. Cells 
were grown to an optical density (OD) of 0.7-0.8 at 600 nm and induced with 0.5 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG). Cultures were incubated with shaking 
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overnight at 18°C. Cells were harvested using a Beckman rotor JLA 8.1000 at 4000 RPM 
for 15 min at 4°C. Pellets were resuspended in 10 mL lysis buffer (50 mM Tris (pH 8.0), 
100 mM NaCl, 5% glycerol, 1 mM DTT, 0.1 mg/ml benzamidine, 0.1 mg/ml DNase) per 
litre of culture. The cells were subjected to cell disruption and centrifugation using JA 
25.50 at 18,000 RPM for 30 min at 4°C. The soluble fractions were first purified using 
affinity chromatography with glutathione-sepharose, and the GST tags were cleaved by 
thrombin while still bound to the column. The proteins were eluted in 50 mM Tris (pH 8.0), 
100 mM NaCl, 5% glycerol, and 1 mM DTT, and then further polished using gel filtration 
chromatography (Superdex 75 or 200, GE healthcare) in a buffer containing 50 mM 
HEPES (pH 8.0), 100 mM NaCl. The fractions corresponding to the respective proteins 
were then pooled and concentrated for ITC experiments or crystallization. 
4.2.3 Isothermal titration calorimetry (ITC) 
ITC experiments were performed on a MicroCal PEAQ-ITC instrument at 25°C. The 
proteins were buffer exchanged into ITC buffer (50 mM HEPES (pH 8.0) and 100 mM 
NaCl) by gel filtration prior to ITC experiments. Transmembrane cargo peptides at 0.75 
mM were titrated into 50 mM PX domain samples. The binding data was processed using 
MicroCal PEAQ-ITC analysis software with a single site-binding model to determine the 
stoichiometry (n), the binding constant (Kd), the estimated heat of binding (ΔH), the Gibbs 
free energy (ΔG) and the binding entropy (ΔS). Three experiments were performed for 
each set of samples to determine the average ± standard error of the mean (SEM) for 
thermodynamic quantities, except for the peptide mutations and SNX32PX interaction 
experiments where only single experiments were performed. For these single experiments, 
all experiments were performed using the same batch of protein to allow direct 
comparisons to be made. 
4.2.4 Protein crystallization, data collection and structure determination 
All proteins were concentrated to 12 mg/ml for crystallization. Four 96-well crystallization 
hanging-drop screens were set up using a Mosquito Liquid Handling robot (TTP LabTech) 
at 20°C in the UQ ROCX facility. After setting up these 96-well screens, the trays were 
incubated at 20°C in a Rockimager storage hotel (Formulatrix), where the drops were 
imaged at different time points for 21 days. Data were collected at the Australian 
Synchrotron MX2 Beamline, integrated with iMOSFLM (93), and scaled with AIMLESS 
(94) in the CCP4 suite (95). The structures were initially solved by molecular replacement 
with PHASER (96) using the SNX5PX-IncE crystal structure as the input model (PDB code 
5TGI) (113). The resulting model was rebuilt with COOT (114), followed by repeated 
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rounds of refinement with PHENIX (98). All structural figures were generated using PyMOL 
(DeLano scientific).  
4.3 Results 
4.3.1 Purification of SNX5PXF136D mutant construct 
To understand the interaction between SNX5PX mutant and different transmembrane 
cargoes through ITC, I successfully expressed and purified SNX5PXF136D mutant 
construct to be used as a negative control. Fig. 36 shows the purification of this construct 
after the removal of the GST tag using a Superdex 200 column. The theoretical molecular 
weight of untagged SNX5PXF136D is around 17 kDa and was eluted as monomeric 
species (when compared to the column standards) between 80 mL and 100 mL on a 
Superdex 200 (16/600) column.   
 
 
Figure 36. FPLC chromatography profile of untagged SNX5PXF136D mutant. The fractions from 
22 to 25 from the major peak around 80-100 mls correspond to the single bands on the gel 
(MW=17 kDa). 
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4.3.2 Interaction studies between the PX domains of SNX5, SNX6, SNX32 and 
SNX5PXF136D with the cytoplasmic tail of transmembrane cargoes 
Having observed interaction of PX domains of SNX5, SNX6 and SNX32 and 
transmembrane cargoes through immunoprecipitations (Simonetti and Cullen, personal 
communication), I investigated whether these SNX-BAR proteins can interact directly with 
the selected transmembrane cargoes CI-MPR_1, IGF1R_1 and SEMA4C using ITC (Fig. 
37).  
The experiments were set up to describe binding of synthetic peptides mimicking 
cytoplasmic tails of transmembrane cargoes to the recombinantly produced PX domains of 
SNX-BAR proteins using isothermal titration calorimetry (ITC). The details of synthetic 
peptides are presented in table 5 under 4.2.1. 
PX domains of SNX5, SNX6 and SNX32 bound directly to CI-MPR_1 with similar 
affinities, with Kd ≈ 26 µM, 25 µM and 28 µM respectively (Fig. 37A). While SNX5PX and 
SNX32PX bound to IGF1R_1 (Kd ≈ 16 µM and 19 µM respectively), SNX6PX failed to do 
so (Fig. 37B). Interestingly, this also correlates with an inability of SNX6 to co-
immunoprecipitate with the IGF1R in cell lysates (Simonetti and Cullen, personal 
communication). SNX5, SNX6 and SNX32 (Kd ≈ 14 µM, 13 µM and 12 µM respectively) 
bound to SEMA4C with similar affinities (Fig. 37C). 
 
A B C 
Figure 37. ITC profiles for the binding of the PX domains of SNX5, SNX6 and SNX32 to the 
transmembrane cargoes (A) CIMPR_1 (SNVSYKYSKVNKEEETDENETEWLMEEIQ), (B) 
IGF1R_1 (GFREVSFYYSEENKL) and (C) SEMA4C (WDPVGYYYSDGSLKIVPGHARCQPG). 
 
To validate the region of binding on the transmembrane cargoes, I tested the 
interaction abilities of mutated residues in the hydrophobic patch on CI-MPR_1 and 
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IGF1R_1 as well as the WLM motif in CI-MPR_1. CI-MPR_1 mutations in the V-x-F-x-Y-S 
motif (CI-MPR_2) blocked binding to the SNX5PX, whereas mutations to the WLM motif 
(CI-MPR_3) reduced the affinity but still bound weakly to SNX5PX (Fig. 38A). The 
IGF1R_1 mutations in the V-x-F-x-Y-Y motif (IGF1R_2) also failed to bind to SNX5PX 
(Fig. 38B), suggesting that the hydrophobic motif in the cytoplasmic tail of the cargoes are 
important in the interaction with the SNX-BAR proteins. The SNX5PX mutant F136D was 
also tested against CIMPR_1 to confirm the importance of this residue in SNX5PX for the 
binding. CIMPR_1 was completely inhibited from binding to SNX5PXF136D (Fig. 37A). 
A B 
Figure 38. ITC profile for the binding of the SNX5PX domain to the CIMPR_1 and IGF1R_1 
mutants; (A) CIMPR_2 (SNVSNKYSKVNKEEETDENETEWLMEEIQ) and CIMPR_3 
(SNVSYKYSKVNKEEETDENETEAAAEEIQ), and (B) IGF1R_2 (REASAYASEENKLPE). 
 
4.3.3 Purification of native and seleno-methionine SNX5PX-CIMPR fusion protein for 
crystallisation 
In order to study the structural interaction between SNX5PX and the cytoplasmic tail of 
CIMPR through X-ray crystallography, I successfully expressed and purified SNX5PX-
CIMPR fusion constructs as described under 4.2.2. Samples from every step of 
purification were analysed on SDS-PAGE to ensure the presence of the protein of 
interest. Fig. 39 shows the purification of the SNX5PX-CIMPR construct after the removal 
of the GST tag using a Superdex 200 column.  
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The theoretical molecular weight of untagged SNX5PX-CIMPR fusion is around 
20.6 kDa and was eluted as dimeric species (when compared to the column standards) 
between 50 mL and 60 mL on a Superdex 200 (16/600) column.  The purification yielded 
recombinant proteins of 27 mg/ml. 
 
 
 
Figure 39. FPLC chromatography profile of untagged SNX5PX-CIMPR fusion. The major peak 
(between 50-70 mls) fractions (13-17) correspond to the single bands on the gel (20.6 kDa).  
 
To allow me to unambiguously assign the binding site of the CIMPR sequence I 
also expressed and purified seleno-methionine SNX5PX-CIMPR fusion protein. As the 
CIMPR sequence includes a Met residue the anomalous signal from the incorporated 
selenium atom should allow me to identify its precise binding site even with low-resolution 
data. The seleno-methionine expression was kindly performed for me by Mr. Ryan Hall 
who is a research assistant in our lab, whereas the purification and crystallisation trials 
were carried out by me. The purification was performed using 50 mM HEPES pH 7.5, 100 
mM NaCl, 2 mM DTT using a Superdex 200 (16/600) column. Fig. 40 shows the 
purification of seleno-methionine SNX5PX-CIMPR fusion. The purification yielded soluble 
proteins of 16 mg/ml.  
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Figure 40. FPLC chromatography profile of untagged seleno-methionine SNX5PX-CIMPR fusion. 
The fractions (20-24) from the major peak between 80-100 mls correspond to the monomeric 
species and the single bands on the gel. 
4.3.4 Crystallisation of native SNX5PX-CIMPR fusion complex and structure 
determination 
96-well crystallisation screens of the native SNX5PX-CIMPR fusion yielded many 
spherulites. A few needle-shaped and rod-shaped crystals were formed under four 
conditions out of nearly 600 initial screen conditions that were set up using commercial 
kits. The needle crystals were sent to MX2 beamline to obtain the initial diffraction data 
(Fig. 41A). The reservoir condition that yielded the diffracting crystal was 30% (v/v) PEG 
300, 0.1 M BIS-TRIS Propane pH 7.0, 15% (w/v) PEG 1000. 
 
A B C D 
Figure 41. Crystals of native SNX5PX-CIMPR fusion from 96-well plates. (A) Needle-crystals that 
were sent to MX2 beamline for the initial diffraction data. (B-D) Crystal hits of native SNX5PX-
CIMPR in other reservoir conditions. 
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After collecting low-resolution diffraction data, I have determined the structure of the 
native SNX5PX-CIMPR complex using molecular replacement, with the SNX5PX structure 
as the initial template model. The small crystals of the native SNX5PX-CIMPR have to 
date only diffracted to a low resolution of 3.1 Å and belong to spacegroup C2221. The C 
terminal of SNX5PX is connected to the N-terminal of CIMPR, and I could determine from 
difference electron density maps that the CIMPR sequence binds to the next SNX5PX in 
the asymmetric unit (Fig. 42). The binding site of CIMPR on SNX5PX is identical to where 
IncE binds to SNX5PX, and the density clearly reveals the formation of a similar β-hairpin 
structure. This provides structural evidence for the claim that IncE displaces CIMPR 
inorder to bind to SNX5PX. 
 
 
Figure 42. Native SNX5PX-CIMPR fusion crystal structure showing the CIMPR peptide (orange) 
bound to SNX5PX (green) as β-hairpin structure. 
The CIMPR forms a long β-hairpin structure that binds within a complementary 
hydrophobic groove, at the base of the unique extended helix-turn-helix insert between the 
ΨPxxPxK loop and α3 helix of SNX5PX, and adjacent to the β-sheet sub-domain (β1, β2 
and β3) (Fig. 42). The main chain hydrogen bonds between CIMPR and SNX5PX are 
visible, but currently the resolution of the crystal structure is too low and the electron 
density is of relatively poor quality (Fig. 43), which prevents me from confidently assigning 
the CIMPR side chains. Thus from these initial small crystals I am currently unable to 
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precisely define the residues that are most important in forming a stable complex with 
SNX5PX. Further optimizations of the SNX5PX-CIMPR crystal hits are being undertaken, 
and I have also successfully reproduced the crystals using SeMet-labeled protein. These 
latter crystals will hopefully allow precise placement of the CIMPR “WLM” sequence within 
the complex crystal structure.  
 
Figure 43. CIMPR peptide 
(orange) modelled into the 
electron density. 
The needle crystals of the native SNX5PX-CIMPR from the 96-well plate that 
produced the above structure is now reproduced in a 24-well sitting drop crystallisation 
plate (Fig. 44A). Seleno-methionine SNX5PX-CIMPR crystals are optimised as well. Sel-
Met SNX5PX-CIMPR produced initial hits in 96-well as clustered crystals in the reservoir 
condition 30% (w/v) PEG 5000 MME, 0.1 M MES pH 6.5, 0.2 M ammonium sulphate (Fig. 
44B). This is now further optimised through addition of different concentrations of glycerol 
(Fig. 44C) and additive screen (Fig. 44D, 44E and 44F), which has yielded promising 
crystals. These will be used to collect X-ray data. 
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Figure 44. (A) Optimised crystals of native SNX5PX-CIMPR in 30% (v/v) PEG 300, 0.1 M BIS-
TRIS Propane pH 7.0, 15% (w/v) PEG 1000; (B) Clustered crystals of seleno-methionine SNX5PX-
CIMPR in 30% (w/v) PEG 5000 MME, 0.1 M MES pH 6.5, 0.2 M ammonium sulphate (C) 
Clustered crystals optimised in 75% of 30% (w/v) PEG 5000 MME, 0.1 M MES pH 6.5, 0.2 M 
ammonium sulphate with 15% glycerol (D-F) Clustered crystal better with the addition of additive 
screen 40% (v/v) Polypropylene glycol P 400, 30% (v/v) (+/-)-2-Methyl-2,4-pentanediol and 50% 
(v/v) Jeffamine M-600 pH 7.0 
4.4 Discussion 
Two recent studies (115,116) reported that transmembrane cargoes depend on the direct 
interaction with the heterodimeric combinations of SNX1 and SNX2 with the SNX5 and 
SNX6 proteins for their retrograde and endosomal recycling, independent of the Vps core 
of retromer complex. This is in contrast to the previously accepted models that proposed 
the Vps core subcomplex makes a direct contact with the transmembrane cargoes 
(119,120). Although the newest studies strongly suggest SNX5, SNX6 (and potentially 
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SNX32) are the cargo-interactive regions; it was unclear how this binding between SNX-
BAR proteins and the cargoes are achieved. In this work I provide the first biochemical 
and structural evidence for the direct interactions of the SNX-BAR proteins with a specific 
cargo-sorting motif.  
My previous SNX5PX-IncE structure and biochemical experiments (113), the 
comparative proteomic reports based on the mutations of the SNX5PX-IncE binding 
residues (115,116), and the displacement experiment reported by Elwell et al. (124), all 
lead to the hypothesis that CIMPR, IGF1R and SEMA4C binds to a common binding 
region within the PX domain of SNX5. In this chapter, using biochemical experiments and 
X-ray crystallography, I have demonstrated that the cytoplasmic tails of transmembrane 
cargoes CIMPR, IGF1R and SEMA4C, containing a conserved V-x-F/Y-x-Y-S region, 
directly interact with the PX domains of SNX5, and its homologues SNX6 and SNX32. 
Using ITC, the binding affinity of each cargo for the SNX-BAR proteins was measured. 
When compared to SNX6 and SNX32, SNX5PX bound tightly to the transmembrane 
cargos trafficked from endosome to the TGN; CIMPR_1, more than to the two other 
endosome to plasma membrane cargoes IGF1R_1 and SEMA4C. While SNX5PX and 
SNX32PX successfully interacted with all three cargoes, SNX6PX failed to bind to 
IGF1R_1. This has also been observed in unpublished immunoprecipitation data (Boris 
Simonetti and Peter Cullen, personal communication). This indicates a specific and likely 
subtle structural motif in SNX5 and SNX32 enables the binding of IGF1R_1, which is 
absent or hindered in SNX6PX. As expected, the ITC experiments using SNX5PXF136D 
mutation was found to block interactions with the cargoes. Mutations to the V-x-F/Y-x-Y-S 
motif and WLM motif of CIMPR as well as the V-x-F/Y-x-Y-S motif of IGF1R cargoes also  
confirms that there are critically important residues within the cargo motifs that are 
essential for the interaction. 
The low-resolution crystal structure of SNX5PX-CIMPR fusion demonstrated and 
provided structural evidence that the CIMPR and IncE binds on the same binding site in 
SNX5PX. Even though CIMPR does not possess sequence similarity with IncE, the 
identified hydrophobic patch in SNX5 is enough for the binding to the CIMPR peptide. The 
poor electron density due to the low-resolution prevents me from confidently modelling the 
side chains at present and thus prevents me from recognising the specific residues in 
CIMPR important in forming a stable complex with SNX5PX. At present I believe the β-
hairpin structure formed by CIMPR is likely to be composed of the N-terminal VSYKYS 
(strand 1) motif and the C-terminal WLM motif (strand 2). I hope to confirm this in future 
work by obtaining a higher resolution crystal structure, and I will also use seleno-
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methionine labelling of the SNX5PX-CIMPR fusion to unambiguously place the WLM motif 
in the correct position within the structure. IGF1R and SEMA4C consist exclusively of the 
V-x-F/Y-x-Y-S region and do not possess the additional WLM motif. This suggests they 
could be potentially forming a single stranded linear structure through their V-x-F/Y-x-Y-S 
region rather than a β-hairpin structure. The crystal structures of SNX5PX with these 
different cargoes will enable us to understand the different conformations cargoes adopt to 
bind to SNX5PX. Structure-based mutagenesis will be performed to confirm the cargo 
interaction mechanisms in vitro, and can be tested for defective cargo trafficking in vivo in 
the future.  
The continuous inflow of cargoes through endocytic routes and transport to different 
intracellular destinations contribute to the complexity of endosomal sorting pathways. 
Different reports of SNX family members as cargo-selective proteins have been published, 
and they have been linked to sorting of cargoes from endosomes to both the trans-Golgi 
network (TGN) and the plasma membrane. SNX3 proteins mediate the retrograde 
trafficking of metal transporter Dmt1-II and Wntless receptor (125,126). The PDZ domain 
of SNX27 forms a complex with the retromer subunit Vps26, and recognises specific 
recycling cargoes in phosphorylated states (127,128).  
In our case, SNX-BAR proteins, SNX5, SNX6 and SNX32 can regulate endosome 
to TGN and endosome to plasma membrane trafficking of cargoes in a sequence-
dependent manner. These diverse recycling pathways logically bring up a challenging 
question of how one protein complex can be involved in trafficking different cargoes to 
their different destinations. There are several possibilities that can be speculated on. One 
would be the formation of specific protein machineries around the SNX-BAR dimer sub 
complex that provide pathway specificity for the different cargo molecules. Kvainickas et 
al. (2017) propose a two-step procedure for the recycling of cargoes. The first step 
involves SNX-BAR complex binding specifically to the cargoes, and diverting them into a 
SNX-BAR tubule thus avoiding degradation of the cargoes. During the second step the 
additional protein machineries such as SNX3-retromer or SNX27-retromer then sort 
cargoes to other destinations  
Understanding the different retromer-SNX cargo sorting pathways is not only 
important for understanding fundamental cellular physiology, but also has important 
implications in neurological diseases. Mutations in Vps35 are known to cause Alzheimer’s 
and Parkinson’s disease (20,129,130), which are found to cause accumulation of cargo in 
endosomes thus connecting neurological diseases to defects in endosomal sorting events. 
A complete understanding of endosomal sorting pathways and their functions will enable 
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us to work with selected trafficking pathways and are likely to open up new opportunities 
for the design of therapeutic interventions in the future. 
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                  Chapter 5 
Designing cyclic peptide inhibitors of the SNX-BAR proteins 
based on the C. trachomatis IncE structure 
5.1 Introduction and significance 
Cyclic peptides are chains of polypeptides that have cyclic ring structure, which are formed 
by linking through four possible ways; the N-terminal end of the peptide to the C-terminal 
end (head-to-tail), side chain-to-side chain, side chain-to-tail or head-to-side chain (Fig. 
45). It has been shown that using cyclised peptides mimicking fragments of native 
structures can lead to the mimicking of their functions, and this has contributed to an 
increased interest in recreating different functional polypeptide regions to produce 
peptidomimetic molecules that are biologically active. Some of the initial targets for this 
interest were towards β- and γ-turns (131-136). But β-strands (137), β-sheets (138) and α-
helices (136) are the most recent targets, which consist of polar NH and CO groups within 
the peptide backbones forming hydrogen bonds to promote and stabilize protein 
secondary structure. 
 
 
Figure 45. Four possible ways of constraining a peptide through macrocyclization (Figure adaped 
from (139). 
  
Even though peptides demonstrate various biological properties, they have been 
typically considered to be relatively poor drug molecules. The reasons include i) poor oral 
absorption ii) rapid metabolic turnover due to degradation by proteolytic enzymes and, iii) 
poor membrane permeability leading to failure of the peptide drug in reaching intracellular 
target. When compared to linear peptides however, cyclized peptides demonstrate 
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superior biological activity and proteolytic stability because of their conformational rigidity 
(140,141). The modification of biologically active peptides by introducing structural 
constraints is the most common way of producing cyclic peptides. Cyclic peptides have 
decreased entropy due to their rigidity, which often manifests as a significant increase in 
binding affinity with the target molecules. Cyclization also provides resistance to proteolytic 
degradation by removing both the free amino and carboxyl termini. Many cyclic peptides 
can also successfully cross the cell membrane, although just because a peptide is cyclised 
does not necessarily guarantee it will possess this property (142).  
My studies described in chapter 2 and chapter 3 defined the molecular basis for 
how the chlamydial effector protein IncE binds and hijacks the SNX5 related proteins 
during chlamydial infection. The results demonstrated that the C-terminal binding 
sequence of IncE binds to the PX domain of the SNX5 and its homologues SNX6 and 
SNX32, forming an extended β-hairpin consisting of two antiparallel β-strands. Connected 
through a β-turn, the two IncE β-strands come together so that their N- and C-terminal 
residues are positioned very close together (Fig. 46). My work in Chapter 4 showed that 
the IncE peptide is mimicking a native receptor interaction with SNX5, albeit with 
significantly higher affinity and using a different sequence. I hypothesized that the two IncE 
β-strands could be linked to form a cyclic peptide that might display superior binding and 
stability to the linear IncE molecule, and thus provide a tool that could be used acutely 
block normal SNX5/6/32 cargo interactions.  
 
Figure 46.  (A) IncE (orange) bound to SNX32PX (green) domain as a β-hairpin; (B) IncE peptide 
with two antiparallel β-strands that is connected through a β-turn and an array of interstrand 
hydrogen bonds to stabilize the structure. 
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In collaboration with Prof. David Fairlie and Dr. Timothy Hill (IMB, University of 
Queensland), around 20 linear and cyclic peptides derived from the sequence of IncE 
were engineered to explore the idea that a structurally constrained cyclic peptide could be 
designed to bind to SNX5, SNX6 and SNX32 with an increased affinity due to its higher 
rigidity and lower entropy. The peptides that were synthesized included truncations of IncE 
to shorten the extended loop, removing residues from the peptide that do not make a 
direct interaction with SNX5 based on our crystal structure, as well as different linkages 
between N- and C- termini to form cyclisation (Table 6). 
In cyclic peptides, turns are motifs that reverse the direction of peptide strands and 
are classified as γ, β, or α depending on the increasing size of the turns. Even though 
cyclisation of peptides is the most commonly used method to stabilize turn structures, it is 
often not sufficient by itself and hence other turn-inducing structural motifs are introduced 
for further cyclic peptide constraints. In the initial round, some of the β-turn inducers were 
introduced to the IncE linear peptide to explore if those helped in forming a stable β-turn. 
Out of all amino acids, proline forms reverse turns in nature. Thus incorporating L-proline 
(peptides 1-3) or heterochiral sequences such as D-proline-L-proline (peptides 4-10,17-18) 
into linear peptides introduces turn-inducing constraints. Heterochirals have been 
previously shown to have the ability to be strong nucleators of β-hairpins (143). From 
peptide 12-16 and 19-21, besides β-turn inducers, cyclisations of the linear peptides were 
also introduced for the further enhancement of constraints of the peptide and to explore 
whether cyclisation increased the affinity of the peptides. Peptides 11-14 contain a hairpin 
sequence of D-Proline-L-Proline for head-to-tail cyclisation to mimic a constrained cyclic 
peptide β-turn. This cyclisation approach has been introduced onto peptides with and 
without semi rigid β-turn inducers within the loop such as L-proline and D-proline-L-proline 
heterochirals. The other amino acid tail to sidechain cyclisation approach is a Lys-Asp 
lactam linker, which was introduced in peptides 15-16 on top of D-Proline-L-Proline β-
hairpin nucleator. The idea behind this in our case was to try and make a less constrained 
cyclic peptide to see if this had any effect on activity. Peptides 19-21 contained δ-linked 
ornithine (δOrn), which mimics a β-turn in a β-hairpin and connects the N-and C-termini.  
Previously in chapter 2 and 3, I have demonstrated that the IncE binds the SNX5 
PX domain with a Kd of ~1.9 µM. In chapter 4, I have discussed that recent reports have 
confirmed that the IncE is able to displace and block the binding of SNX5 to its selected 
transmembrane cargoes thus disrupting its trafficking (116,124). The cyclic peptides in this 
chapter will allow me to produce higher affinity IncE that can compete with the cargo 
binding to SNX5 in vitro, and in the future if we can confirm an ability to cross the cell 
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membrane to block the cargo binding in vivo, thus enabling me to make a specific 
inhibitory tool to study the role of SNX5 in membrane trafficking.  
In this chapter, using Isothermal titration calorimetry (ITC), I demonstrate and 
confirm the hypothesis that one of the cyclised IncE peptide binds to the PX domain of 
SNX5 with an increased affinity, which is nearly 30x more than the standard IncE peptide, 
and ~300x higher affinity than endogenous cargo molecules. This cyclised peptide was 
also able to inhibit the binding of a transmembrane cargo, CIMPR to SNX5 in vitro. These 
results are very promising, and I am currently optimising crystals of this cyclic peptide 
complex to analyse its specific binding mechanism using X-ray crystallography. This 
information will be used to fine-tune this cyclic peptide to have even higher affinity and 
solubility, and the ability to cross the cell membrane thus leading to my final goal.  
5.2 Materials and methods 
5.2.1 Peptides 
All linear and cyclic IncE-derived peptides used for ITC and crystallisation experiments 
were synthesised by Dr. Timothy Hill from Prof. David Fairlie’s laboratory (IMB, UQ) (Table 
6; at the end of the section 5.2). For the ITC experiments, peptides were weighed and 
dissolved in 50 mM HEPES (pH 8.0) and 100 mM NaCl (ITC buffer) to make a stock 
peptide concentration of 2 mM, which was diluted to 0.75 mM before use. The bacterial 
expression construct for human SNX5 PX domain proteins (SNX5 residues 26–170) were 
synthesized and cloned into pGEX-4T-2 by Genscript (USA). The constructs are N-
terminally GST-tagged with site- specific thrombin cleavage sequence located between 
the GST moiety and the protein of interest. The CI-MPR peptide was purchased from 
Genscript (Hong Kong).  
5.2.2 Isothermal titration calorimetry 
ITC experiments were performed on a MicroCal PEAQ-ITC instrument at 25°C. The 
proteins were buffer exchanged into ITC buffer (50 mM HEPES (pH 8.0) and 100 mM 
NaCl) by gel filtration prior to ITC experiments. Linear and cyclic peptides at 0.75 mM were 
titrated into 0.05 mM SNX5PX in the cell. The binding data was processed using MicroCal 
PEAQ-ITC analysis software with a single site-binding model to determine the 
stoichiometry (n), the binding constant (Kd), the estimated heat of binding (ΔH), the Gibbs 
free energy (ΔG) and the binding entropy (ΔS). Three experiments were performed for 
each set of samples to determine the average ± standard error of the mean (SEM) for 
thermodynamic quantities, except for the linear peptides and the ones that did not interact 
 92 
with SNX5PX experiments as well as the control, where only single experiments were 
performed. For these single experiments, all experiments were performed using the same 
batch of protein to allow direct comparisons to be made. 
5.2.3 Crystallisation of cyclic peptide complexes 
SNX5, SNX6 and SNX32 PX domains were concentrated to 12 mg/ml for crystallization 
with cyclic peptide 12 (Table 6). These proteins were directly mixed together with the 
appropriate peptide at a 1:2 molar ratio of protein to peptide and were incubated on ice for 
1 h. Three 96-well crystallization hanging-drop screens for each experiment were set up 
using a Mosquito Liquid Handling robot (TTP LabTech) at 20°C in the UQ ROCX facility. 
After setting up these 96-well screens, the trays were incubated at 20°C in a Rockimager 
storage hotel (Formulatrix), where the drops were imaged at different time points for 21 
days.  
 
Table 6. List of linear and cyclic peptides 
C             PAVQFFKGKNGSADQVILV Control 
1             PAVQFFKGKNPSADQVILV Linear 
2             PAVQFFKGKPGSADQVILV Linear 
3             PAVQFFKPKNGSADQVILV Linear 
4             PAVQFFKGKpPSADQVILV Linear 
5             PAVQFFKpPNGSADQVILV Linear 
6             PAVQFFKGKPpSADQVILV Linear 
7 SPANGPAVQFFKGKpPSADQVILVTQ Linear 
8 SPANGPAVQFFKGpPGSADQVILVTQ Linear 
9 SPANGPAVQFFKpPNGSADQVILVTQ Linear 
10 SPANGPAVQFFKGPpGSADQVILVTQ Linear 
11             PAVQFFKGKDQVILVp Head-to-tail cyclisation 
12             PAVQFFKGKNPSADQVILVp Head-to-tail cyclisation 
13             PAVQFFKGKDQVILVPp Head-to-tail cyclisation 
14            PAVQFFKGKpPSADQVILVp Head-to-tail cyclisation 
15      AcKPAVQFFKGKpPSADQVILVD Side chain-to-side chain cyclisation 
16         AcKAVQFFKGKpPSADQVILD Side chain-to-side chain cyclisation 
17             KADQVILVpPAVQFFK Linear 
18             KDQVILVpPAVQFFK Linear 
19               AVQFFKGKDQVILVO Head-to-side chain cyclisation  
20               AVQFFKGKNPSADQVILVO Head-to-side chain cyclisation  
21             VAVQFFKGKNPSADQVILVO Head-to-side chain cyclisation  
P= L-Proline; p= D-Proline; pP=D-proline-L-proline heterochirals; O= δ-linked ornithine (δOrn) 
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5.3 Results 
5.3.1 Interaction studies of linear and cyclic peptides with SNX5PX using ITC 
The numbering scheme for the IncE peptide is taken from the original IncE sequence from 
C. trachomatis serovar L2 (Pro112, Ala113, Val114, Gln115, Phe116, Phe117, Lys118, 
Gly119, Lys120, Asn121, Gly122, Ser123, Ala124, Asp125, Gln126, Val127, Ile128, 
Leu129, Val130) and is used for all the peptides in this chapter. 
Control IncE peptide was used as the binding reference. This peptide demonstrated 
a Kd of 1.9 µM to SNX5PX (Fig. 47A). Peptides 1-10 and 16-17 were generated during the 
first round of linear IncE peptides that were synthesised. A single batch of SNX5 PX 
domain was tested for binding against all the linear IncE peptides.  
Peptides 1-3 consist of all residues from Pro112 to Val130, with one residue in loop 
region (Gly119-Ala124) being replaced by L-proline at a time. Peptides 1-2 showed similar 
Kd (1.6 µM and 1.7 µM) to the control (Fig. 47B and 47C), which showed replacement of 
either Gly122 or Asn121 with L-proline does not improve affinity, whereas results from 
peptide 3 (replacement of Gly119 with L-proline) are inconclusive due to the difficulty in 
dissolving the peptides in the buffer (Fig. 47D).  
 
Figure 47. ITC profiles for the binding 
of IncE linear peptides to SNX5PX 
domain. (A) Control 
(PAVQFFKGKNGSADQVILV), 
(B) Peptide 1 
(PAVQFFKGKNPSADQVILV),  
(C) Peptide 2 
(PAVQFFKGKPGSADQVILV) and  
(D) Peptide 3 
(PAVQFFKPKNGSADQVILV) vs 
SNX5PX. 
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   Instead of L-proline, residues in the loop region in peptides 4-6 are replaced by D-
proline-L-proline or L-proline-D-proline heterochirals. The loop region residues Asn121 and 
Gly122 are replaced with D-proline-L-proline in peptide 4, which improved the Kd (1.07 
µM) when compared to the binding reference (Fig. 48A). Peptide 5 has the D-proline-L-
proline two residues downstream compared to peptide 4 at Gly119 and Lys120, which 
demonstrated no binding (Fig. 48B). Peptide 6 is similar to peptide 4 in regards to the 
residues present, except the D-proline-L-proline heterochirals at Asn121 and Gly122 are 
replaced with L-proline-D-proline (Fig. 48C). This reversal of prolines in peptide 6 did not 
favour an improved binding affinity (2.6 µM) more than peptide 4.  
 
Figure 48. ITC profiles for the binding of IncE linear peptides to SNX5PX domain. (A) Peptide 4 
(PAVQFFKGKpPSADQVILV), (B) Peptide 5 (PAVQFFKpPNGSADQVILV), and (C) Peptide 6 
(PAVQFFKGKPpSADQVILV) vs SNX5PX. 
 
Peptides 7-10 have either D-proline-L-proline or L-proline-D-proline heterochirals at 
the loop region with extended IncE residues on the N- and C- termini (Ser107, Pro108, 
Ala109, Asn110, Gly111 from N-terminus and Thr131, Gln132 from C-terminus). Peptide 7 
consists of D-proline-L-proline at Asn121 and Gly122 as in peptide 4, but on top of that it 
possesses the extended N- and C- termini residues as well, which yielded identical Kd 
(1.09 µM) to peptide 4 (Fig 49A). This demonstrates that these extended residues 
(Ser107, Pro108, Ala109, Asn110, Gly111 from N-terminus and Thr131, Gln132 from C-
terminus) do not contribute towards any important interactions with SNX5 PX as 
demonstrated in Paul et al. (113), but the D-proline-L-Proline in the loop region is better 
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than L-proline alone (peptides 1-3). Peptides 8 and 9 consist of D-proline-L-proline 
heterochirals one residue downstream of each other at positions Lys120, Asn121 and 
Gly119, Lys 120 respectively. Peptide 10 has the heterochirals reversed at Lys120 and 
Asn121. Peptides 8 and 10 demonstrated weaker binding affinity (31 µM and 7.7 µM 
respectively) (Fig. 49B and 49D) than peptide 7, whereas peptide 9 showed lack of 
binding. The binding affinity of peptide 9 is inconclusive because this peptide was not 
completely dissolvable in buffer (Fig. 49C). This result indicates even a simple shift in the 
replacement of residues can affect affinity and solubility of peptides. Thus out of all the 
linear peptides, peptide 4 and 7 (1.07 µM and 1.09 µM) were the best when compared to 
the Kd of reference peptide (Fig. 48A and 49A). 
 
Figure 49. ITC profiles for the binding of IncE linear peptides to SNX5PX domain. (A) Peptide 7 
(SPANGPAVQFFKGKpPSADQVILVTQ), (B) Peptide 8 (SPANGPAVQFFKGpPGSADQVILVTQ), 
(C) Peptide 9 (SPANGPAVQFFKpPNGSADQVILVTQ), and (D) Peptide 10 
(SPANGPAVQFFKGPpGSADQVILVTQ) vs SNX5PX. 
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Peptides 11-21 were cyclised to test the theory that the binding affinity could be 
increased compared to linear peptides. Cyclisation of linear peptides were implemented 
through L-proline-D-proline N-to C (head-to-tail) linkage (peptides 11-14), Asp-Lys lactam 
side chain-to-side chain linkage (peptides 15-16) and δ-linked ornithine (δOrn) head-to-
side chain linkages (peptides 19-21). Peptide 12 (L-pro-D-pro head-to-tail linkage, with L-
proline at position Gly122) demonstrated the highest affinity of 67 nM (Fig. 50B), whereas 
peptide 11 with L-proline-D-proline linkage, with no L-proline at position Gly122 showed 
much weaker binding (25 µM) (Fig. 50A). Peptide 14 was synthesised to determine if the 
affinity of peptide 12 can be improved with D-proline-L-proline heterochiral at the same 
loop region (Asn121, Gly122) instead of L-proline alone. This peptide yielded an improved 
affinity  (0.6 µM) (Fig. 50D) over the linear reference but lower affinity than peptide 12. 
 
Figure 50. ITC profiles for the binding of cyclic IncE peptides to SNX5PX domain. (A) Peptide 11 
(PAVQFFKGKDQVILVp), (B) Peptide 12 (PAVQFFKGKNPSADQVILVp), (C) Peptide 13 
(PAVQFFKGKDQVILVPp), and (D) Peptide 14 (PAVQFFKGKpPSADQVILVp) vs SNX5PX. 
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Cyclic peptides 15 and 16 with Asp-Lys cyclisation demonstrated a slightly better Kd 
than the reference peptide (1.8 µM and 1.54 µM respectively) (Fig. 51A and 51B).  
?? 
Figure 51. ITC profiles for the binding of cyclic IncE peptides to SNX5PX domain. (A) Peptide 15 
(AcKPAVQFFKGKpPSADQVILVD) and (B) Peptide 16 (AcKAVQFFKGKpPSADQVILD) vs 
SNX5PX. 
 
Peptides 20 and 21 with ornithine linkages demonstrated weaker affinity of 16.6 µM 
and 7 µM (Fig. 52B and 52C), whereas peptide 19 showed no binding (Fig. 52A). Since 
peptide 12 demonstrated nearly 30x more stronger affinity than the reference, this peptide 
was used for further in vitro inhibition experiments and crystallisation trials. 
 
Figure 52. ITC profiles for the binding of cyclic IncE peptides to SNX5PX domain. (A) Peptide 19 
(AVQFFKGKDQVILVO), (B) Peptide 20 (AVQFFKGKNPSADQVILVO) and (C) Peptide 21 
(VAVQFFKGKNPSADQVILVO) vs SNX5PX. 
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Table 7. Thermodynamic parameters of the SNX5PX vs linear and cyclic peptides 
Sample 
cell 
Titrant ΔH 
(kcal/mol) 
TΔS 
(kcal/mol) 
ΔG 
(kcal/mol) 
Kd 
(µM) 
N 
SNX5 
PX 
Control -0.202 -7.59 -7.79 1.96 0.999 
  1 -3.81      -4.11 -7.91 1.59 0.953 
2 -2.52 -5.33 -7.85 1.77 1.02 
3 / / / /          / 
4 -3.69 -4.46 -8.15 1.07 0.980 
5 / / / / / 
6       -3.37 -4.23 -7.60 2.68 1.03 
7 -3.44 -4.70 -8.14 1.09 0.965 
8 -1.92 -4.22 -6.14 31.5 1.02 
9         / / / /           / 
10       -1.22 -5.75 -6.97 7.7 1.08 
11      -7.52 -1.25 -6.27 25.4 0.958 
12 -6.1 ± 0.9 -3.94 ± 0.68 -8.9 ± 0.94 0.067 ± 0.01 1.07 ± 0.05 
13 -5.26 ± 0.29 -3.16 ± 0.19  -8.42 ± 0.101 0.69 ± 0.09 1.09 ± 0.07 
14 -8.23 ± 0.28 -3.88 ± 1.21 -8.48 ± 0.05  0.6 ± 0.05 0.97 ± 0.15 
15 -3.52 ± 0.77 -2.45 ± 0.15  -7.81 ± 0.12 1.8 ± 0.21 1.06 ± 0.12  
16 -5.59 ± 0.7 -2.71 ± 0.78 -8.06 ± 0.33 1.54 ± 0.37  1.07 ± 0.04 
17 -0.704 -7.90 -7.20 5.28 1.02 
18 / / / / / 
19 / / / / / 
20 -1.78 -4.85 -6.54 16.1 1.01 
21 -0.644 -6.32 -7.02 7.18 1.19 
       ΔH – enthalpy, T- absolute temperature, ΔS –change in entropy, ΔG – Gibbs free energy,  
Kd – dissociate constant, N – stoichiometry 
5.3.2 Binding inhibition of transmembrane cargo to SN5PX by cyclic peptide  
Using ITC, a simple inhibition experiment using cyclic peptide 12 was performed. The 
reaction cell was filled with a mix of SNX5 PX with a linear peptide from the 
transmembrane cargo CIMPR, where cyclic peptide 12 was titrated into the cell. This cyclic 
peptide successfully displaces CIMPR and binds to SNX5PX with an apparent Kd of 125 
nM, in agreement with the high affinity of the cyclic peptide 12 alone. Interestingly, the 
binding profile indicates an endothermic interaction occurs rather than the exothermic 
interaction of peptide 12 alone. This may be due to the pre-binding of the CI-MPR peptide 
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leading to the stabilisation of the bent SNX5 conformation being primed for cyclic peptide 
displacement, and a subsequent change in the apparent thermodynamics of peptide 12 
binding. In reciprocal experiments, the CIMPR failed to displace the cyclic peptide, 
showing no significant binding to SNX5 when pre-incubated with the high-affinity peptide 
12 prior to titration (Fig. 53). 
 
Figure 53. ITC profiles showing the binding inhibition of transmembrane cargo, CIMPR by the 
cyclic IncE Peptide 12 (PAVQFFKGKNPSADQVILVp). (A) Peptide 12 titrated into cell 
containing SNX5PX and CIMPR and (B) CIMPR titrated into cell containing SNX5PX and 
Peptide 12. 
 
 
 
5.3.3 Crystallisation trials of SNX5PX, SNX6PX and SNX32PX in complex with cyclic 
peptide 
Out of a variety of initial crystallisation screens that I attempted in 96-well trays, one 
condition for SNX6 PX-cyclic peptide 12 and two for SNX32 PX-cyclic peptide 12 
produced initial hits (Fig. 54). The reservoir condition that gave the initial hit of SNX6 PX-
cyclic peptide 12 is 0.16 M calcium acetate, 0.08 M sodium cacodylate pH 6.5, 14.4% 
(w/v) PEG 8000 and 20% (v/v) glycerol. The first SNX32 PX-cyclic peptide 12 initial hit 
was obtained in 40% (v/v) PEG 600, 0.1 M sodium cacodylate pH 6.5, 0.2 M calcium 
acetate and the second hit was in the reservoir condition 0.2 M calcium chloride, 0.1 M 
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HEPES sodium salt pH 7.5, 48% (w/v) PEG 400. These conditions are currently being 
optimised to obtain macrocrystals large enough for a high-resolution structural analysis. 
A 
B 
 
 
 
 
 
 
 
C 
Figure 54. Crystals of (A) SNX6PX-cyclic peptide 12 complex; (B-C) SNX32PX-cyclic peptide 12 
complex. 
5.4 Discussion 
In virtually all cellular processes, biological functions are influenced by protein–protein 
interactions (PPIs). These PPIs can be formed between two protein domains that are 
structured, a structured domain and a short peptide, or even between two peptides. One of 
the currently promising strategies in therapeutics is to modulate these PPIs (144), a 
strategy that also leads to the generation of reagents that can be used to better 
understand the biological processes being targeted (144-146). Peptides and 
peptidomimetics are an important class of molecules with particular relevance to 
modulating PPI interactions, especially when structural information can be used to guide 
the design of these PPI inhibitors. When separated from their protein-bound state, 
peptides generally will lose their secondary structure and conform to a flexible nature in 
solution. These flexible peptides are exposed to degradation through proteolysis, and also 
typically show lower affinity for their target. Thus mimicking the peptides in their most 
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efficient and bioactive conformation has been one of the goals for the successful designing 
of cyclic peptides as protein-protein interaction inhibitors.  
The chlamydial effector protein IncE (residues 112-130) was found to form a β-
hairpin structure when bound to SNX5 and SNX32. The N-terminal βA strand of the IncE 
sequence consists of Gly112-Lys118 and the antiparallel C-terminal βB strand of IncE is 
formed by Asp125-Val130. These two strands are connected by a short loop (Gly119-
Ala124). The IncE βA strand forms main chain hydrogen bonds with the SNX5 PX β-sheet, 
whereas βB forms an interface with the α-helical region of SNX5. The IncE loop region 
does not make any direct contact with the SNX5 protein. In an attempt to explore the idea 
of deriving cyclic peptides from linear IncE sequences several different approaches were 
tried. As explained previously under section 5.1, these different approaches included 
introduction of different β-turn inducers, different cyclisation approaches, and different 
truncations of the βA, βB and the loop regions that potentially will affect the affinity and 
solubility. 
Isothermal titration calorimetry was used to characterize the binding affinity of all the 
above-mentioned (Table 6) linear and cyclic peptides with the SNX5PX domain. Besides 
β-turn inducers and cyclisation approaches, the importance of IncE residues from βA and 
βB strands and loop regions were also investigated using truncations and replacement of 
residues to explore whether any of these approaches increase the affinity and solubility. 
Single residue positions in the loop region were screened by replacement with L-proline. 
Single replacements of Gly119, Asn121 or Gly122 in the loop region with L-proline did not 
make an improvement in Kd when compared to the control (Kd 1.9 uM). But replacements 
of both Asn121 and Gly122 with D-proline-L-proline heterochirals made approximately 2x 
improvement in Kd. On the other hand, switching of heterochirals to L-proline-D-proline at 
the same positions under the same conditions yielded weaker Kd. Introduction of D-
proline-L-proline heterochirals at Gly119 and Lys120, as well as at Lys120 and Asn121 
also suffered loss of affinity. Thus linear peptides with truncations of a few residues from 
the N and C termini and replacements of loop region residues with the D-proline-L-proline 
heterochiral β-turn inducer demonstrated to have improved affinity for SNX5PX. 
Cyclisation of linear peptides besides different β-turn inducers were found to improve the 
affinity significantly. The D-proline-L-proline and Asp-Lys lactam cyclisations together with 
the D-proline-L-proline β-turn inducers in the IncE loop region demonstrated similar Kd 
indicating similar contacts in the protein-peptide interface. Cyclised peptide (L-proline-D-
proline) with deletion of a part of the loop region (Asn121, Gly122, Ser123, Ala124) as well 
as the introduction of L-proline on βB strand at Arg126 position also demonstrated similar 
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but slight weaker affinity. The same conditions without the L-proline or any other β-turn 
inducers demonstrated much weaker Kd of 25 uM, whereas re-introduction of the deleted 
loop region and L-proline at the Gly122 position yielded a Kd of 56 nM. The same 
condition, but the δOrn linker only demonstrated a Kd of 16 uM. Thus a L-proline-D-proline 
cyclisation with the replacement of Gly122 loop residue to L-proline improved the binding 
of this IncE cyclic peptide with SNX5PX by 30x more than the control.   
In the future, the crystal structure of the cyclic peptide in complex with SNX5PX or 
its homologues will enable us to understand and validate biophysical data using X-ray 
structural data. The structural data will confirm the backbone conformation and sidechain 
interactions established by the cyclic peptide to the protein, providing insights into the 
mechanism leading to higher affinity when compared to the linear peptide. The interactions 
formed between the cyclic peptide with the protein are expected to be similar to the 
interactions established by the linear IncE peptide with the protein however, and the 
biggest contributor to the increased affinity is likely to be pre-stabilisation of the peptide 
backbone due to residue substitutions that allows a better fit of the cyclic peptide in the 
protein binding pocket. It is possible that further modifications such as cross-linking of the 
β-strands might lead to even further improvements in affinity.  
The ability of the higher affinity cyclic peptide 12 to inhibit binding of 
transmembrane cargo CIMPR to SNX5PX in vitro demonstrates the potential to take up 
this positive cyclic peptide hit as a starting point, to improve its affinity and solubility to use 
as an inhibitory tool. The next steps will be to determine if the peptide is able to cross the 
cell membrane. On top of cyclisation, certain structural features of a peptide are typically 
associated with an improved ability to cross the cell membrane. Cyclosporin A, a well-
known immunosuppressant, is a good example of a cyclic peptide that is cell permeable. 
This cyclic peptide keeps the hydrophilic groups away from the surface of the molecule 
through several intra-molecular hydrogen bonds. Our future goals include testing the cell 
permeability of the cyclic peptides to explore whether they can cross the cell membrane 
and block the binding of transmembrane cargoes in situ, and if required working on the 
modifications of this cyclic peptide to increase its cell permeability without negatively 
affecting its solubility and affinity.  
As indicated in the previous chapters, SNX-BAR proteins are emerging as key 
players in retromer-independent trafficking pathways. Understanding these pathways are 
important since the transmembrane cargoes that are trafficked by SNX-BAR proteins, are 
involved in cancer and neurodegenerative diseases. The new cyclic peptides can be 
developed to fine-tune the SNX-BAR mediated trafficking pathways by inhibiting its 
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interaction with cargos. As one example, antagonists to IGF1R and NRP1 are being 
developed as cancer therapeutics, and blocking their SNX5-mediated trafficking could 
provide an alternative approach for reducing receptor activity. The knowledge and the 
molecules we develop here will enable future studies to directly assess the effect of 
retromer targeting as a potential therapeutic strategy. 
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 Chapter 6 
The GAP activity of SNX-RGS proteins 
6.1 Introduction and significance 
Regulator of G-protein signalling (RGS) proteins bind to activated Gα subunits proteins 
and serves as GTPase activating proteins (GAPs) by accelerating GTP hydrolysis and 
thus attenuating G-protein mediated signalling. To date, RGS proteins that are GAPs for 
Gi, Gαq and Gα12/13 are the best studied, whereas details on RGS proteins that regulate 
Gαs are very limited (147-149).  
Zheng et al., has previously identified the RGS domain of SNX13 as GAP protein 
for Gαs, thus contributing to the regulation of cellular responses mediated by Gαs including 
adenyl cyclases and cAMP production (48). Recently SNX14 was found to bind and 
sequester Gαs even though it did not appear to regulate its GTPase activity (49). Neither 
the binding ability of SNX25 to Gαs nor its GAP activity has been studied so far.  
The primary sequences of RGS domains and Gαs proteins may partly explain the 
specificity of the interaction between Gαs subunits and SNX-RGS proteins. The Asp229 of 
Gαs has been suggested to be the major barrier of Gαs interaction with other RGS 
proteins. Mutation of this residue to match the corresponding Ser206 of Gαi allowed the 
binding of RGS4 and RGS16 to the mutated GαsD229S.  The crystal structure of the Gαi1-
RGS4 complex reveals that the Ser206 of Gαi1 interacts with Glu126 and Asn128 of RGS4 
to form a stable complex (150). Other amino acid residues occupy these positions in the 
RGS domains of SNX13, SNX14 and SNX25. This suggests that these nonconserved 
amino acid substitutions might contribute to the specificity of Gαs-SNXRGS interaction. 
In this chapter, I have expressed and purified the RGS domains from human 
SNX13, SNX14 and SNX25, as well as Gαs. Using GST-pull down assays and isothermal 
titration calorimetry (ITC) experiments, I have systematically tested the binding affinity of 
the RGS domains of SNX13, SNX14 and SNX25 for Gαs in its inactive state (Gαs-GDP 
bound), transition state mimic (Gαs-GDP.AlF4- bound) and activated state (Gαs-GPPNHP 
bound). I have shown that these RGS proteins bind to Gαs in both its active and inactive 
state, as opposed to previously published reports (48,49), although they display relatively 
low affinities for the inactive state. However, although the RGS proteins can form stable 
complexes with different Gαs-nucleotide states, HPLC experiments indicate that the SNX-
RGS domains do not appear to function as GTPase activating proteins for Gαs. In this 
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chapter the first crystal structure of the SNX25 RGS domain begins to shed light on how 
these proteins might interact with and regulate Gαs-mediated signaling. Future work will 
aim to determine the crystal structures of the RGS domains in complex with Gαs in 
different nucleotide-bound states to determine the precise residues defining specificity 
between these protein partners.  
6.2 Materials and Methods 
6.2.1 Construct and plasmid design  
All bacterial expression constructs were synthesized and cloned into pGEX-4T-2 (RGS 
domains) or pET-28b(+) (Gαs) by Genscript (USA). The constructs in pGEX-4T-2 are the 
RGS domains of SNX13, SNX14 and SNX25. The pGEX-4T-2 constructs are N-terminally 
GST-tagged with site- specific thrombin cleavage sequence located between the GST 
moiety and the protein of interest. The pET-28b(+) construct is N-terminally 6x His-tagged 
(H6).  
6.2.2 Recombinant protein production 
The same protocol was used to express all the proteins mentioned under 6.2.1. The 
vectors encoding the genes of interest were transformed into competent Escherichia coli 
BL21 CODON-Plus cells. Cells were cultivated in Luria Bertani (LB) media at 37°C under 
agitation until the optical density at 600 nm (OD600) reached 0.5-0.7 and expression was 
induced with 0.5 mM IPTG (except for Gαs where the OD600 was reached 0.8 and induced 
with 0.1 mM IPTG), and growth continued at 18°C for 16 h. The cells were harvested by 
centrifugation (4,000 x g, 15 min) and the resulting pellets resuspended in lysis buffer (50 
mM Tris pH 8.0, 500 mM NaCl, 5% glycerol, 50 µg/mL benzamidine and 1 µg/mL DNAseI. 
The cell suspension was lysed using a cell disruptor at 27 Kpsi and cellular components 
were pelleted at 16000 RPM using JA 25.50 for 30 min. The supernatant was collected 
and the proteins were bound to an equilibrated glutathione sepharose 4B resin (GE 
Healthcare) or Talon metal affinity resin (Clontech) for 1 h at 4°C. The resins were washed 
with 10 column volumes of equilibration buffer (50 mM Tris pH 8.0, 500 mM NaCl, 5% 
glycerol buffer with and without 1 mM DTT for glutathione-S-transferase (GST) fusion RGS 
proteins and hexahistidine (H6) Gαs respectively). The H6-tagged Gαs protein was eluted in 
5 fractions of 5 mL equilibration buffer containing 250 mM Imidazole. GST-tagged RGS 
proteins were cleaved on column by 100 units of thrombin overnight and were eluted the 
next day using the equilibration buffer. Both GST and H6 tags were left uncleaved to 
perform invitro pull-down assays, whereas the GST tag was cleaved off for ITC and 
 107 
crystallisation experiments. The cleaved proteins were then purified in gel filtration (GF) 
buffer (50 mM HEPES pH 8.0, 100 mM NaCl) by GF on a Superdex 200 16/60 size 
exclusion chromatography (SEC) column. These proteins were further dialysed into 
appropriate buffers according to the experiment performed. 
6.2.3 Making Gαs – Guanine nucleotide complexes 
100 µM Gαs protein was incubated with 1 mM GDP and GPPNHP in 20 mM HEPES pH 
8.0, 200 mM NaCl, 1 mM DTT, 1 mM EDTA and with additional 10 µM GDP, 30 µM AlCl3, 
and 10 mM NaF for the Gαs with GDP·AlF4- complex at room temperature. After an hour of 
incubation, 10 mM MgCl2 was added to the mixture and was incubated for further 1 h. To 
remove excess nucleotides, these mixtures were then dialysed into buffers suitable for 
further experiments. 
6.2.4 In vitro GST-pull downs 
The RGS proteins were tested for interaction with Gαs in the presence of GDP, GDP.ALF4- 
and GPPNHP using GST pull-down assays. GST-tagged RGS domains were dialysed into 
50 mM HEPES pH 8.0, 200 mM NaCl, 1 mM DTT, 1 mM EDTA and 0.1% IGEPAL CA-630                                                                                                                                                                                                                                               
and the Gαs–nucleotide complexes were dialysed into 50 mM HEPES pH 8.0, 200 mM 
NaCl, 1 mM DTT, 1 mM EDTA, 10 mM MgCl2 and 0.1% IGEPAL CA-630 for GDP and 
GPPNHP bound states, whereas the Gαs–GDP.ALF4- complex was dialysed into 50 mM 
HEPES pH 8.0, 200 mM NaCl, 1 mM DTT, 1 mM EDTA, 10 mM MgCl2, 10 µM GDP, 30 
µM AlCl3, 10 mM NaF and 0.1% IGEPAL CA-630. 1.25 nmol of RGS proteins were mixed 
with 2.5 nmol H6- Gαs-nucleotide complexes for 1 h at 4°C, After 1 h incubation, these 
mixtures are bound to 250 µL of pre-equilibrated glutathione sepharose resin in respective 
pull-down buffers and were incubated for further 1 h. The resin was washed 4 times with 1 
ml of appropriate pull down buffer. After the last spin, the supernatant was pipetted off, 
and the beads were spun full speed for 30 extra secs. Equal volume of SDS-sample buffer 
was added and SDS-PAGE analysis was performed. Western blot analysis was done 
using a nitrocellulose membrane and the iBlot semi-dry transfer system (Life 
technologies). Detection was performed using a primary mouse anti-(His)6 and secondary 
goat anti-mouse ECL-coupled antibodies and a photographic film with the BioRad ECL 
detection system.  
6.2.5 Isothermal titration calorimetry (ITC) 
Isothermal titration calorimetry (ITC) was performed at 10°C using a MicroCal PEAQ-ITC 
calorimeter. Both RGS and Gαs–nucleotide protein samples were dialysed against 50 mM 
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HEPES pH 8.0, 100 mM NaCl, 10 mM MgCl2, and 1 mM EDTA for measurement of the 
GDP and GPPNHP states, and with an additional 10 µM GDP, 30 µM AlCl3, and 10 mM 
NaF for the Gαs-GDP·AlF4- complex. Contents of the sample cell were stirred continuously 
at 750 rpm during the experiment. 13 injections were involved in an experiment and 50 µM 
of Gαs were titrated into 500 µM of RGS proteins. The binding data was processed using 
MicroCal PEAQ-ITC analysis software with a single site-binding model to determine the 
stoichiometry (n), the binding constant (Kd), the estimated heat of binding (ΔH), the Gibbs 
free energy (ΔG) and the binding entropy (ΔS).  
6.2.6 GTPase activation assay experiments using HPLC 
The nucleotide analyses were performed using C-18 reversed phase column (Aeris 
peptide from Phenomenex; 250 mm x 4.6 mm) filled with 3.6 µm (particle size) silica. The 
column was equilibrated with buffer containing 100 mM potassium phosphate buffer (pH 
6.5), 10 mM tetrabutylammonium bromide and 7.5% acetonitrile, and isocratic elution was 
performed at ambient temperature with a flow rate of 0.750 mL/min. The nucleotides were 
detected at 254 nm absorbance. In this system, the order of elution of guanine nucleotides 
was GDP and GTP (retention times of ∼ 7 and 12 min, respectively). 8 µM Gαs protein was 
mixed with 80 µM RGS protein in GAP buffer (30 mM Tris-HCl pH 7.5, 10 mM MgCl2, 3 
mM DTT, 10 mM potassium phosphate buffer pH 7.4) and were pre-incubated at room 
temperature. 100 µM GTP solution was added to the premixed GTPase solution. 30 µL 
samples were collected at different time points (0, 1, 2, 5, 10, 15, 20 and 30 mins) and 
were snap frozen in liquid nitrogen. Each sample was boiled for 3 min at 100°C and 
centrifuged at 13000g for 10 min to remove the denatured protein. An aliquot of the 
supernatant (20 µL) was injected into the HPLC column. The column was calibrated with 
25, 50, 100, and 200 µM solutions of the different guanine nucleotides (GDP and GTP). 
The relative amount of GTP was calculated using the GTP and GDP peak areas measured 
using the HPLC integrator and were introduced into the following equation: 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒  𝑎𝑚𝑜𝑢𝑛𝑡  𝑜𝑓  𝐺𝑇𝑃 = 𝐺𝑇𝑃𝐺𝑇𝑃 + 𝐺𝐷𝑃 
The GTP content (Y-axis) was then plotted against the time of incubation (X-axis) using a 
single exponential function. 
6.2.7 Protein crystallisation, data collection and structural determination 
Initial crystallisation screens in small volumes were set up using four 96-well crystallisation 
screens for each protein sample. 8 mg/ml of SNX13, SNX14 and SNX25 RGS domains 
were mixed and incubated on ice with Gαs-GDP, Gαs-GDP.ALF4-, and Gαs-GPPNHP in a 
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1:1 stoichiometry. RGS domains in their apo state were also set up for crystallisation. 200 
nL 1:1 hanging drops of proteins were dispensed using the Mosquito robot (TTP labtech) 
in the UQ ROCX facility. After setting up these initial screens, the trays were incubated at 
20°C in a Rockimager storage hotel (Formulatrix), where the drops were imaged at 
different time points. Data were collected at the Australian Synchrotron MX2 Beamlines, 
integrated with iMOSFLM (93), and scaled with AIMLESS (94) in the CCP4 suite (95). The 
structure of the SNX25 RGS domain was solved by molecular replacement with PHASER 
using the RGS1 structure as input (PDB ID 2BV1) (96). The resulting model was rebuilt 
with COOT (114), followed by repeated rounds of refinement with PHENIX (98). All 
structural figures were generated using PyMOL (DeLano scientific). 
6.6 Results 
6.6.1 Recombinant protein expression and purification 
Purifications of SNX13-RGS, SNX14-RGS and SNX25-RGS were performed using a two-
step protocol; affinity chromatography with glutathione sepharose followed by gel filtration 
using Superdex 75 (16/600) column. The proteins were eluted at the expected molecular 
weight. Samples from every step of purification were collected for SDS-PAGE and were 
analysed for the presence of successfully purified proteins of interest (Fig. 55A, 55B and 
55C). Fractions were found to be relatively pure and dimeric. Upon addition of DTT, the 
protein seems to be monomerised (Fig. 55A-C, Lane 3), which lead us to believe the 
dimer was formed through disulphide bonds. The fractions were pooled together for further 
experiments. After the gel filtration, the yield of SNX13-RGS, SNX14-RGS and SNX25-
RGS were around 15 mg/mL, 18 mg/mL and 10 mg/mL respectively.  
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Figure 55. FPLC chromatography profile and SDS-PAGE of untagged RGS domains of (A) 
SNX13 (17.3 kDa), (B) SNX14 (16.5 kDa) and (C) SNX25 (14 kDa). The fractions from the major 
peak between 60-80 mls correspond to the single bands on the gel. 
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6.6.2 GST-pull down experiments to verify the interaction between SNX-RGS 
proteins and Gαs-nucleotide complexes 
The GST pull-down assay was performed to obtain a qualitative understanding about the 
interaction between RGS proteins and the Gαs in its inactive (GDP-bound form), active 
(GPPNHP-bound form) and transition state conformations (GDP.AlF4- bound form). As 
opposed to previous observations (48), the RGS domains of SNX13 and SNX14 were 
found to interact with the inactive form of Gαs, whereas SNX25 showed no binding (Fig. 
56).  
 
Figure 56. GST pull down experiment of GST-RGS proteins vs His-Gαs-GDP. (Left) SDS-PAGE 
gel and (Right) western blot containing the Pellet (P) or Resin and supernatant (S) fractions from 
the experiment. Experiment between GST and   His-Gαs-GDP was performed as the negative 
control. GST  =  26  kDa, His-Gαs-GDP=46 kDa, GST-SNX13RGS=43 kDa, GST-SNX14RGS=42.5 
kDa, GST-SNX25RGS=40 kDa and His-Gαs protein=46 kDa. 
 
SNX13-RGS protein showed interaction with both the active and transition forms of 
Gαs, whereas SNX14-RGS showed preference for the GDP. AlF4- bound state of Gαs over 
the GPPNHP bound state (Fig. 57). SNX25 showed interaction with both GDP.AlF4- and 
GPPNHP bound states of Gαs. In contrast, in the control pull-down assay, none of the 
combinations of the GST-alone protein with the His-tagged Gαs-nucleotide proteins 
interacted in the analyses (Figs. 56 and 57).  
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Figure 57. GST pull down experiments of (A) GST-RGS proteins vs His-Gαs-GDP.AlF4- and (B) 
GST-RGS proteins vs His-Gαs-GPPNHP. (Left) SDS-PAGE gel and (Right) western blot 
containing the Pellet (P) or Resin and supernatant (S) fractions from the experiments. Experiment 
between GST vs His-Gαs-GDP.AlF4- and His-Gαs-GPPNHP were performed as the negative 
control. GST  =  26  kDa, His-Gαs-GDP.AlF4- and His-Gαs-GPPNHP =46 kDa, GST-SNX13RGS=43 
kDa, GST-SNX14RGS=42.5 kDa, GST-SNX25RGS=40 kDa and His-Gαs protein=46 kDa. 
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6.6.3 RGS domains of SNX-RGS proteins bind to both inactive and active forms of 
Gαs 
Previous studies report that most RGS domains typically bind to the transition state 
conformation (GDP·AlF4-) of Gα proteins with the highest affinity (151-153). To measure 
the binding affinities of the SNX-RGS domains for different Gαs nucleotide state I used 
ITC. The dissociation constants for binding of SNX13RGS with the GDP·AlF4 and 
GPPNHP forms of Gαs were 6 µM and 14.3 µM respectively (Fig. 58).  
 
 
Figure 58. ITC profiles for the binding of the RGS domain of SNX13 vs Gαs·GDP (left), 
Gαs·GDP·AlF4− (middle), and Gαs·GPPNHP (right). Thermodynamic parameters are presented in 
Table 8 at the end of this chapter. 
 
SNX14RGS bound preferentially to GDP·AlF4 form of Gαs with a Kd of 12.5 µM and 
showed no binding to Gαs-GPPNHP (Fig. 59 top). In contrast, SNX25RGS was found by 
ITC to bind with highest affinity (Kd ~ 40 µM) to the GPPNHP bound form of Gαs and with 
somewhat lower affinity (Kd ~ 72.4 µM) to the Gαs-GDP·AlF4- complex (Fig. 59 bottom). 
SNX13 and SNX14 RGS domains have lower, but still substantial affinity for the Gαs-GDP 
complex (Kd ~ 193 µM and 66 µM respectively) (Fig. 58-59) (Table 8). 
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Figure 59. ITC profiles for the binding of the RGS domain of (Top) SNX14 and (Bottom) SNX25 
vs Gαs·GDP (left), Gαs·GDP·AlF4− (middle), and Gαs·GPPNHP (right). Thermodynamic 
parameters are presented in Table 8 at the end of this chapter. 
 
6.6.4 GAP activity 
Previous studies report SNX13RGS possess GAP activity for Gαs, whereas SNX14RGS 
protein do not. Whether SNX25RGS possess GAP activity is unknown. To understand 
whether the RGS domains of SNX13, SNX14 and SNX25 possess GAP activity for Gαs, 
HPLC assay was used. The preliminary results demonstrated no conversion of GTP to 
GDP by the SNX-RGS proteins (Fig. 60). To confirm the assay protocol, positive control 
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experiments are currently being performed. RGS16 is a GAP protein of Gαiq subunit and 
these constructs will be used to perform positive control assays. 
 
 
Figure 60. HPLC‐based analysis of the SNX-RGS stimulated GAP activity. 
6.6.5 Crystal structure of apo-SNX25 RGS 
I next used X-ray crystallography to determine the crystal structure of the apo RGS 
domain of SNX25 as a path to understanding its complex structure with Gαs. After setting 
up 96-well screens I identified many crystal hits. Around six different conditions with crystal 
hits were immediately set up in a 24-well sitting drop plate to optimize crystal size for data 
collection. Almost all conditions gave larger well-formed crystals. An apo SNX25RGS 
crystal (Fig. 61) (reservoir condition: 30% PEG 4000, 0.2 M Sodium acetate, 0.1 M Tris pH 
8.5) was sent to the Australian Synchrotron and the structure was solved to a resolution of 
2.4 Å using molecular replacement (Table 9).  
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Figure 61. Crystals of apo SNX25RGS in a 24-
well plate. The reservoir condition is 30% PEG 
4000, 0.2 M Sodium acetate, 0.1 M Tris pH 8.5. 
The majority of apo-RGS domain structures conform to the typical structural fold 
seen in RGS4, which is a nine-helix bundle with two lobes formed by the I, II, III, VIII, and 
IX helices and the IV, V, VI, and VII helices, respectively. The SNX25 RGS protein also 
conforms to the canonical folds as seen in Fig. 62A. When superimposed with some of the 
other known structures of RGS, the α6 helix seemed to have a tilt, which also causes a 
conformational change in the α5- α6 loop as well (Fig. 62B). There is a cysteine residue 
where the tilt is seen in α6 helix, which makes a disulphide bond with a neighbouring 
protein in the crystal lattice. This needs to be further examined to determine if it is 
influencing the unusual structure of the SNX25 RGS domain, especially as the α5- α6 
helical area of RGS proteins is known to interact with Gα subunits. 
A B 
Figure 62. (A) Apo SNX25 RGS structure with the alpha-helical folds as expected; (B) 
Superimposition of apo SNX25 RGS (Yellow) with other RGS such as RGS1 (green, PDB code: 
2BV1), RGS2 (Cyan, PDB Code: 2AF0), RGS4 (Peach, PDB code: 1AGR), RGS8 (Magenta, PDB 
code: 2IHD) and RGS10 (Grey, PDB code: 2IHB). 
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Table 9. Summary of crystallographic structure determination statistics  
 
Data collection 
 
Wavelength (Å) 1.0064 
Space group P121 
Cell dimensions    
    a, b, c (Å) 48.61, 57.12, 66.98 
    a, b, g  (°)  90, 109.49, 90 
Resolution (Å) 63.2-2.53 (2.69-2.53) 
Rmerge 0.025 (0.373) 
Rmeas 0.079 (0.508) 
Rpim 0.025 (0.343) 
<I> / sI 14.5 (3.2) 
Total number reflections 42496 (4932) 
Total unique reflections 11564 (1381) 
Completeness (%) 99.6 (98.3) 
Multiplicity 3.7 (3.6) 
Half-set correlation (CC(1/2)) 0.996 (0.864) 
  
Refinement  
Resolution (Å) 45.8- 2.5 (2.65-2.53) 
No. reflections/No. Rfree 10881/ 1107 
Rwork/Rfree 0.186/0.235(0.193/ 0.231) 
No. atoms  
   Protein 2083 
   Solvent 20 
Average B-factor (Å2) 33.5 
R.m.s deviations  
    Bond lengths (Å) 0.016 
    Bond angles (°) 1.931 
 
6.6.6 Crystallisation trials of RGS- Gαs complexes 
Out of different initial screens that I tried in 96-well trays, several conditions produced 
microcrystals of SNX13RGS-Gαs.GDP.AlF4-, SNX14RGS-Gαs.GDP.AlF4-, and 
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SNX25RGS-Gαs.GPPNHP (Fig. 63). These conditions are currently being optimised to 
obtain macrocrystals good enough for a high-resolution structural analysis. 
A                                                     B          C 
   
Figure 63. 96-well plate crystals of SNX13RGS-Gαs.GDP.AlF4- (30% PEG 400, 0.1 M CAPS pH 
10.5, 0.5 M (NH4)2SO4, 10%(v/v) glycerol; SNX14RGS-Gαs.GDP.AlF4-,(30% PEG 200, 0.1 M TRIS 
pH 8.5, 0.2 M (NH4)2HPO4 and SNX25RGS-Gαs.GPPNHP (0.05 M Tris HCl pH 8.5, 22%(w/v) PEG 
4000). 
6.7 Discussion 
The drug selectivity of G-protein-coupled receptors has been therapeutically used to target 
various cellular processes (154-156). The selectivity of G-proteins for different RGS 
proteins is now also being considered as a pharmacological target for the regulation of G-
protein-regulated signaling (157,158). So far, the activity of different G-proteins in specific 
signaling pathways has been studied in great detail, but the role of RGS proteins exhibiting 
selectivity and GAP activity for these G-proteins is largely unexplored, particularly for the 
pharmacologically important Gαs. Most of the first known RGS family members were 
shown to have GAP activity towards Gα proteins (42,159,160). However, although RGS 
proteins bind to Gα subunits, not all RGS domains function as GAPs for GTP hydrolysis. 
The results of this chapter demonstrate the ability of the RGS domains of SNX-RGS 
proteins (SNX13, SNX14 and SNX25) to bind to Gαs using in vitro GST-pull down and ITC 
experiments. Further, we report that there are differences in the relative affinities of the 
SNX-RGS proteins for the different Gαs- nucleotide complexes. In general there is a 
preference for either the transition state conformation or the active state of the Gαs protein, 
although there is also a weaker interaction between SNX13 and SNX14 with the inactive 
state of the molecule. Finally, my studies demonstrated that even though all these SNX-
RGS proteins successfully interact with Gαs, none of them were found to possess GAP 
activity. Positive control assays will be performed inorder to confirm this assay protocol 
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and thus validate my findings. 
In contrast to the previous reports by Zheng et al. (48), the RGS domains of SNX13 
and SNX14 interacted with both inactive and active form of Gαs (although more strongly 
with the latter), whereas SNX25 showed no binding to the inactive form. SNX13 RGS 
protein showed interaction with the active and transition forms of Gαs, whereas SNX14-
RGS showed preference for the transition state over the active state. On the contrary, 
SNX25 showed preferential interaction with the active form over the transition state of Gαs. 
While this confirms that each of these proteins possess the amino acids necessary for the 
interaction with Gαs, the preference of RGS domains for one Gαs–nucleotide bound state 
over the other suggests that the binding sites of the RGS proteins adopting different 
favourable conformations to bind the preferred Gαs state.   
Although GAPs have been described for most G-proteins, a GAP for Gαs remained 
elusive until the original studies of SNX13-RGS appeared to answer this question, 
identifying a potential Gαs-GAP activity (48). But no follow-up studies about this GAP 
activity have been reported since. Ha et al. recently reported that SNX14-RGS, even 
though it successfully binds and sequesters Gαs, does not appear to regulate its GTPase 
activity (49). A potential flaw in this study however, is that no comparison was made with 
SNX13 (or SNX25), and in addition no positive control was used to confirm that the assay 
was working robustly. No studies have been reported on the GAP activity of SNX25-RGS. 
In this work, I have so far not been able to measure GAP activity for any of the SNX RGS 
domains, supporting the results of Ha et al. on SNX14, but in contrast to the reports by 
Zheng et al. on SNX13. The next steps in order to confirm this assay using a positive 
control are currently underway. Even though all three SNX-RGS proteins possess the 
required residues for the stable Gαs binding, my initial results did not demonstrate GAP 
acitivity. If this is the case, then the SNX-RGS proteins may still act as negative regulators 
of Gαs signaling by the mechanism proposed by Ha et al., whereby they will sequester the 
G-protein and prevent its interactions with downstream effectors. Alternatively, the SNX-
RGS proteins may not be regulators of Gαs, but may in themselves be specific effectors of 
these signaling molecules.  
RGS proteins have previously been shown to be regulated either by 
phosphorylation, or by palmitoylation on cysteine residues. For example, RGS2 showed 
decreased GAP activity following protein-kinase C (PKC)-mediated phosphorylation (161), 
whereas RGS-GAIP showed increased GAP activity after ERK-mediated phosphorylation 
(162). RGS4 and RGS10 demonstrated decreased GAP activity through the palmitoylation 
of Cys95 and Cys66 residues respectively (163). Even though my studies demonstrate the 
 120 
RGS domains of SNX-RGS do not possess GAP activity for Gαs, both SNX13 and SNX14 
proteins are previously reported to regulate cAMP signaling (48,49). As mentioned above, 
Ha et al. suggested the SNX14 RGS domain can regulate cAMP signalling without 
GTPase activity by directly sequestering Gαs and thus inhibiting downstream cAMP 
production, essentially resulting in a similar functional outcome to activating GTP 
hydrolysis. In addition, Protein Kinase A (PKA)- mediated phosphorylation of the SNX14-
RGS domain at Ser382/Ser388 considerably decreased its affinity for Gαs thus reducing its 
inhibition of Gαs, which in turn promotes downstream cAMP signalling pathways (49). 
When compared to other known structures of RGS, the structural data of apo SNX25-RGS 
shows an unsual tilt where there is a cysteine (Cys76) residue on the α6 helix. Whether 
SNX13-RGS and SNX25-RGS share similar pathways of feedback phosphorylation or 
palmitoylation for the regulation of cAMP signalling are yet to be explored. These results 
contribute to the suggestion that Gαs proteins may differ from other G-proteins with regard 
to its regulation by GAPs. 
The next intriguing result from this chapter was the RGS domains of SNX13 and 
SNX14 (193 µM and 66 µM respectively) formed a relatively low affinity interaction with the 
Gαs in its GDP-bound state. While the affinity of SNX-RGS for the Gαs-GDP was 
considerably lower than for the stable and transition state of Gαs, the interaction is 
significant and leads us to believe that the inactive Gαs subunit can potentially be 
functionally important in its interaction with SNX-RGS proteins. Though with lower affinity, 
Gαs-GDP had been previously reported to stimulate the activity of adenylyl cyclase (164). 
This might suggest that GTP hydrolysis by Gα alone is not enough to fully terminate 
signaling and further sequestration of Gαs-GDP by other proteins such as SNX-RGS may 
play a key role. Other RGS proteins have been shown to possess guanine nucleotide 
dissociation inhibitor (GDI) activity due to their ability to bind to the inactive state of Gα 
subunits (165,166). Whether SNX-RGS proteins possess GDI activity to promote the 
suppression of activation of Gαs are yet to be explored.  
In the future, the crystal structures of the RGS domains in complex with Gαs will 
enable us to understand the residues providing specificity between these partners and 
how they achieve preference for the different Gαs-nucleotide states. The longer-term goal 
will be to properly define the physiological purpose of SNX-RGS proteins in regulating Gαs 
mediated cAMP signaling. As discussed in previous chapters, SNX-RGS proteins have 
been implicated as key players in ER-endosomal membrane tethering that controls 
trafficking, signaling and exchange of lipids between the ER, LDs and endosomal 
compartments. Although the role in GPCRs in ER and LD function is complex and poorly 
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understood, it is interesting to note that the activation of Gαs-coupled β-adrenergic 
receptors results in phosphorylation of hormone sensitive lipase (HSL), rapid recruitment 
of HSL to LDs and subsequent production of free-fatty acids from stored triacylglycerol 
(167). This suggests one possible connection between the SNX-RGS proteins and GPCR 
mediated cellular signalling pathways, and these integrated processes of inter-organelle 
exchange and protein and lipid homeostasis are widely emerging as potential therapeutic 
targets in a number of neurodegenerative diseases.  
 
Table 8. Thermodynamic parameters of the RGS proteins- Gαs interactions 
Sample cell Titrant ΔH 
(kcal/mol) 
TΔS 
(kcal/mol) 
ΔG 
(kcal/mol) 
Kd 
(uM) 
N 
SNX13 
RGS 
Gαs·GDP -2.01 -2.85 -4.85 193 1.05 
 Gαs·GDP.AlF4- -0.389 -6.42 -6.81 6 1.09 
 Gαs·GPPNHP -0.815 -5.51 -6.32 14.3 1.01 
SNX14 
RGS 
Gαs·GDP -0.704 -4.75 -5.45 66 1.18 
 Gαs·GDP. AlF4- -1.66 -4.72 -6.38 12.9 1.01 
 Gαs·GPPNHP / / / / / 
SNX25 
RGS 
Gαs·GDP / / / / / 
 Gαs·GDP. AlF4- -1.02 -4.38 -5.40 72.4 1.09 
 Gαs·GPPNHP -1.55 -4.19 -5.78 40.3 1.16 
ΔH – enthalpy, T- absolute temperature, ΔS –change in entropy, ΔG – Gibbs free energy,  
Kd – dissociate constant, N – stoichiometry 
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          Chapter 7 
Towards the structure and function of the unique PXA domain 
from the SNX-RGS protein family 
7.1 Introduction and significance 
The SNX-RGS subfamily of proteins consists of four human homologues SNX14, SNX13, 
SNX19 and SNX25, and a single homologue in Saccharomyces cerevisiae called Mdm1p. 
This subfamily is unique amongst the other SNX proteins because they possess 
transmembrane domains (Chapter 1, Fig. 9). Besides the two N-terminal transmembrane 
helices this subfamily also contain an N-terminal PX-associated domain (PXA), a regulator 
of G-protein coupled receptor (RGS) domain (present in all proteins except SNX19), a 
central PX domain, and a C-terminal PX-associated domain (PXC) (8,38).  
Recent studies have demonstrated the involvement of SNX14 in human 
neurological disease. SNX14 mutations were found in cerebellar ataxia, which is a 
condition caused by inflammation in the cerebellum of Purkinje cells, resulting in defective 
control over muscle movements. At the cellular level the major observation in both patients 
and morpholino depleted zebrafish was an accumulation of autophagic structures 
containing undigested material, suggesting a deficiency in lysosomal maturation and 
normal cellular degradation (54,55). Henne et al. (2015) reported perhaps the most 
insightful mechanistic studies on the cellular role of SNX-RGS proteins, demonstrating that 
the yeast homologue Mdm1p is an ER-vacuole tethering protein. Overexpression of 
Mdm1p led to enlarged nuclear ER-vacuole junctions (NVJs), which suggests SNX14- 
related proteins can act as interorganelle tethering proteins by anchoring them to ER via 
their two N-terminal transmembrane domains and by binding to the phospholipids on the 
endosomal membranes through the PX domain. MDM1 deletions based on the disease-
causing truncations in human SNX14 in turn lead to unsuccessful localisation to the NVJs 
(59). In a more recent study, Henne et al., found that Mdm1p localises to ER-vacuole 
junctions and regulates lipid droplet budding during nutrient starvation (60). They are also 
found to interact with fatty-acyl CoA synthases including Faa1 (60), potentially through the 
PXA domain (Mike Henne, personal communication). Thin layer chromatography of 
purified Mdm1p PXA domain revealed the presence of co-purified long chain free fatty 
acids and the lipids potentially seen on the lipid droplet monolayer (Mike Henne, personal 
communication). The accumulation of lipid droplets at the ER-vacuole interface could be a 
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strategy used by the cell to regulate the formation of lipid droplets where they maybe 
easily transferred to the vacuole and eventually digested through lipophagy (168).  
These studies lead us to believe that SNX-RGS proteins can encourage membrane 
contacts at the ER-endosome sites that regulate normal lipid metabolism and transport. 
The disease causing truncations in SNX14 can lead to defective ER, LD and endosomal 
communication, which could subsequently lead to defective lipophagy or autophagy, which 
leads to neurological disease due to disrupted neuronal homeostasis. Although SNX-RGS 
protein family members are highly conserved and are involved in such important and 
diverse roles there is still no proper understanding of the structural or functional details of 
these proteins. Our lab recently published crystal structures of the PX domains from 
SNX14 and SNX19 (38), and in the previous chapter I described my structure and 
characterisation of the RGS domains from this protein family. In this chapter I focussed on 
the PXA and PXC domains of the SNX-RGS proteins as these domains are completely 
structurally uncharacterised, and any new structural information should provide significant 
new insights into the molecular mechanisms by which these domain bind to lipids and 
proteins (50,51), and how they function in regulation of lipid droplet biogenesis at the ER-
LD contact site.  
In this chapter I have detailed the initial efforts I made to optimise the expression 
and purification of a number of recombinant PXA domains from various homologues and 
across several species, as well as a small number of PXC domain constructs. In 
collaboration with Assoc. Prof. Mike Henne and his laboratory at the University of Texas I 
have demonstrated a successful method to express and purify the PXA domain from 
Oryzias latipes (Japanese rice fish), leading to some initial crystallisation hits that I hope in 
the future will lead to a high-resolution structure of this unique protein module.  
7.2 Materials and methods  
7.2.1 Construct design 
The bacterial constructs used in this chapter are from mouse, human, zebrafish and 
Chaetomium thermophilum (thermophilic filamentous fungi) (Table 10). Some of these 
constructs including construct numbers 1, 6-7, 11-12, 15, 17 were cloned by previous lab 
members. I cloned constructs 2 and 16 (mSNX13 PXC and mSNX25 PXA). All remaining 
human, C.thermophilum and zebrafish constructs (3-5, 8-10, 13-14, 18-19) containing PXA 
and RGS domains or PXA domain alone, were synthesised and cloned by Genscript 
(USA) in pGEX-4T-2. The domain boundaries were decided based on the previous studies 
 125 
published by our lab that demonstrates the SNX-RGS protein domain architecture as well 
as the secondary structure predictions (38).  
Bacterial constructs 20-22 were generated and kindly sent to us by Ryan Feathers 
from the lab of Assoc. Prof. Mike Henne (UTSW, USA). These constructs are from 
O.latipes and are cloned in pET28(a) with a His-SUMO tag.  
 
Table. 10: Summary of PXA domain constructs used for recombinant bacterial 
protein expression and purification. 
No Construct Vector/ Tag Cleavage site 
 SNX13 
1 mSNX13 (97-284) PXA pGEX-4T-2/ N-term GST Thrombin 
2 mSNX13 (772-957) PXC pGEX-4T-2/ N-term GST Thrombin 
3 hSNX13 (97-496) PXA-RGS pGEX-4T-2/ N-term GST Thrombin 
4 ct19887 (116-578) PXA-RGS pGEX-4T-2/ N-term GST Thrombin 
5 zSNX13 (114-570) PXA-RGS pGEX-4T-2/ N-term GST Thrombin 
 SNX14 
6 mSNX14 (126-303) PXA pGEX-4T-2/ N-term GST Thrombin 
7 mSNX14 (768-937) PXC pGEX-4T-2/ N-term GST Thrombin 
8 hSNX14 (130-304) PXA pGEX-4T-2/ N-term GST Thrombin 
9 ct18515 (191-373) PXA pGEX-4T-2/ N-term GST Thrombin 
10 zSNX14 (129-303) PXA pGEX-4T-2/ N-term GST Thrombin 
 SNX19 
11 mSNX19 (87-271) PXA pGEX-4T-2/ N-term GST Thrombin 
12 mSNX19 (822-997) PXC pGEX-4T-2/ N-term GST Thrombin 
13 hSNX19_(95-272) PXA-OPT pGEX-4T-2/ N-term GST Thrombin 
14 zSNX19_(89-262) PXA-OPT pGEX-4T-2/ N-term GST Thrombin 
15 mSNX19 (93-274) PXA Ligation Independent Cloning 
(LIC)/ N-term HIS6 
TEV 
 SNX25  
16 mSNX25 (1-164) PXA pGEX-4T-2/ N-term GST Thrombin 
17 mSNX25 PXC pGEX-4T-2/ N-term GST Thrombin 
18 hSNX25 (1-401) PXA-RGS pGEX-4T-2/ N-term GST Thrombin 
19 zSNX25 (121- 527) PXA-RGS pGEX-4T-2/ N-term GST Thrombin 
 In Collaboration with Assoc. Prof. Mike Henne (UT) 
20 olSNX14 PXA (129-228) pET28(a)/ N-term His-SUMO SUMO protease (ULP) 
21 olSNX14 PXA (129-264) pET28(a)/ N-term His-SUMO SUMO protease (ULP) 
22 olSNX14 PXA (129-306) pET28(a)/ N-term His-SUMO SUMO protease (ULP) 
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7.2.2 Transformation and expression of SNX-RGS proteins in E. coli  
Plasmid DNA coding SNX-RGS domains (except constructs 20-21) were transformed into 
E. coli strain Rosetta cells for expression with ampicillin and chloramphenicol (Amp+/Cm+) 
antibiotics. A single colony was picked from the LB agar plate and inoculated into 50 mL 
LB2+ with ampicillin (0.1 mg/mL) and chloramphenicol (0.1 mg/mL). It was then incubated 
at 37°C with shaking overnight. The following day, 30 mL from the overnight culture was 
used to inoculate 1 L LB media containing ampicillin (0.1 mg/mL) and chloramphenicol 
(0.1 mg/mL) and incubated at 37°C. Cells were grown to an optical density (OD) of 0.1- 
0.2 at 600 nm absorbance and induced with 0.2 mM IPTG. This induced bacterial culture 
was incubated on the shaker overnight at 16°C until the cells reach an O.D of 3.0 (~ 24 h). 
Cells were harvested by pelleting the culture using Beckman rotor JLA 8.1000 at an RPM 
of 4000 for 30 min at 4°C. Pellets were resuspended in 10 mL lysis buffer (50 mM Tris pH 
8.0, 500 mM NaCL, 5% glycerol, 1 mM DTT, 0.1 mg/ml benzamidin, 0.1 mg/ml DNase) per 
litre of culture, and stored at –80°C until required or are directly subjected to cell disruption 
to continue with protein purification. 
Constructs 20-22 were sent to us as agar stabs in NiCo21 (DE3) E.coli competent 
cells. The agar stab was inoculated into 50 mL LB2+ with kanamycin (0.1 mg/mL). The 
following day, 50 mL from the overnight culture was used to inoculate 1 L terrific broth (TB) 
containing kanamycin (0.1 mg/mL) and 70 µM oleic acid incubated at 37°C. Cells were 
grown to an optical density (OD) of 0.6- 0.7 at 600 nm absorbance and induced with 0.2 
mM IPTG. This induced bacterial culture was incubated on the shaker overnight at 16°C 
until the cells reach an O.D of 3.0 (~ 24 h). Cells were harvested by pelleting the culture 
using Beckman rotor JLA 8.1000 at an RPM of 4000 for 30 min at 4°C. Pellets were 
resuspended in 10 mL lysis buffer (50 mM Tris pH 8.0, 500 mM NaCL, 5% glycerol, 1 mM 
β-octylglucoside, 0.1 mg/ml benzamidin, 0.1 mg/ml DNase) per litre of culture. 
7.2.3 Recombinant protein purification of SNX-RGS 
The stored resuspended pellets were thawed at room temperature. The thawed pellets 
were then subjected to cell disruption at 27 kpsi at 5ºC. Samples were collected from lysed 
cells and dissolved into SDS loading dye and checked by SDS-PAGE analysis. The cells 
were then centrifuged using JA25.50 rotor at 18,000 RPM for 30 min. The supernatant 
was incubated with Glutathione-S-Sepharose resin for 30 min before eluting the flow 
through. After incubation, the flow through was removed and the resin was washed with 5 
column volumes of buffer A (50 mM Tris pH 8.0, 500 mM NaCl, 5% glycerol, 1 mM DTT). 
After washing, beads were mixed with 5 mL of buffer A and 100 U of Thrombin protease 
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(Sigma-Aldrich) and the mixture was incubated at room temperature overnight to remove 
the GST tag. The next morning, the cleaved protein was collected in the flow through. 
SDS-PAGE was used to analyse the samples from each step of the purification. Used 
resin was regenerated using 40 mM reduced L-glutathione followed by column 
regeneration using 6 M guanidine HCl with 0.2 M acetic acid, which was then equilibrated 
using buffer A. 
For the constructs 20-22, the purification was done using the buffer 50 mM Tris pH 
8.0, 500 mM NaCl, 5% glycerol, 1 mM β-octylglucoside. After cell disruption, the cells were 
centrifuged and the supernatant was collected. The supernatant was incubated with Talon 
resin for 30 min before eluting the flow through. After incubation, the flow through was 
removed and the protein was eluted using 50 mM TRIS pH 8.0, 500 mM NaCl, 5% 
glycerol, 1 mM β-octylglucoside, 250 mM imidazole. The eluted protein was then mixed 
with 2 mg of SUMO protease (ULP) and incubated overnight in the cold room, while the 
mixture was dialysed into 50 mM TRIS pH 8.0, 150 mM NaCl, 5% glycerol, and 1 mM β-
octylglucoside. The next morning, the cleaved protein was incubated again with Talon 
resin to remove uncleaved His-SUMO SNX14 PXA protein. After incubation, the cleaved 
protein was collected in the flow through. The eluted cleaved protein was then subjected to 
gel filtration using a Superdex 75 column (10/300) which was equilibrated in 50 mM Tris 
pH 8.0, 150 mM NaCl, 5% glycerol, and 1 mM β-octylglucoside.  SDS-PAGE was used to 
analyse the samples from each step of the purification. The successfully eluted and pooled 
protein was then dialysed into 20 mM Tris pH 8.0, 150 mM NaCl for further crystallisation 
experiments. 
7.2.4 CD spectroscopy 
The structure of proteins 20-22 in solution (0.2 mg/ml) was determined in a quartz cuvette 
of 1.0 mm path length using a standardized methodology for CD spectropolarimeter 
(Jasco J-810). The blank was 10 mM sodium phosphate pH 7.4. Each CD spectrum 
consisting of the ellipticity and absorbance values, was obtained over a wavelength range 
from 190 to 250 nm, at a scan rate of 50 nm/min and a response time of 0.25 sec. Each 
spectrum represented an accumulation of 3 scans. The data was analysed using the 
spectra analysis program in the spectra manager software.  
7.2.5 Construct design for The BAC-TO-BAC® Baculovirus Expression System 
The BAC-TO-BAC® Baculovirus Expression System (Invitrogen) was used to generate 
recombinant baculovirus stocks for the expression of hSNX13 PXA-RGS, ct19887 
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(SNX13) PXA-RGS, hSNX14 PXA, ct19557 (SNX14) PXA and hSNX25 PXA. An overview 
of the steps involved in this procedure is shown schematically in Fig. 64. 
 
Figure 64. Overview of the steps involved in the generation of recombinant baculoviruses using 
the BAC-TO-BAC® Expression System. 
7.2.6 Design of oligonucleotides  
To facilitate purification, human and C.thermophilum SNX13 and SNX14 constructs were 
expressed as hexahistidine (6His)-tagged fusion proteins. Primers were designed to 
generate PCR products that could be cloned directly into the BamHI and XhoI sites of the 
multiple cloning site of the pFastBac1 vector. For the generation of N-terminal His-tagged 
proteins, the 5' primers have the following features: i) three extra 5' bases for stability as 
recommended by New England Biolabs (NEB); ii) a BamHI restriction site; iii) an additional 
methionine codon to initiate translation, followed by a serine residue to promote stability; 
and iv) six consecutive histidine residues. The 3' primers have two stop codons to ensure 
translation termination followed by a XhoI restriction site. C-terminal His-tagged proteins 
were generated as follows: The 5'-primers were designed to have a BamHI restriction site, 
followed by a start codon (ATG) and 3'-primers included six consecutive histidine residues, 
followed by two stop codons and a XhoI restriction site.   
7.2.7 Amplification of DNA by PCR  
DNA fragments of the required length were generated by the polymerase chain reaction 
(PCR) Standard PCR reactions contained 10 µl 5X Phusion HF buffer, 500 ng Template 
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DNA, 1 µl dNTP mixture (10 mM), 10 µM each of forward and reverse primers and 0.5 µl 
of Phusion DNA polymerase (NEB). The reaction volume was adjusted to 50 µl with sterile 
MilliQ™ H2O. Thermocycling conditions used to produce SNX13 and SNX14 gene 
products were as follows: 
 
Step Time Temperature Cycles 
Initial Denaturation 30 s 98°C 1X 
Denaturation 20 s 98°C  
25-35X Annealing 30 s 60°C 
Extension 2 min 72°C 
Final Extension 7 min 72°C 1X 
 
7.2.8 Purification of PCR fragments  
Amplified PCR reactions were purified using a Nucleospin Gel and PCR Clean-up Kit 
(Machery Nagel) following the manufacturer’s protocol. PCR products were eluted in 35 
µls of EB buffer. 
7.2.9 Analysis of DNA by agarose gel electrophoresis 
DNA was characterised by gel electrophoresis to confirm purity and molecular weight. 
Agarose gels of 1% (Molecular Biology Grade, Progen) were electrophoresed at 100 V for 
30 minutes in 1X TAE buffer. DNA was loaded in either DNA Sample Buffer or 50% 
glycerol. Molecular weight markers used were the GeneRuler™1 kB and 100 bp DNA 
ladders (Bioline and NEB). DNA was visualised by SYBR Safe staining.  
7.2.10 Restriction-enzyme digestion of PCR products and pFastBac1 DNA 
Restriction enzymes and digestion buffers were used according to the manufacturer’s 
instructions (NEB). Vector (pFastBac1) and PCR products were double digested with 
BamHI and XhoI in Cutsmart buffer. Reactions were incubated at 37°C for 2 h. After 
digestion was complete, vector DNA was dephosphorylated to prevent self-ligation. 
Antarctic alkaline phosphatase was added directly to the digestion mixture that was 
incubated for a further 30 min at 37°C. 
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7.2.11 Ligation of DNA 
The calculated molar ratio of vector to insert DNA in ligations was generally 1:3. Ligation 
reactions were prepared in a volume of 20 µL containing 50-100 ng of vector DNA, a 
corresponding amount of insert, 5X Ligation Buffer and 1 unit of bacteriophage T4 DNA 
ligase (NEB). Reactions were incubated for 4 h at 16°C.  An aliquot (2-10 µL) of the 
reaction mixture was used to transform into competent E. coli DH5α cells. 
7.2.12 Transformation of plasmid DNA and ligation mixtures into Escherichia coli  
Plasmid DNA or ligation products were transformed into chemically competent DH5α cells. 
Competent cells (100 µl aliquots) were thawed on ice. Plasmid DNA (1-10 ng) or ligation 
mixtures (2-10 µL) were gently added and mixture transferred to a chilled 14 ml 
polypropylene culture tube (Falcon) and incubated on ice for 30 min. The cell/DNA mix 
was heat-shocked by incubation in a heating block at 42°C for 60 s and immediately 
cooled on ice for 2 min. A pre-warmed aliquot of LB medium (900 µl) was added to each 
culture. Samples were incubated with shaking (250 rpm) at 37°C for 1 h. Aliquots (50-200 
µl) from each transformation culture were plated onto LB agar plates containing 100 µg/ml 
ampicillin (or other appropriate antibiotics) and incubated overnight at 37 °C.  
7.2.13 Preparation and purification of plasmid DNA 
A single colony containing plasmid DNA of interest was used to inoculate 3 ml of 1X LB 
broth (containing 100 µg/ml ampicillin). Cultures were incubated with vigorous shaking at 
37°C for 12-16 h. Cells were collected by centrifugation (JS 5.3, 5000 rpm, 10 min, RT) 
and the pellet was processed according to the Nucleospin Plasmid kit manufacturers 
protocol (Machery Nagel). Purified DNA was digested as described above to confirm the 
presence of cloning junctions and an insert of correct size before sequencing. 
7.2.14 Nucleotide sequence analysis  
Purified products were sent the Australian Genome Research Facility (Brisbane) for 
automated analysis. DNA sequences were analysed using MacVector (version 12.0.6) and 
ExPASy. 
7.2.15 Transposition 
Transposition Media plates [LB plates containing containing kanamycin (50 µg/ml), 
gentamicin (7 µg/ml), and tetracycline (10 µg/ml), 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal) (200 µg/ml) and isopropyl-β-D-thiogalactopyranoside (IPTG) (40 
µg/ml)] were prepared. DH10Bac™ MAX EFFICIENCY competent cells (Life 
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Technologies, Invitrogen) were thawed on ice and 50 µl aliquots were dispensed into 
chilled 14 ml polypropylene culture tubes (Falcon 2059). Recombinant donor plasmid 
(approximately 1 ng diluted in 5 µl sterile H2O) was gently added to the cells. The mixture 
was incubated on ice for 30 min, transferred to a 42°C heating block, heat-shocked for 45 
s and immediately chilled on ice for 2 min. SOC medium (900 µl) was added and the 
culture was incubated at 37°C with medium agitation (200 rpm) for 4 h. Aliquots (50, 100 
and 200 µl) were plated onto Transposition Media plates and incubated for 48 h at 37°C. A 
positive control (pUC19 DNA) was used to assess the transformation efficiency of the 
DH10Bac™ cells. White E. coli colonies containing recombinant bacmid were generally 
larger and readily distinguishable from non-recombinant blue colonies after incubation at 
37°C for 24 h. Before isolating recombinant bacmid DNA, candidate colonies were re-
streaked onto fresh Transposition Media plates to verify their phenotype.  
7.2.16 Purification of recombinant bacmid DNA 
A single isolated bacterial colony, confirmed as having a white phenotype on plates 
containing Bluo-gal and IPTG, was inoculated into LB medium (3 mL) supplemented with 
50 µg/mL kanamycin, 7 µg/ml gentamicin and 10 µg/ml tetracycline. Cultures were grown 
at 37°C with orbital shaking (250-300 rpm) to stationary phase (up to 24 h). Bacterial cells 
were recovered by centrifugation (5000 rpm, 5 min, RT) and the pellet was re-suspended 
in 300 µl Resuspension Buffer (solutions from Nucleospin Plasmid kit - Machery Nagel). 
Lysis Solution (300 µl) was added and the suspension was gently mixed and incubated at 
room temperature for 5 min, changing from turbid to almost translucent in appearance. 
Neutralisation Solution (300 µl) was slowly added with gentle mixing and a thick white 
precipitate of protein and E. coli genomic DNA formed. The sample was incubated on ice 
for 5 to 10 min before centrifugation (14000 rpm, 10 min, 4°C). The supernatant, 
containing recombinant bacmid DNA, was carefully transferred (to avoid carry-over of any 
white precipitated material) to a sterile Eppendorf tube containing 800 µl isopropanol. The 
solution was mixed by gentle inversion, placed on ice for 10 min to precipitate the DNA 
and centrifuged  (14000 rpm, 15 min, RT). The supernatant was removed and 70% 
ethanol (500 µl) was added to each tube to wash the pellet. The mixture was centrifuged 
(14000 rpm, 5 min, RT) and washing with 70% ethanol was repeated. The supernatant 
was removed, ensuring the pellet was not dislodged. The pellet was air-dried at RT for 5 to 
10 min, and the DNA was then dissolved in EB buffer (40 µl). Bacmid DNA was stored at –
20°C in small aliquots to avoid repeated freeze/thaw cycles that can cause a significant 
reduction in transfection efficiency. 
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7.2.17 PCR analysis of recombinant bacmid DNA 
As the recombinant bacmid DNA is greater than 135 kb in size, verification of insertion of 
the gene of interest is difficult using classical restriction endonuclease digestion analysis. It 
is therefore more effective to use PCR to confirm that the gene of interest has transposed 
to the bacmid. The pUC/M13 amplification primers are directed at sequences on either 
side of the mini-attTn7 site within the lacZα-complementation region of the bacmid (Fig. 
65).  
 
Figure 65. M13 forward and reverse priming sites within the pFastBac1 vector. Location of M13 
Forward (-40) and M13 Reverse priming sites flanking the mini-attTn7 site within the lacZα-
complementation region to facilitate PCR analysis. (Source: 
https://tools.thermofisher.com/content/sfs/manuals/bactobac_man.pdf).  
 
These two primers have the following sequences:                                                                  
(i) pUC/M13 Forward: 5’-CCCAGTCACGACGTTGTAAAACG-3’ 
(ii) pUC/M13 Reverse 5’-AGCGGATAACAATTTCACACAGG-3’ 
A PCR reaction was set up for each recombinant bacmid DNA sample containing 
10 µl 5X Phusion HF buffer, ~100 ng bacmid DNA, 1 µl dNTP mixture (10 mM), 10 µM 
each of forward and reverse primers and 0.5 µl of Phusion DNA polymerase (NEB). The 
reaction volume was adjusted to 50 µl with sterile H2O. The following parameters were 
were used for amplification: 
Step Time Temperature Cycles 
Initial Denaturation 3 min 94°C 1X 
Denaturation 45 s 94°C  
25-35X Annealing 45 s 55°C 
Extension 5 min 72°C 
Final Extension 7 min 72°C 1X 
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An aliquot from each reaction (5-10 µl) was analysed by gel electrophoresis. If 
transposition has occurred (bacmid transposed with pFastBac1), a PCR product of ~2430 
bp plus the size of the SNX13/14 inserts should be generated. 
7.2.18 Protein Production and Insect cell culture 
Spodoptera frugiperda (Sf9) and Trichoplusia ni (BTI-TN-5BI4) (High FiveTM) insect cells 
were purchased from Invitrogen. Both cell lines were maintained in suspension culture in 
shaker flasks, incubated at 27°C and 120 rpm. Sf9 cells were cultured in Sf-900 II SFM 
(Invitrogen) and High FiveTM cells were maintained in Express Five® SFM (Invitrogen) 
supplemented with L-Glutamine. Cells were routinely cultured until they reached 4 X 106 
cells/ml and were then diluted to 1 X 106 cells/ml to ensure that cells were maintained in 
exponential growth phase with maximum viability. Sf9 cells were used for all transfections, 
amplification of viral stocks, plaque assays and protein production. As High FiveTM cells 
generally transfect less efficiently, they were used solely for protein expression.  
7.2.19 Transfection of Sf9 cells with recombinant bacmid DNA 
Each transfection was performed in duplicate using Sf9 cells in mid-exponential growth 
phase with a viability of >97%. Approximately 9x105 cells were seeded in each 35mm well 
(of a Nunc 6-well plate) in Sf-900 II SFM (2 ml). Cells were allowed to attach for at least 1 
h at 27°C. During this time, two solutions were prepared: Solution A: For each transfection, 
~10 µl of purified bacmid DNA was diluted into 100 µl Sf-900II SFM without antibiotics. 
Solution B: For each transfection ~10 µl Cellfectin® Reagent was diluted into 100 µl Sf-
900II SFM without antibiotics. Cellfectin® Reagent is a 1:1.5 (M/M) liposome formulation of 
the cationic lipid N,NI,NII,NIII-Tetramethyl-N,NI,NII,NIII-tetrapalmitylspermine (TM-TPS) 
and dioleoyl phosphatidylethanolamine (DOPE) in membrane-filtered water. These 
solutions were combined, mixed gently and incubated for 45 min at RT. Sf-900 II SFM 
(800 µl) was added to each tube containing the lipid-DNA complexes and diluted lipid-DNA 
complexes were gently overlaid onto the cells. Cultures were incubated for 5 h at 27°C. 
The transfection mixtures were gently removed by aspiration and 3 ml of Sf-900 II SFM 
(containing antibiotics/antimycotic) was added. Cells were incubated at 27°C for a further 
72 h. Transfection supernatants containing recombinant baculovirus were harvested by 
centrifugation (3000 rpm, 5 min, RT) and duplicate transfection supernatants were pooled. 
This initial transfection viral stock (designated P1) was used as the inoculum to amplify 
recombinant baculovirus in Sf9 cells.  
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7.2.20 Amplification of initial transfection (P1) baculoviral stock to generate P2 
intermediate and P3 high titre stocks 
The P1 viral stock generated by each transfection was used to infect a monolayer culture 
to generate an intermediate P2 viral stock. Sf9 cells were grown in suspension culture to 
mid-exponential phase with >97% viability. Cells were seeded in T-175 tissue culture 
flasks (Nunc) at a density of 3 x 107 cells/flask in 15 ml Sf-900 II SFM and allowed to 
adhere for 1 h. Attachment and confluency was assessed by examination of the 
monolayer using an inverted microscope. It was assumed that the titre of the initial viral 
stock obtained from transfecting Sf9 cells generally ranges from 1 x 106 to 1 x107 plaque 
forming units pfu/ml (as outlined the Invitrogen Guide to Baculovirus Expression Vector 
Systems (BEVS) and Insect Cell Culture Techniques) and it is recommended that infection 
using a multiplicity of infection (MOI) of 0.01 to 0.1 will result in approximately 100-fold 
amplification of the virus. MOI is defined as the number of virus particles per cell.  The 
following formula was used to calculate the volume of viral stock to add to obtain a specific 
MOI:  
 𝐼𝑛𝑜𝑐𝑢𝑙𝑢𝑚  𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑   𝑚𝑙 = !"#   !"#!"## !  !"#$%&  !"  !"##$!"!#$  !"  !"#$%  !"#$%  (!"#!" )  
 
After cells had firmly adhered, media was aspirated from the cell monolayer and 
viral inoculum was added (1-2 ml of P1 stock diluted into approximately 15 ml Sf-900 II 
ensuring that the cell monolayer was covered). The virus was allowed to adsorb at RT for 
1 h and a further 40-50 ml of Sf-900 II media was added. Cultures were incubated at 27°C 
for 48-72 h. Optimal harvest times can vary and were determined for each baculoviral 
construct. The supernatant from this amplification was harvested, clarified in a benchtop 
centrifuge (3000 rpm, 5 min, RT) and 5 ml of this amplified supernatant was added directly 
to Sf9 cells in suspension culture (400 ml) at a density of 2 x 106 cells/ml. This culture 
(designated P3), was incubated at 27°C and 120 rpm and recombinant baculovirus was 
harvested 3 days post-infection by centrifugation (3000 rpm, 5 min, RT). FBS was added 
as a preservative to a final concentration of 2% to the clarified viral stocks which were 
stored at 4°C, protected from light. A small aliquot was also stored at –70°C. This 
amplification procedure allows production of a high titre P3 viral stock with a titre ranging 
from 1 x 107 to 1 x 108 pfu/ml, recommended for expression studies.  
7.2.21 Test expressions  
The expression of each recombinant protein of interest was initially analysed in static Sf9 
cultures. Sf9 cells were grown in suspension culture to mid-exponential phase with >97% 
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viability. Cells were then seeded in T-175 tissue culture flasks (Nunc) at a density of 3 x 
107 cells/flask in 15 ml Sf-900 II SFM and allowed to adhere for 1 h. Approximately 2-3 ml 
of the intermediate P2 viral stock for each recombinant protein was used to infect each the 
monolayer culture. The virus was allowed to adsorb at RT for 1 h and a further 40-50 ml of 
Sf-900 II media was added. Cultures were incubated at 27°C for 72 h.  
7.2.22 Harvesting and analysis of recombinant expression 
Recombinant SNX13 and SNX14 proteins accumulated intracellularly. Infected insect cells 
were harvested (from T-175 flasks) at 72 h post-infection and cells collected by low speed 
centrifugation (3000 rpm, 10 min, RT). Insect cell pellets were washed once with 
phosphate-buffered saline (PBS) and then resuspended in 3 ml PBS. Cells were lysed by 
sonication (typically 1 x 30s burst at 60W using a Misonix Sonicator 3000). The sonication 
was repeated until microscopic observation of the culture revealed few intact cells. The 
lysate was clarified by centrifugation (14 000 rpm, 10 min, 4°C). The supernatant and 
pellets were then analysed by SDS-PAGE, followed by Western blotting. Soluble 
cytoplasmic proteins are found in the supernatant, with insoluble material retained in the 
pellet.  
7.2.23 Western blotting 
Proteins were separated by SDS-PAGE as previously described membrane using the iBlot 
Dry Blotting System (Life Technologies, Invitrogen). A pre-stained molecular weight 
marker (BLUltra, GenedireX) was used to monitor the transfer of proteins to the 
membrane. Membranes were blocked with 5% skim milk powder in PBS for 2 h at RT and 
then incubated overnight with the primary monoclonal antibody [Penta•His (Qiagen)] 
diluted 1:1 000 in PBS-skim milk. After 2 x 5 min washes in PBS, membranes were then 
incubated for 1 h with a goat anti-mouse-horseradish peroxidase (HRPO) conjugated 
secondary antibody (Life Technologies, Invitrogen) diluted 1:2000 in PBS-skim milk. 
Membranes were then washed for 3 x 5 min in PBS to remove unbound conjugate, and 
developed using a Novex ECL Chemiluminescent Substrate Kit (Life Technologies, 
Invitrogen). Proteins were detected on X-ray film (Kodak). 
7.2.24 Infection of insect cells with recombinant baculoviruses 
One large scale infection of Sf9 cells (6 L) with hSNX13 PXA-RGS was performed to 
generate protein for an investigation of whether SNX13 and SNX14 proteins expressed in 
insect cells could be purified without the detergent required for proteins produced in the 
bacterial system. Cells were infected whilst in the mid-logarithmic phase of growth at a 
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density of 2 x 106 cells/ml at a MOI of ~5. Cultures were incubated at 27°C with shaking at 
120 rpm. Cells were harvested at 72 h post-infection by centrifugation (3000 rpm, 10 min, 
RT). Similar purification procedures were then used for both bacterial and insect cells. As 
infection conditions in insect cells can vary, optimisation experiments will need to be 
performed to determine optimal infection parameters, particularly cell line, MOI and 
establishment of the time course of protein production for each recombinant baculovirus.  
7.3 Results 
7.3.1 SNX-RGS bacterial protein test expression and purification trials 
When I started working on the PXA constructs from SNX-RGS proteins, the only known 
information was this domain could be a protein-protein interaction region. These 
purification trials were done based on the available information, treating the proteins as 
typical small globular domains that should be soluble in standard ionic buffer solutions.  
Test expressions of all constructs using 1 L cultures were performed for the 
constructs 1-2, 6-7, 11-12, 15, 16-17 (Table 10). Figures show that GST-tagged mSNX13 
PXA, mSNX13 PXC (Fig. 66A), mSNX14 PXA, mSNX14 PXC (Fig. 66B), mSNX25 PXA, 
mSNX25 PXC (Fig. 66C), mSXN19 PXA and mSNX19 PXC (Fig. 66D) all exhibit a 
significant degree of soluble expression (protein remaining in the soluble supernatant) and 
bind to the glutathione-resin. Even though it appears the cleaving of GST tag is 
successful, all of the tested proteins failed to elute off the GST column after the thrombin 
cleavage, suggesting poor folding or solubility for the isolated PXA and PXC domains.  
Expression of each of these constructs suggested that significant amounts of 
soluble GST-fusion proteins could be produced; however the lack of elution from 
glutathione affinity matrix was puzzling. This suggested possible aggregation or mis-
folding of these constructs. 
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Figure 66. SDS-PAGE analysis of affinity chromatography purification of GST-tagged (A) mSNX13 
PXA and PXC (MW=46 kDa), (B) mSNX14 PXA and PXC (MW=47 kDa), (C) mSNX25 PXA and 
PXC (MW=56 kDa), and (D) mSNX19 PXA and PXC (MW=52 kDa) showing the presence of 
expressed protein at their respective expected molecular weights. Even though the fractions of 
GST resin showed their presence, these proteins failed to elute from glutathione sepharose after 
the thrombin cleavage of the GST tags.   
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We next decided to test additional constructs of this protein from different species 
(constructs 3-5, 8-10, 13-14, 18-19). The other species were human, zebrafish and 
Chaetomium thermophillum. Some of these constructs had both PXA and RGS domains to 
test whether the presence of an additional domain might provide extra stability or solubility. 
Even though these constructs were all also highly expressed, as for the mouse constructs 
the elutions were again unsuccessful. Examples of two constructs are shown in Fig. 67A. 
Since all the proteins were expressed but failed to elute after thrombin cleavage to 
remove GST (or using glutathione elution of the GST-tagged proteins (not shown), I 
speculated the problem might be protein misfolding or hydrophobicity leading to 
aggregation, making them difficult to elute it off the column in typical aqueous buffer. 
Different buffer conditions were therefore tried to see if these could help reduce any non-
specific binding of the proteins to the glutathione sepharose. When 0.2% Triton X-100 was 
added to the elution buffer the GST-tagged fusion proteins began eluting off the column, 
suggesting the non-specific binding of a hydrophobic protein to the GST resin. As seen in 
the Fig. 67B, the elution with the triton detergent helped regardless of the buffer condition. 
 
Figure 67. SDS-PAGE gel analysis of fractions from (A) affinity chromatography of GST-tagged 
hSNX13 PXA-RGS (MW=82 kDa) and ct19887 PXA-RGS (MW=80 kDa) showing the presence of 
expressed protein. (B) Elution of hSNX13 PXA-RGS and ct19887 PXA-RGS using 0.2% Triton X-
100 with buffer conditions containing different salt concentrations (50 mM Tris pH 8.0, 30 mM L-
glutathione reduced, with 500 mM NaCl, 200 mM NaCl, 150 mM NaCl, and 100 mM NaCl). 
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I next attempted to cleave the GST tag using thrombin in-solution rather than on the 
beads, which did yield the protein of interest, albeit in a relatively impure state (Fig. 68, 
right). The next hurdle was to remove the Triton using biobeads from the eluted protein, 
which was unfortunately not successful in yielding a pure and homogeneous hSNX13 
PXA-RGS protein. The other protocol I tried to improve the solubility was by co-expressing 
with molecular chaperons (169), which also proved to be unsuccessful in our case. Co-
expression as well as co-purification with a potential binding partner, CARD domain from 
ARC (50) was also performed with no success. 
 
 
Figure 68. (Left) SDS-PAGE showing the elution of hSNX13 PXA-RGS protein (around 82 
kDa) using 0.2% Triton X-100; (Right) SDS-PAGE showing the presence of the cleaved 
hSNX13 PXA-RGS protein of interest after cleaving off the GST-tag. GST is present at slightly 
higher than 25 kDa. 
 
While it was speculative at this stage, these results from the recombinant 
expression of the PXA and PXC domains of human, mouse and C. thermophilum SNX-
RGS proteins began to suggest that these domains might be lacking a key co-factor or 
ligand required for their stability. When Mike Henne and his group published the potential 
role of SNX-RGS proteins in ER-endosome interactions (59), I began to speculate that 
these unknown PXA and PXC domains could regulate lipid interactions or lipid transfer 
analogous to other proteins such as the ORP family members (170). Thus my results 
suggested to me that these PXA proteins are highly hydrophobic and may require a ligand 
such as a lipid or another molecule that is just not present in bacteria. If so it is possible 
that bacterial protein expression is unable to provide a potential lipid co-factor required for 
protein stability. Hence the next step included further exploration of expression and 
purification of these SNX-RGS constructs in insect cells with the hope that this will allow 
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the proteins to be correctly folded and to incorporate any potential native ligands not 
present in bacteria. 
Expression of SNX-RGS constructs in insect cells has been performed with 
assistance from Dr. Suzanne Norwood. I performed all of the cloning experiments and 
transpositions, and Dr. Suzanne Norwood performed transfections, test expression and 
assisted with Western-blotting.  
Most PCR reactions generated one dominant fragment of the correct size and the 
amplified inserts were digested and directly ligated into the pFastBac1 expression vector 
without requiring further purification (Fig. 69).   
 
Figure 69. Restriction digestion on ligation colonies showing the presence of inserts. 
 
After the transposition reaction had been successfully performed, high molecular 
weight recombinant bacmid DNA was isolated, purified and used to transfect insect cells to 
generate recombinant baculoviruses, which were used for preliminary expression 
experiments. The initial transfection baculoviral stock (P1) was only amplified twice (to 
avoid the introduction of mutations) and this generated intermediate (P2) and high titre 
(P3) stocks that were used to infect insect cells for initial test expressions and large-scale 
expression. In test expressions, the recombinant hSNX13 PXA-RGS construct expressed 
well compared to the ASIC channel construct used as a control, but the C. thermophilum 
SNX13 homologue was not (Fig. 70). Both PXA and PXC domains from C. thermophilum 
SNX14 proteins were also expressed and soluble. Despite these promising results I was 
not able to purifiy significant amounts of soluble homogeneous protein following large-
scale expressions. However this was only attempted once and bears repeating in the 
future. 
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Figure 70. Western blot of the test expressions demonstrating the presence of soluble proteins. 
 
7.3.2 Recombinant protein expression and purification of constructs 20-22 
The constructs 20-22 from O. latipes SNX14 (will be addressed as OL1, OL2 and OL3 
herein) were cloned by Ryan Feathers and a gift from the lab of Assoc. Prof. Mike Henne 
(UTSW). These three bacterial constructs were designed based on in silico predictions of 
different secondary structure elements in the domain. OL1 is missing 77 AAs, whereas 
OL2 is missing 37 AAs from the C-terminal α-helical region when compared to the full-
length construct OL3 (Fig. 71). 
 
 
Figure 71. Three SNX14 PXA (O. latipes) constructs (OL1, OL2 and OL3) designed based on the 
predicted sequence-based protein solubility. 
 
Purification of constructs OL1, OL2 and OL3 was performed using affinity 
chromatography with Talon resin followed by gel filtration using Superdex 75 (10/300) 
column. Samples from every step of purification were collected for SDS-PAGE and were 
analysed for the presence of successfully purified proteins of interest (Fig. 72). Fractions 
that are found to be relatively pure were pooled together for further experiments. After the 
gel filtration, the yield of construct 1 was around 20 mg/ml. The constructs 2 and 3 failed to 
successfully express soluble proteins.  
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Figure 72. (A) SDS-PAGE analysis of elution fractions from the Affinity chromatography of His-
SUMO (12 kDa) tagged construct OL1 SNX14 PXA protein demonstrating the presence of 
expressed soluble protein at the expected molecular weight around 23 kDa; (B) FPLC 
chromatogram of cleaved SNX14 PXA construct OL1 (11 kDa) and SDS-PAGE gel of fractions 
corresponding to the major peak; (C) SDS-PAGE gel showing FPLC purified tagless construct OL1 
that was expressed without and with oleic acid. 
 
I also decided to test the addition of Oleic acid (70 µM) to the culture medium during 
the protein expression since the PXA domain was found to bind to long chain fatty acids 
(Mike Henne, unpublished). Oleic acid helped protein expression and constructs OL2 and 
OL3 expressed soluble proteins and seemed to be less aggregated, even though the 
B A 
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yields of construct OL3 was low (Fig. 72C and 73). Using analytical ultracentrifugation and 
crosslinking, the laboratory of Mike Henne has confirmed the presence of multimeric 
species in the soluble OlSNX14 protein. 
 
 
  
Figure 73. (A) SDS-PAGE analysis of elution fractions from the affinity purification of His-SUMO 
(12 kDa) tagged SNX14 PXA (around 28 kDa) construct OL2 expressed without and with oleic 
acid; The expression of OL2 without oleic acid is very poor, whereas the gel demonstrate the 
presence of soluble protein when oleic acid is introduced during protein expression (B) SDS-PAGE 
gel of the FPLC purified tagless construct OL2 (around 16 kDa) (expressed with OA); (C) SDS-
PAGE gel of the FPLC purified tagless OL3 (around 20.3 kDa) (expressed with OA). 
 
Construct OL2 yielded around 12 mg/ml whereas construct 3 yielded only 7 mg/ml 
after concentrating down the eluted and pooled fractions. Thus when expressed with low 
concentrations of oleic acid and purified with low concentrations of β-octylglucoside 
detergent, all three constructs of SNX14 PXA (O.latipes) were found to be soluble. These 
proteins were also folded and showed the presence of α-helical structure as expected 
from secondary structure predictions when tested using CD spectroscopy (Fig. 74). 
 
A                                                                B                                      C 
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Figure 74. CD spectra of OL1, OL2 and OL3 constructs of SNX14 PXA (O.latipes) showing the α-
helical structure as expected thus confirming the soluble proteins are properly folded.   
 
7.3.3 Crystallisation trials of SNX14 PXA (Oryzias latipes) 
All three constructs of SNX14 PXA from O. latipes produced needle crystals in both 96-
well crystallization screens and also 24-well optimization grids. The conditions that gave 
these crystals are listed in Table 11. Low concentrations of oleic acid were also added to 
the purified PXA protein to observe any improvements in the crystals. Some of the small 
needle crystals obtained is shown in Fig. 75. Clearly these crystals are currently too small 
for high-resolution structure determination, but are promising leads for further optimization 
of both sample preparation and crystallization conditions. 
 
Figure 75. Crystals of from 24-well optimization plates (A) Needle crystals of OL1 SNX14 PXA; (B-
C) Crystals of OL2 SNX14PXA; (D) Crystals of OL3 SNX14PXA 
 145 
Table 11. Some of the crystallisation reservoir conditions that produced positive 
crystal hits of OL1, OL2 and OL3 SNX14 PXA (O. latipes) 
1.  10% (v/v) 2-propanol, 0.1 M HEPES pH 7.5, 0.2 M NaCl 
2. 10% (w/v) PEG-3000, 0.1 M CHES pH 9.5  
3. 20% (w/v) PEG-1000, 0.1 M Na/K phosphate pH 6.2, 0.2 M NaCl 
4.  10% (w/v) PEG-3000, 0.1 M imidazole pH 8.0, 0.2 M Li2SO4 
5. 1.26 M (NH4)2SO4, 0.1 M HEPES pH 7.5 
6. 10% (v/v) 2-propanol, 0.1 M cacodylate pH 6.5, 0.2 M Zn(OAc)2 
7. 50% (v/v) ethylene glycol, 0.1 M imidazole pH 8.0 
8. 50% (v/v) ethylene glycol, 0.1 M HEPES pH 7.5, 0.2 M Li2SO4 
9. 40% (v/v) ethylene glycol, 0.1 M Tris pH 7.0 
10. 30% (v/v) PEG-200, 0.1 M CAPS pH 10.5, 0.2 M (NH4)2SO4 
11. 10% (v/v) 2-propanol, 0.1 M HEPES pH 7.5, 0.2 M NaCl 
12. 30% (w/v) PEG-3000, 0.1 MCHES pH 9.5 
13. 20% (w/v) PEG-8000, 0.1 M CAPS pH 10.5, 0.2 M NaCl 
7.4 Discussion 
Deciphering the molecular mechanisms by which the SNX-RGS proteins interact with their 
protein/lipid-binding partners will be an important contribution towards understanding their 
functional role in the cell. The PXA and PXC domains from SNX-RGS proteins are 
conserved in SNX14 homologues and appear to be unique to the family, with no 
recognisable structural or sequence homologues. The Mdm1p PXA domain from yeast 
cells was found to interact with free fatty acids using TLC (Mike Henne, Personal 
communication), whereas proteomic studies also revealed that the PXA domain interacts 
with the fatty acid-CoA synthetase, Faa1 (60). 
In this chapter, I have described the expression and purification trials of various 
PXA and PXC domains from several species in both bacterial and insect cell expression 
systems. The His-tagged PXA domain from O. latipes was eventually optimized to produce 
soluble and folded proteins when expressed with low concentrations of oleic acid and 
purified with low concentrations of β-octylglucoside detergent. Although I recently obtained 
micro-needle crystals of PXA domain, I have not yet been able to produce macro-crystals 
from these conditions. Therefore the structural studies of the PXA domain will still require 
optimisation in the future. If successful, these studies will help us to identify binding sites 
for proteins and/or lipids, thus allowing a molecular characterisation of its functional 
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importance in the cell.  
 The interaction of ER with the endolysosomal system is rapidly emerging as an 
area of immense interest in the field of cell biology, but the specific protein machineries 
that mediate these interactions remain poorly characterized. As the SNX14-related 
proteins are themselves emerging as key players in this process, and are also involved in 
human neurological disorders, further molecular insights will be important to allow us to 
understand how this domain mediates membrane tethering, and other processes such as 
lipid metabolism, lipophagy and autophagy.  
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    Chapter 8 
Summary and Future Directions 
 
Although all sorting nexin (SNX) proteins fall under the same larger protein family, the PX-
proteins, their diversity of structures and functions mean it is impossible to provide a single 
succinct description of their cellular roles. Over the past decade there has been a great 
deal of progress in understanding how the Phox-homology (PX) domain of SNX proteins 
mediates their membrane-localization and recruitment to specific cellular organelles. 
Although we now have a reasonable structural understanding of how the PX domain 
interacts with lipids, in particular the endosomal phosphoinositide phosphatidylinositol-3-
phosphate (PtdIns3P), there is a lack of information regarding how the PX domain 
regulates various protein–protein interactions. It is crucial to combine both the cellular and 
structural insights into the molecular functions of the PX proteins to gain a better 
understanding of how they regulate cellular trafficking and signaling. There is also a lack of 
knowledge regarding the structures of many of the associated domains within the PX 
proteins, outside the PX domain itself. 
In this thesis, I have studied two subfamilies of the PX-proteins; the SNX-BAR and 
the SNX-RGS subfamilies. In the first part of my thesis (Chapters 2-5), my work focused 
on the role of PX domains of the distinct SNX-BAR proteins (SNX5, SNX6 and SNX32) in 
pathogen invasion, and provided the very first look into the structural mechanism of how 
the PX domains interact with another protein. These chapters provide information 
regarding how PX domains regulate protein-protein interactions and also demonstrate the 
potential functional role of SNX-BAR PX domains as a site for the normal transporting of 
proteins/cargoes that is fundamental to all living cells. In the second part of my thesis 
(Chapters 6-7), my studies are focused on the structural and functional characterization of 
domains other than the PX-domain in the SNX-RGS subfamily, with a major focus on the 
RGS domain and the structurally uncharacterised PXA domain. The RGS domain 
potentially acts as GAP proteins for Gαs subunits, whereas the PXA domain has not only 
been shown to have the ability to bind to both proteins and lipids but could also control 
membrane tethering and regulate lipid transfer analogous to other proteins such as the 
ORP family members (Mesmin et al., 2013). This domain may also play a role in regulation 
of lipid droplet biogenesis at the ER-lipid droplet contact site. 
 Chapter 6 reports my findings about the GTPase binding and GAP activity of the 
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RGS domains of the three human SNX-RGS proteins, which tells us a confirming story of 
some aspects of previously published studies (48), but questioning others. Chapter 7 
details the extensive efforts I made to optimise the expression and purification of a number 
of recombinant PXA domains from various homologues and species (Chapter 7, Table 7).  
8.1 The first insights into how PX domains regulate protein-protein interactions  
Chlamydia trachomatis, commonly known as chlamydia, must enter the human host cell to 
replicate and eventually cause infection. Once inside the host cell, the bacteria develop 
certain membrane-bound structures called inclusions, where they grow and multiply. As 
the infection progresses, this inclusion membrane gets modified with many bacterial 
effector proteins called inclusion membrane proteins. The major role of these inclusion 
membrane proteins is to hijack host cell proteins and lipids to maintain the inclusion 
membrane for their own survival within the host cell. SNX5, SNX6 and SNX32 proteins 
from the SNX-BAR subfamily were previously shown to be hijacked by one such 
Chlamydial effector protein called Inclusion membrane protein E (IncE) and recruited to 
the inclusion membrane during Chlamydial infection (26,113). How IncE or any other 
inclusion membrane proteins hijack human host cell proteins were unknown until now.  
Chapter 2 deciphers the structural mechanism through which IncE specifically 
binds to SNX5, SNX6 and SNX32 proteins. The direct association between the C-terminal 
region of IncE and the PX domains of SNX5, SNX6 and SNX32 were confirmed using 
isothermal titration calorimetry. The affinities (Kd) of IncE for SNX5, SNX6 and SNX32 
were essentially similar (0.9, 1.1 and 1 uM respectively), which confirms a common 
recruitment motif within these proteins (Chapter 2, Fig. 16), which was further confirmed 
by recruitment of these proteins to inclusion membranes in infected cells (Chapter 2, Fig. 
15). The three-dimensional crystal structure of SNX5 PX in complex with the C-terminal 
region of IncE reveals the IncE forms a long β-hairpin when bound to SNX5 at the base of 
the extended helical region (Chapter 2, Fig. 18), which is a unique structural element 
found only in SNX5, SNX6 and SNX32 and not in any other SNXs. Chapter 3 reports the 
crystal structure of SNX32PX-IncE complex, which confirms the biophysical data from 
chapter 2. The binding mechanism of SNX32PX-IncE is essentially identical to the 
SNX5PX-IncE binding mechanism thus further confirming the common binding motif within 
these proteins required for the IncE binding (Chapter 3, Fig. 32). From the perspective of 
understanding the endogenous functions of the SNX5, SNX6 and SNX32 proteins, the 
work in chapter 2 and 3 reveal that the PX domains of these proteins bind IncE using a 
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site that is both different to the usual lipid binding region common to other PX domains, but 
is very highly conserved in the protein family. This led me to speculate that IncE might be 
mimicking and displacing certain important host cell transmembrane proteins/cargo that 
would normally bind to SNX5, SNX32 and SNX6 (Fig. 76). In Chapter 4 I present 
important new unpublished data that this is indeed the case, demonstrating the functional 
role of these specific SNX-BAR proteins as a scaffolds for the binding and normal 
recycling of cargoes such as the CI-MPR in the cell. 
What other potential cargoes might bind to the PX domains of SNX5, SNX6 and 
SNX32? Chapter 4 reports initial answers to this question. The Vps retromer core (Vps35, 
Vps29 and Vps26) and SNX-BAR dimers (SNX1 or SNX2 heterodimerised with SNX5 or 
SNX6) have long been considered the core retromer components in mammalian cells. 
Even though no proper biochemical evidence of a stable interaction between the Vps core 
and SNX-BAR sub complexes in mammalian cells are reported, their mutual functional role 
in the retrograde trafficking of of cation-independent mannose 6-phosphate (CI-MPR) was 
accepted as a connection between these two sub complexes. This cooperation of 
subcomplexes and thus the model of retromer activity were recently questioned by two 
different labs (115,116), where they found SNX-BAR proteins play a key role in CI-MPR 
cargo recruitment that appears to be independent of the retromer Vps core. Besides CI-
MPR, proteomic studies have revealed many cargos that depend on SNX5, SNX6 and 
SNX32 for their recycling, including IGF1R and SEMA4C. In collaboration with Dr. Boris 
Simonetti and Prof. Pete Cullen (University of Bristol, UK), the potential regions on the 
cytoplasmic tails of these cargoes that bind to SNX5 were mapped. In Chapter 4, using 
isothermal titration calorimetry, the PX domains of SNX5, SNX6 and SNX32 were 
confirmed to directly bind to the cytoplasmic tails from CIMPR, IGF1R and SEMA4C. The 
first crystal structure of a PX domain of a SNX5 in complex with a transmembrane cargo, 
CIMPR is also reported in this chapter, which confirms the binding site on SNX5PX as the 
same binding site recognised by IncE thus confirming my hypothesis from chapter 2 and 3 
that the PX domains from SNX5, SNX6 and SNX32 proteins act as a site for trafficking of 
cargos. This study also validates the hypothesis from the recent publications that SNX-
BAR proteins can bind directly to cargos and function independent of the Vps core 
subcomplex. Since the crystal structure data of SNX5PX-CIMPR is of low resolution, 
optimisation of native and seleno-methione crystals of SNX5PX-CIMPR complex are 
underway, which will enable me to understand the interactions and to perform structure-
based mutagenesis to confirm the cargo interaction mechanisms in vitro, and to test for 
defective cargo trafficking in vivo. In the future, crystal structures of SNX5PX with IGF1R 
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and SEMA4C, besides CIMPR, will enable us to understand the different conformations 
these cargoes adopt to bind to SNX5PX, as well as provide insights into how SNX-BAR 
protein can allow the trafficking of these cargos to different destinations. Since retromer-
SNX cargo sorting pathways has important implications in neurological diseases, a 
complete understanding of these selected endosomal sorting pathways are likely to open 
up new opportunities for the design of therapeutic interventions in the future. 
As I discussed in chapter 2 and 3, IncE binds to SNX-BAR proteins as a β-hairpin 
consisting of two antiparallel β-strands, which are connected through a β-turn. Since the 
two IncE β-strands are positioned close together I developed an idea that the N and C 
termini of IncE could be linked to form a cyclic peptide, which might demonstrate increased 
binding for SNX-BAR proteins and stability when compared to the linear IncE peptide, due 
to the increased rigidity and decreased entropy. Chapter 5 explores this idea of a more 
stable cyclic IncE peptide, which in the future, could be used as a specific inhibitory tool to 
study the role of SNX5 in membrane trafficking. The work reported in this chapter was 
performed in collaboration with Prof. David Fairlie and Dr. Timothy Hill (IMB, University of 
Queensland). In this chapter, I have identified a cyclic IncE peptide that has the ability to 
bind to SNX5 PX domain with an increased binding affinity, which is nearly 30x higher than 
the standard IncE peptide, and ~300x higher than cellular cargo molecules. This suggests 
a strong potential to inhibit the binding of a transmembrane cargo such as CIMPR, 
confirmed in vitro, and the next steps will be to determine the ability of such peptides to 
cross the membrane so that they can be used as tools for studying the trafficking of SNX-
bound cargos. Further into the future such peptides may have additional uses such as 
testing the importance of such pathways in disease states and their therapeutic targeting 
potential. 
 
Figure 76. Schematic representation of the involvement of PX domains of SNX5, SNX6 and 
SNX32 in interaction with IncE which mimicks the transmembrane cargos CIMPR, IGF1R and 
SEMA4C that normally binds to SNX-BAR proteins for their proper recycling. 
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8.2 Understanding the various functions of different domains in the SNX-RGS 
subfamily of proteins and insights into how they might be working together in our 
cell. 
In studies of a different sub-family of SNX proteins, Chapter 6 explores the ability of the 
RGS domains of SNX-RGS proteins (SNX13, SNX14 and SNX25) to bind to Gαs and their 
ability to hydrolyze GTP and attenuate Gαs signaling. Even though my studies 
demonstrated the ability of SNX-RGS proteins to successfully interact with Gαs, none of 
them were found to possess substantial GAP activity. This result is in contrast to the 
original studies of SNX13-RGS, which identified a potential Gαs-GAP activity (48), 
whereas it is in support to the results of Ha et al. (49), which failed to identify a GAP 
activity for SNX14. This leads me to the speculate that since SNX-RGS proteins bind to 
Gαs, these proteins may still act as negative regulators of Gαs signaling, whereby they will 
sequester the G-protein and prevent its interactions with downstream effectors. 
Alternatively, the SNX-RGS proteins may not be regulators of Gαs, but may in themselves 
act as specific effectors of these signaling molecules. My studies (chapter 6) also reported 
SNX-RGS proteins having different affinities for different Gαs-nucleotide complexes. They 
exhibited a preference for either the transition state conformation or the active state of the 
Gαs protein. In contrast to the previous reports by Zheng et al. (48), SNX13 and SNX14 
RGS proteins also demonstrated weaker interaction with the inactive state of the molecule; 
Gαs-GDP. This result led me to conclude that hydrolysis of GTP by Gαs may not be 
enough to fully terminate SNX-RGS binding, and/or the SNX-RGS might play a role in 
suppressing the signaling of Gαs signaling by also sequestering Gαs-GDP. The preference 
of RGS domains for one Gαs–nucleotide bound state over the other also suggests that the 
binding sites of the RGS proteins adopts different favourable conformations to bind the 
preferred Gαs state. Most RGS domain interactions are typically in the micromolar range 
similar to what I saw in my experiments, which means these interactions are quite likely to 
occur physiologically. Even though my preliminary studies demonstrate the RGS domains 
of SNX-RGS do not possess GAP activity for Gαs, both SNX13 and SNX14 proteins are 
previously reported to regulate cAMP signaling (48,49). Whether RGS domains from SNX-
RGS proteins share pathways of feedback phosphorylation or palmitoylation for the 
regulation of cAMP signalling like other classical RGS proteins, are yet to be explored. In 
the future, the crystal structures of the RGS domains in complex with Gαs will enable us to 
understand the residues providing specificity between these partners and how they 
achieve preference for the different Gαs-nucleotide states. The longer-term goal is to 
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define the physiological purpose of SNX-RGS proteins in regulating Gαs mediated cAMP 
signaling. An open question is also where these Gαs interactions occur in the cell. As 
described in past work by the Collins lab and others, the various SNX-RGS proteins 
appear to be predominantly associated with internal organelles including the ER and 
endosomes, as well as lipid droplet contact sites. Thus the role of SNX-RGS interactions 
with Gαs is likely to be specifically associated with intracellular compartments distinct from 
the site of GPCR-Gα activation at the cell surface. 
Exploring the structure of the uncharacterised PXA domain of SNX-RGS proteins 
will enable us to understand the molecular mechanisms by which this domain binds to 
lipids and proteins, and reveal how they contribute towards their function in regulation of 
lipid droplet biogenesis at the ER-LD contact site.   
 
Figure 77. A) RGS proteins with GAP activity. B) RGS domains of SNX-RGS might act as 
negative regulators of Gαs signaling by sequestering the G-protein, whereas the increased cAMP 
production can be regulated by either palmytoylation or feedback phosphorylation of RGS and thus 
inhibiting its affinity for Gαs. C) Could RGS domain be involved in lipophagy by regulating cAMP 
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production? D) Schematic representation of the involvement of SNX-RGS protein in lipid droplet 
biogenesis. 
 
 Chapter 7 describes in detail the efforts to successfully express and purify various 
PXA domains from a wide variety of species in both bacterial and insect cell expression 
systems. Even though this chapter presents many difficulties while trying to express and 
purify these domains, I report how I eventually optimized the conditions to successfully 
produce soluble and folded PXA domain protein. Out of the various constructs from 
different species that I tried, the His-tagged PXA domain constructs from Oryzias latipes 
(Chapter 7, Table 10) (in collaboration with Assoc. Prof. Mike Henne, University of Texas) 
lead to the production of folded protein, which in turn produced micro needle crystals. The 
condition that proved to be efficient for the successful expression and purification was the 
expression of these constructs with low concentrations of oleic acid and purification with 
low concentrations of β-octylglucoside detergent. Future efforts will now hopefully extend 
these preliminary studies to produce diffraction quality crystals suitable for structure 
determination, which will provide important insights into their so far unknown structures 
and functions. 
8.3 Concluding remarks  
Overall, the research presented in this thesis describes the first protein-protein structural 
analysis of a PX domain of the SNX subfamily, which is usually known for its PI3P binding 
abilities, and how domains other than the PX domain work for the normal functioning of the 
SNX proteins in the cell. My work has provided new insights into how the PX domains 
regulate protein-protein interactions, how they contribute to pathogen invasion and 
different diseases, and should inform future studies to determine whether they might be 
suitable as therapeutic targets and if so, how such interventions can be achieved. 
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